US20200149108A1 - Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction - Google Patents
Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction Download PDFInfo
- Publication number
- US20200149108A1 US20200149108A1 US16/659,277 US201916659277A US2020149108A1 US 20200149108 A1 US20200149108 A1 US 20200149108A1 US 201916659277 A US201916659277 A US 201916659277A US 2020149108 A1 US2020149108 A1 US 2020149108A1
- Authority
- US
- United States
- Prior art keywords
- snp
- nucleic acid
- antigen
- immune tolerance
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000006058 immune tolerance Effects 0.000 title claims abstract description 72
- 239000002773 nucleotide Substances 0.000 title claims description 40
- 125000003729 nucleotide group Chemical group 0.000 title claims description 40
- 230000006698 induction Effects 0.000 title description 25
- 102000054765 polymorphisms of proteins Human genes 0.000 title description 7
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 214
- 238000000034 method Methods 0.000 claims abstract description 133
- 108091007433 antigens Proteins 0.000 claims abstract description 119
- 102000036639 antigens Human genes 0.000 claims abstract description 119
- 239000000427 antigen Substances 0.000 claims abstract description 118
- 108020004707 nucleic acids Proteins 0.000 claims description 160
- 102000039446 nucleic acids Human genes 0.000 claims description 160
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 82
- 239000000523 sample Substances 0.000 claims description 76
- 201000010099 disease Diseases 0.000 claims description 58
- 238000003556 assay Methods 0.000 claims description 55
- 108700028369 Alleles Proteins 0.000 claims description 29
- 102000008186 Collagen Human genes 0.000 claims description 26
- 108010035532 Collagen Proteins 0.000 claims description 26
- 229920001436 collagen Polymers 0.000 claims description 26
- 238000003205 genotyping method Methods 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 24
- 238000009396 hybridization Methods 0.000 claims description 23
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 19
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 238000012216 screening Methods 0.000 claims description 17
- 108020004414 DNA Proteins 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 15
- 230000003321 amplification Effects 0.000 claims description 14
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 206010052804 Drug tolerance Diseases 0.000 claims description 9
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 101710163270 Nuclease Proteins 0.000 claims description 6
- 238000004590 computer program Methods 0.000 claims description 6
- 230000002596 correlated effect Effects 0.000 claims description 5
- 210000004209 hair Anatomy 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 210000001138 tear Anatomy 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 230000002784 sclerotic effect Effects 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000004381 amniotic fluid Anatomy 0.000 claims description 3
- 210000005178 buccal mucosa Anatomy 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000003756 cervix mucus Anatomy 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 210000003722 extracellular fluid Anatomy 0.000 claims description 3
- 210000000416 exudates and transudate Anatomy 0.000 claims description 3
- 230000002550 fecal effect Effects 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims description 3
- 230000000762 glandular Effects 0.000 claims description 3
- 210000004880 lymph fluid Anatomy 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 59
- 108090000765 processed proteins & peptides Proteins 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 44
- 238000001514 detection method Methods 0.000 description 41
- 102000004196 processed proteins & peptides Human genes 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 238000011282 treatment Methods 0.000 description 31
- 241000283690 Bos taurus Species 0.000 description 30
- 230000004044 response Effects 0.000 description 30
- 230000028993 immune response Effects 0.000 description 29
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 29
- 229920001184 polypeptide Polymers 0.000 description 29
- 239000003153 chemical reaction reagent Substances 0.000 description 27
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 21
- 101150051438 CYP gene Proteins 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 101150069538 ROT1 gene Proteins 0.000 description 20
- 206010039073 rheumatoid arthritis Diseases 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 19
- 229960002702 piroxicam Drugs 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 239000000975 dye Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 102000012432 Collagen Type V Human genes 0.000 description 15
- 108010022514 Collagen Type V Proteins 0.000 description 15
- 108090000174 Interleukin-10 Proteins 0.000 description 15
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 210000004989 spleen cell Anatomy 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 14
- 238000004949 mass spectrometry Methods 0.000 description 14
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 230000002068 genetic effect Effects 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 208000011231 Crohn disease Diseases 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000001363 autoimmune Effects 0.000 description 10
- 239000012472 biological sample Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000011269 treatment regimen Methods 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000003491 array Methods 0.000 description 8
- 230000000899 immune system response Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000002917 arthritic effect Effects 0.000 description 6
- 238000013500 data storage Methods 0.000 description 6
- 230000035611 feeding Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000007577 Desmoglein 3 Human genes 0.000 description 5
- 108010032035 Desmoglein 3 Proteins 0.000 description 5
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000031261 interleukin-10 production Effects 0.000 description 5
- 239000000123 paper Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 210000001986 peyer's patch Anatomy 0.000 description 5
- 230000024664 tolerance induction Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 108010045579 Desmoglein 1 Proteins 0.000 description 4
- 102100034579 Desmoglein-1 Human genes 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 201000011152 Pemphigus Diseases 0.000 description 4
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 230000005784 autoimmunity Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- -1 but not limited to Chemical class 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 102000054766 genetic haplotypes Human genes 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 108010041390 Collagen Type II Proteins 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 241000721454 Pemphigus Species 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 229940111134 coxibs Drugs 0.000 description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 229940124622 immune-modulator drug Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002032 lab-on-a-chip Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 3
- 229960005249 misoprostol Drugs 0.000 description 3
- 238000003499 nucleic acid array Methods 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 102100038910 Alpha-enolase Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000032081 Cabezas type X-linked intellectual disability Diseases 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 208000007058 Donnai-Barrow syndrome Diseases 0.000 description 2
- 102100023115 Dual specificity tyrosine-phosphorylation-regulated kinase 2 Human genes 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001049990 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 2 Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 108010015372 Low Density Lipoprotein Receptor-Related Protein-2 Proteins 0.000 description 2
- 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 108010047956 Nucleosomes Proteins 0.000 description 2
- 102100034574 P protein Human genes 0.000 description 2
- 101710181008 P protein Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101710177166 Phosphoprotein Proteins 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010025934 hnRNP A2 Proteins 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000002794 lymphocyte assay Methods 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-methyl-PhOH Natural products CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 210000001623 nucleosome Anatomy 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000002213 purine nucleotide Substances 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 201000001872 syndromic X-linked intellectual disability Cabezas type Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- HOURAEXAZWBEAW-UHFFFAOYSA-N 1-aminopropane-1,1,3-tricarboxylic acid Chemical compound OC(=O)C(C(O)=O)(N)CCC(O)=O HOURAEXAZWBEAW-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 102100030088 ATP-dependent RNA helicase A Human genes 0.000 description 1
- 101710164022 ATP-dependent RNA helicase A Proteins 0.000 description 1
- 206010058820 Acantholysis Diseases 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 102100036601 Aggrecan core protein Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102100034278 Annexin A6 Human genes 0.000 description 1
- 108090000656 Annexin A6 Proteins 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000399988 Carinoma Species 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 101000573882 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP3 Proteins 0.000 description 1
- 102000004510 Collagen Type VII Human genes 0.000 description 1
- 108010017377 Collagen Type VII Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 102100021202 Desmocollin-1 Human genes 0.000 description 1
- 101710157876 Desmocollin-1 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100038055 Glutathione S-transferase theta-1 Human genes 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 102000036541 Heterogeneous Nuclear Ribonucleoprotein D0 Human genes 0.000 description 1
- 108091021225 Heterogeneous Nuclear Ribonucleoprotein D0 Proteins 0.000 description 1
- 101710156363 Heterogeneous nuclear ribonucleoprotein A/B Proteins 0.000 description 1
- 102100035617 Heterogeneous nuclear ribonucleoprotein A/B Human genes 0.000 description 1
- 102100028818 Heterogeneous nuclear ribonucleoprotein L Human genes 0.000 description 1
- 108010084674 Heterogeneous-Nuclear Ribonucleoprotein L Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000838703 Homo sapiens Putative HTLV-1-related endogenous sequence Proteins 0.000 description 1
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 description 1
- 101000612981 Homo sapiens Testis-specific gene 10 protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 208000012528 Juvenile dermatomyositis Diseases 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 101710183404 Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 102100035414 Neurofascin Human genes 0.000 description 1
- 101710189786 Neurofascin Proteins 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010068786 Overlap syndrome Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100029008 Putative HTLV-1-related endogenous sequence Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000014113 Rabaptin-5 Human genes 0.000 description 1
- 108050003998 Rabaptin-5 Proteins 0.000 description 1
- 102100038914 RalA-binding protein 1 Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- 206010042342 Subcorneal pustular dermatosis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091053398 TRIM/RBCC family Proteins 0.000 description 1
- 102100040873 Testis-specific gene 10 protein Human genes 0.000 description 1
- 102100027188 Thyroid peroxidase Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 102000011408 Tripartite Motif Proteins Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000014926 Vesiculobullous Skin disease Diseases 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 108010023562 beta 2-Glycoprotein I Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 108010027853 glutathione S-transferase T1 Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 description 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000000504 luminescence detection Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 229930182817 methionine Chemical group 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 206010057887 neonatal lupus erythematosus Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 125000000405 phenylalanyl group Chemical group 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Chemical group 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940087462 relafen Drugs 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 102000029751 selenium binding Human genes 0.000 description 1
- 108091022876 selenium binding Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 208000037369 susceptibility to malaria Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000006226 wash reagent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention is in the field of the immune system and therapy.
- the present invention relates to specific nucleic acid sequences in the human genome, and their association with diseases and pathologies as well as immune tolerance induction. Based on differences in allele frequencies in the patient population relative to normal individuals, the naturally-occurring nucleic acid sequences disclosed herein can be used as targets for the design of diagnostic reagents and the development of therapeutic agents, as well as for disease association and linkage analysis.
- the nucleic acid sequences of the present invention are useful for identifying an individual (e.g., patient) who is at an increased or decreased risk of developing a disease or pathology and for early detection of the disease or pathology, for providing clinically important information for the prevention and/or treatment of disease or pathology, and for screening and selecting therapeutic agents.
- the presence or absence of one or more nucleic acid sequences may be used to determine the type and dose of antigen given to induce immune tolerance.
- One or more antigens may be administered to a patient having or not having a particular nucleic acid sequence, where the antigen may induce immune tolerance in a patient.
- the nucleic acid sequences disclosed herein are also useful for human identification applications. Methods, assays, kits, and reagents for detecting the presence of these polymorphisms and their encoded products are also provided.
- the invention addresses the use or absence of non-steroidal anti-inflammatory drugs in therapy.
- a variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form or may be neutral.
- a variant form confers an evolutionary advantage to the species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form.
- the effects of a variant form may be both beneficial and detrimental, depending on the circumstances. For example, a heterozygous sickle cell mutation confers resistance to malaria, but a homozygous sickle cell mutation is usually lethal. In many cases, both progenitor and variant forms survive and co-exist in a species population.
- SNPs single nucleotide polymorphisms
- SNPs can also arise in areas of the genome with no apparent function, but the SNP can be genetically linked to a variant sequence in the genome. Thus, the SNP can closely correlate with the variant sequence of the genome, depending on how close the genetic linkage is.
- SNPs are single base positions in DNA at which different alleles, or alternative nucleotides, exist in a population.
- the SNP position (interchangeably referred to herein as SNP, SNP site, or SNP locus) is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations).
- An individual may be homozygous or heterozygous for an allele at each SNP position.
- Immune or immunological tolerance is the process by which the immune system does not mount an immune response to an otherwise immunogenic antigen, or has its immune response redirected in a suppressive manner.
- Acquired or induced tolerance refers to the immune system's adaptation to external antigens characterized by a specific non-reactivity of the lymphoid tissues to a given antigen that in other circumstances would likely induce cell-mediated or humoral immunity.
- One of the most important natural kinds of acquired tolerance occurs during pregnancy, where the fetus and the placenta must be tolerated by the maternal immune system.
- There are numerous models for the induction of tolerance including use of the eutherian fetoembryonic defense system and induction of tolerance primarily requires the participation of regulatory T cells.
- immune tolerance is the specific suppression of cellular and/or humoral immune reactivity to an antigen by prior administration of the antigen by the oral route, probably evolved to prevent hypersensitivity reactions to food proteins and bacterial antigens present in the mucosal flora. It is of immense immunological importance, since it is a continuous natural immunologic event driven by exogenous antigen. Due to their privileged access to the internal milieu, antigens that continuously contact the mucosa represent a frontier between foreign and self components. Oral tolerance evolved to treat external agents that gain access to the body via a natural route as internal components without danger signals, which then become part of self.
- the inventors are credited with providing methods, reagents, kits and assays that merge genomics with immune tolerance. As such, the inventors are able to detect nucleic acid sequences, and based on the presence and/or absence of nucleic acid sequences; tailor a method of care for the patient who desires induction of immune tolerance.
- the nucleic acid sequences of interest are SNPs.
- the present invention relates to correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. This correlation may be used to assist with induction of immune tolerance.
- the invention concerns tolerance induced by repeated administration of very large doses of antigen, or of small doses that are below the threshold required for stimulation of an immune response.
- tolerance is most readily induced by soluble antigens administered either intravenously or sublingually.
- immunosuppression also facilitates the induction of tolerance.
- the present invention also provides for methods of detecting variants.
- the nucleic acid sequences of interest are SNPs.
- embodiments of the invention address the use or avoidance of non steroidal anti inflammatory drugs in therapy.
- the invention includes a method for screening for susceptibility to immune tolerance development, comprising screening for at least one SNP.
- the method of screening may include FISH, use of a DNA array, and/or hybridizing a polynucleotide probe.
- the invention includes a method for screening for susceptibility to immune tolerance development, including use of allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and/or single-stranded conformation polymorphism.
- the invention includes a method for screening for susceptibility to immune tolerance development, including correlating the presence or absence of the at least one SNP with ability of a host to develop immune tolerance as a result of administration of one or more antigens or therapeutic agents to the host.
- the antigen may be collagen, including collagen selected from the group types consisting of I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII and XXVIII.
- the invention includes a method for screening for susceptibility to immune tolerance development, including obtaining a sample from said host comprising nucleic acid; isolating nucleic acid from said sample; assaying said sample for the presence or absence of at least one SNP, wherein the presence or absence of the at least one SNP is indicative of an increased susceptibility to develop immune tolerance.
- the sample may be whole blood, blood plasma, urine, tears, semen, saliva, buccal mucosa, interstitial fluid, lymph fluid, meningeal fluid, amniotic fluid, glandular fluid, sputum, feces, perspiration, mucous, vaginal secretion, cerebrospinal fluid, hair, skin, fecal material, wound exudate, wound homogenate, and wound fluid.
- the method may include induction of immune tolerance by administration of at least one antigen to the host, where the antigen can be a type of collagen.
- the immune tolerance may be to any autoimmune disease such as sclerotic disease like systemic sclerosis.
- the invention includes a method for screening for susceptibility to immune tolerance development, including use of one or more computer programs for use with at least one computer system, where computer program includes a plurality of instructions including at least one instruction for aiding in identification of the presence or absence of said at least one SNP; at least one instruction for associating the presence or absence of said at least one SNP with at least one disease state; and at least one instruction for correlating the presence or absence of said at least one SNP with a score indicating susceptibility of a host to develop immune tolerance.
- the computer may also generate a report including the results of the plurality of instruction, where the report may be transmitted over a network, on-line portal, by paper or e-mail in a secure or non-secure manner.
- the invention includes a method of administering at least one therapeutic agent, the method comprising genotyping one or more SNP(s) in the nucleic acid of a host, correlating the one or more SNP(s) with one or more diseases or disorders, using a mathematical algorithm to determine probability that said host will respond positively or negatively to administration of at least one therapeutic agent, and administrating or not administrating a therapeutic agent to the host based on the results of said mathematical algorithm.
- the invention includes a method for conducting a clinical trial in which one or more antigen(s) are evaluated, including genotyping one or more SNP(s) relating to one or more diseases or disorders; analyzing the genotyping results; determining a course of action based on the results of said genotyping, wherein said course of action comprises including individual in the clinical trial based on the results of said genotyping having indicated that said individuals are likely to respond to said one or more antigen(s), and/or excluding individuals from participating in the clinical trial based on the results of said genotyping having indicated that said individuals are not likely to respond to said one or more antigen(s).
- the invention includes a method for identifying an individual who has an altered risk for developing an autoimmune disease, comprising detecting a single nucleotide polymorphism (SNP) in SEQ ID NO: 1 in said individual's nucleic acids, wherein the presence of the SNP is correlated with an altered risk for autoimmune disease.
- SNP single nucleotide polymorphism
- FIG. 1 illustrates a flow chart in accordance with some embodiments of the invention, demonstrating a process of determining if one or more nucleic acids is correlated with induction of immune tolerance.
- FIG. 2 illustrates a flow chart in accordance with some embodiments of the invention, demonstrating a process of determining an individual's treatment regimen by the presence of absence of one or more nucleic acids.
- FIG. 3 illustrates a flow chart in accordance with some embodiments of the invention, demonstrating a process of determining an individual's treatment regimen by the presence of absence of one or more nucleic acids.
- FIG. 4 illustrates a flow chart in accordance with some embodiments of the invention, demonstrating a process of determining an individual's treatment regimen by the presence of absence of one or more nucleic acids.
- FIG. 5 illustrates a flow chart in accordance with some embodiments of the invention, demonstrating a process of determining an individual's treatment regimen by the presence of absence of one or more polypeptides.
- FIG. 6 is a chart showing the percent of arthritic joints correlated with quantity of collagen II given by gavage to mice.
- FIG. 7 is a chart showing abrogation of certain forms of oral tolerance by piroxicam.
- FIG. 8 is a chart showing IFN- ⁇ production by al (II) stimulated spleen cells.
- FIG. 9 is a chart showing COX-2 inhibitor SC′236 abrogates oral tolerance induction.
- FIG. 10 is a chart showing persistent abrogation of oral tolerance by piroxicam.
- FIG. 11 is a chart showing the effect of piroxicam or CII on Peyer's patch spleen co-culture.
- FIG. 12 is a chart showing the effect of piroxicam or CII on mesenteric lymph node cell proliferation
- FIG. 13 is a chart showing the effect of oral collagen II treatment of rheumatoid arthritis patients and how it modulates PBMC IFN production by PBMC.
- FIG. 14 is a chart the genotyping of persons with rheumatoid arthritis and their ability to induce immune tolerance.
- FIG. 15 is a chart showing the markers and genes contain potential SNPs of interest.
- FIG. 16 is a chart showing a significant reduction in MRSS at 12 months versus placebo patients.
- nucleic acid refers to deoxyribonucleotides or ribonucleotides in either single- or double-stranded form. Those skilled in the art will readily recognize that reference to a particular site on one strand refers, as well, to the corresponding site on a complementary strand. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides.
- nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated.
- degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues.
- nucleic acid is used interchangeably with “nucleic acid sequence,” “gene,” “cDNA,” and “mRNA” encoded by a gene.
- amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
- Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ -carboxyglutamate, and O-phosphoserine.
- Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
- Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
- Amino acids may be referred to herein by either the commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
- genotyp as used herein broadly refers to the genetic composition of an organism, including, for example, whether a diploid organism is heterozygous or homozygous for one or more variant alleles of interest.
- references to “SNPs” and “SNP genotypes” include individual SNPs and/or haplotypes, which are groups of SNPs that are generally inherited together. Haplotypes can have stronger correlations with diseases or other phenotypic effects compared with individual SNPs, and therefore may provide increased diagnostic accuracy in some cases.
- the SNPs of the current invention may arise from a synonymous codon change, or silent mutation/SNP (terms such as “SNP”, “polymorphism”, “mutation”, “mutant”, “variation”, and “variant” are used herein interchangeably), is one that does not result in a change of amino acid due to the degeneracy of the genetic code.
- a substitution that changes a codon coding for one amino acid to a codon coding for a different amino acid i.e., a non-synonymous codon change
- a missense mutation is referred to as a missense mutation.
- a nonsense mutation results in a type of non-synonymous codon change in which a stop codon is formed, thereby leading to premature termination of a polypeptide chain and a truncated protein.
- a read-through mutation is another type of non-synonymous codon change that causes the destruction of a stop codon, thereby resulting in an extended polypeptide product.
- SNPs may include all allelics, including bi-, tri-, or tetra-allelics.
- a SNP position, SNP allele, or nucleotide sequence reference to an adenine, a thymine (uridine), a cytosine, or a guanine at a particular site on one strand of a nucleic acid molecule also defines the thymine (uridine), adenine, guanine, or cytosine (respectively) at the corresponding site on a complementary strand of the nucleic acid molecule.
- uridine adenine, guanine, or cytosine
- Probes and primers may be designed to hybridize to either strand and SNP genotyping methods disclosed herein may generally target either strand.
- polypeptide “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues.
- the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
- the terms encompass amino acid chains of any length, including full-length proteins (i.e., antigens), wherein the amino acid residues are linked by covalent peptide bonds.
- references to “polypeptides,” “peptides” or “proteins” of the present invention include peptides, polypeptides, proteins, or fragments thereof, that contain at least one amino acid residue that differs from the corresponding amino acid sequence of the art-known peptide/polypeptide/protein (the protein may be interchangeably referred to as the “wild-type”, “reference”, or “normal” protein).
- Such variant peptides/polypeptides/proteins can result from a codon change caused by a nonsynonymous nucleotide substitution at a protein-coding position (i.e., a missense mutation) disclosed by the present invention.
- Variant peptides/polypeptides/proteins of the present invention can also result from a nonsense mutation, i.e., a SNP that creates a premature stop codon, a SNP that generates a read-through mutation by abolishing a stop codon, or due to any SNP disclosed by the present invention that otherwise alters the structure, function/activity, or expression of a protein, such as a SNP in a regulatory region (e.g., a promoter or enhancer) or a SNP that leads to alternative or defective splicing, such as a SNP in an intron or a SNP at an exon/intron boundary.
- a regulatory region e.g., a promoter or enhancer
- SNP that leads to alternative or defective splicing, such as a SNP in an intron or a SNP at an exon/intron boundary.
- the terms “polypeptide”, “peptide”, and “protein” are used interchangeably.
- the terms “individual” and “host” are used interchangably, and are not limited to humans.
- the “individual” may be any vertebrate, including mammals such as primates and including humans, dogs, cats, cows, goats, pigs, sheep, and monkeys.
- the disclosed invention may be applicable to treatment of animals through, for example, animal water, animal feed, animal pharmaceuticals, and the like.
- the individual may be healthy or suffering from a disease.
- methods of the present invention can be effectively used if applied to a human who suffers from an auto-immunity disease or a disease caused by a pathogenic microorganism and a type of a certain nucleic acid sequence in the individual.
- altered may be used herein to encompass either an increased or a decreased risk/likelihood.
- specific disease encompasses auto antibody diseases as well as diseases associated with a pathogenic microorganism, such as for example, a virus, bacterium, yeast or mycoplasma as well as oncological diseases.
- a pathogenic microorganism such as for example, a virus, bacterium, yeast or mycoplasma
- oncological diseases such as for example, a virus, bacterium, yeast or mycoplasma
- the disease is not particularly limited.
- the present invention provides methods of determining if an individual is likely to develop immune tolerance by detecting the altered expression (either higher or lower expression) or unique expression of nucleic acid sequences, as well as the gene sequence in the individual, even if they are not expressed or only transiently expressed.
- some embodiments provide methods to determine if an individual that has the ability to develop immune tolerance has a differential and unique expression of known and unknown nucleic acid sequence from those individuals who do not have the ability to develop immune tolerance.
- the nucleic acid sequences are SNPs.
- the present invention also provides nucleic acid sequences, methods and reagents for detecting the nucleic acid sequences, uses of nucleic acid sequences in kits or assays for use in advance of inducing immune tolerance.
- the invention contemplates use of nucleic acid sequences that are associated with either an increased risk of having or developing immune tolerance, or a decreased risk of having or developing immune tolerance.
- the presence of certain nucleic acid sequences (or their mRNA or protein encoded products) can be assayed to determine whether an individual possesses a nucleic acid sequences that is indicative of an increased risk of having or developing immune tolerance or a decreased risk of having or developing immune tolerance.
- nucleic acid sequences of the present invention can be associated with either an increased or decreased likelihood of responding to a particular treatment or antigen, or an increased or decreased likelihood of developing immune tolerance to the particular treatment or antigen.
- the nucleic acid sequences are SNPs.
- Such nucleic acid variation can be assayed in a number of different methods that are well known to those of skill in the art, including PCR, RFLP, hybridization and direct sequencing.
- One embodiment is to a method to determine nucleic acid sequences that are present or absent in an individual who is susceptible to immune tolerance development, comprising screening for at least one nucleic acid sequence, as show in FIG. 1 .
- the medical practitioner first administers an oral antigen to a patient to induce immune tolerance ( 101 ).
- Antigens suitable for use in the present invention include, but are not limited to, synthetic or naturally derived proteins and peptides, and particularly those which by themselves require high doses to induce oral tolerance; carbohydrates including, but not limited to, polysaccharides and lipopolysaccharides; and antigens isolated from biological sources such as, for example, those associated with or responsible for the induction of auto-immune diseases, clinical (allergic) hypersensitivities, and allograft rejection and subunits or extracts therefrom; or any combination thereof.
- the antigens may be any associated with or responsible for the induction of auto-immune diseases, clinical (allergic) hypersensitivities, and allograft rejection, and subunits or extracts therefrom; or recombinantly generated whole proteins, subunits or fragments thereof; or any combination thereof.
- the collagen may also be a fragment thereof.
- the collagen may be one or more fragments produced by CNBr cleavage of ⁇ 1(I), which yields eight CB fragments: CB0, CB1, CB2, CB4, CB5, CB8, CB3, CB7 and CB6.
- the collagen may be one or more fragments produced by cCNBr cleavage of ⁇ 2(I), which yields six CB fragments: CB1, CB0, CB4, CB2, CB3 and CB5.
- the disease is a sclerotic disease. In another embodiment, the disease is multiple sclerosis.
- collagen is the antigen used to induce immune tolerance to the disease idiopathic pulmonary fibrosis.
- ⁇ -enolase is an antigen used to induce immune tolerance for the disease asthma.
- a suitable single dose is a dose that is capable of altering a biological response in an animal when administered one or more times over a suitable time period (e.g., from minutes to days over weeks).
- a dose comprises from about 1 ⁇ g of the antigen per kilogram of body weight (ng/kg) to about 1 gram of antigen per kilogram of body weight (gm/kg), more preferably 100 ⁇ g/kg to about 100 milligrams/kilogram (mg/kg), and even more preferably from about 10 microgram of the antigen per kilogram body weight ( ⁇ /kg) to about 10 mg/kg.
- the dose of antigen may not be determined upon the body weight of the patient.
- the dose may be at least 1 ⁇ g/day of antigen.
- the dose ranges from 10 ⁇ g/day of antigen to 5000 ⁇ g/day.
- the dose ranges from 10 ⁇ g/day of antigen to 500 ⁇ g/day.
- the dose ranges from 30 ⁇ g/day of antigen to 200 ⁇ g/day.
- the dose of antigen is below the threshold required for stimulation of an immune response. In another embodiment, the dose of antigen is above the threshold, thereby stimulating an immune response.
- Modes of administration can include, but are not limited to, aerosolized, subcutaneous, rectally, intradermal, intravenous, nasal, oral, transdermal and intramuscular routes.
- the antigen is given orally.
- the antigen is given intraveneously or sublingually.
- the antigen can be combined with other components such as a pharmaceutically acceptable excipient and/or a carrier, prior to administration to the individual.
- a pharmaceutically acceptable excipient and/or a carrier prior to administration to the individual.
- the other components will depend upon the mode of administration, storage needs, and the like.
- excipients examples include water, saline, Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions.
- Nonaqueous vehicles such as fixed oils, sesame oil, ethyl oleate, or triglycerides may also be used.
- Other useful formulations include suspensions containing viscosity-enhancing agents, such as sodium carboxymethylcellulose, sorbitol, or dextran.
- Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability.
- buffers include, but are not limited to, phosphate buffer, bicarbonate buffer and Tris buffer, while examples of preservatives include, but are not limited to, thimerosal, m- or o-cresol, formalin and benzyl alcohol.
- Standard formulations can either be liquid injectables or solids that can be taken up in a suitable liquid as a suspension or solution for injection.
- Carriers are typically compounds that increase the half-life of an antigen in the treated individual. Suitable carriers include, but are not limited to, polymeric controlled release vehicles, biodegradable implants, liposomes, bacteria, viruses, oils, esters, and glycols. Preferred controlled release formulations are capable of slowly releasing the antigen of the present invention into an individual. Suitable controlled release vehicles include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres, and transdermal delivery systems. Other controlled release vehicles of the present invention include liquids that, upon administration to an individual, form a solid or a gel in situ. Preferred controlled release vehicles are biodegradable (i.e., bioerodible).
- a biological sample also referred to as a “sample”, is taken from the individual for use in determining the individual's immune response ( 102 ).
- sample preparation components can be used to produce nucleic acid extracts (including DNA and/or RNA), proteins or membrane extracts from any bodily fluids (such as blood, serum, plasma, urine, saliva, phlegm, gastric juices, semen, tears, sweat, etc.), skin, hair, cells (especially nucleated cells), biopsies, buccal swabs or tissue specimens.
- the frequency of taking samples, and its use will vary based on such factors as the scoring method, assay format, nature of the detection method, and the specific tissues, cells or extracts used as the test sample to be assayed.
- Methods of preparing nucleic acids, proteins, and cell extracts from the biological sample are well known in the art and can be readily adapted to obtain a sample that is compatible with the system utilized.
- the individual immune system response to the antigen is determined, and the individuals are scored based upon their response ( 103 ).
- the method of scoring is dependent upon the practitioner, and includes any methods that separate patients based upon their immune response to the antigen. For instance, the patient may be scored based on antigen specific and antigen non-specific assays. Antigen specific assays measure the response of T and B cells to specific antigens, whereas antigen non-specific assays determine the phenotype of surface markers or functional state of cells for patterns associated with a particular clinical status.
- the practitioner may use any means convenient to determine the immune system response, including but not limited to, use of an enzyme-linked immunoabsorbent assay (ELISA), ELISA/ACT® Lymphocyte Response Assay (LRA), in vitro measurement of antibody production, mixed leukocyte reaction, cytotoxic T lymphocyte assay, flow cytometry, Western blots, limiting dilution assay, mass spectroscopy, immunoprecipitation and immunofluorescence.
- ELISA enzyme-linked immunoabsorbent assay
- LRA Lymphocyte Response Assay
- an ELISPOT assay is used to determine the individual immune response.
- an ELISPOT assay includes incubating immune cells in plates coated with a capture antibody against a cytokine of interest. Cytokines released by the cell membrane are then captured by the capture antibody during the incubation period. The cells are removed and the bound cytokine is detected using a labeling system, such as for example, a labeled secondary antibody against a different epitope of the same cytokine. This assay results in a cytokine footprint of a single cell.
- a transvivo DTH assay is used to determine individual immune response.
- cells from the individual are injected into the footpads of immune-deficient mice together with the antigen.
- the index of reactivity of T cells to the antigens is then measured by quantification of resultant swelling in the footpad.
- a tetramer assay is used.
- the frequency of T cells is measured by their binding to specific peptide-MHC complexes using flow cytometry.
- a CFSE assay measures the proliferation of T cells by dilution of a CFSE dye in the dividing cells. This assay may include use of flow cytometry.
- intracellular staining of the T cells can be used to determine the frequency of cytokine-producing T cells by, for example, flow cytometry.
- the patients are scored based upon the respective levels and/or changes in IFN- ⁇ production before, during and/or after receiving the antigen.
- other cytokines may be measured to determine individual scores. For instance, levels of IL-10 in ⁇ 1(I)- and ⁇ 2(I)-stimulated PBMC culture supernatants and/or sIL-2R may be used to score a patient.
- TCR repertoire may include use of quantitative PCR, gel electrophoresis and DNA sequencing to determine the proporation of T cells that use the V ⁇ chains to determine the CFR3 length distribution along the V ⁇ gene product.
- Another means to determine immune system response may include T cell responses to polyclonal, non-antigen-specific stimulation.
- the whole blood is stimulated with phytohemagglutinin for a period of time, CD4+ T cells are then isolated, and the extent of early CD4+ T cell activation is measured by the synthesis and accumulation of intracellular ATP measured after cell lysis.
- Hybridization techniques involve detecting the hybridization of two or more nucleic acid molecules, where detection is achieved in a variety of ways, including labeling the nucleic acid molecules and observing the signal generated from such a label.
- Hybridization techniques may include any of the following: Northern and Southern blotting, cycling probe reaction, branched DNA, InvaderTM Assay, and Hybrid Capture.
- Hybridization techniques may also be used to identify a specific sequence of nucleic acid present in a sample by using microarrays (or “bioarrays”) of known nucleic acid sequences to probe a sample.
- Bioarray technologies generally use known single stranded nucleic acid, where each unique short chain is attached in a specific known location and then adding the sample nucleic acid and allowing sequences present in the sample to hybridize to the immobilized strands. Detection of this hybridization is then carried out by labeling, typically end labeling, of the fragments of the sample to be detected prior to the hybridization. Further, hybridization may be determined by use of a fluorescent in situ hybridization technique.
- proteomics approach may be used.
- protein microarrays or mass spectrometry may be used to determine the presence and quantification of protein fragments present in an individual's sample.
- mass spectrometry may be used to determine the presence and quantification of protein fragments present in an individual's sample.
- the practitioner can determine the immune response by the unique patterns of protein expression in the individual.
- the practitioner may measure compare the immune response before, during and/or after receiving the antigen. The determination of when the immune response is measured, and what method is used, is based upon the practitioner needs. Further, it is contemplated that the practitioner may further take into consideration other physiological factors of the individual, such as other cytokines, percentage of T cell, NK cell, B cell, dendritic cell, monocyte, subpopulations, oxidative radicals, connective tissue growth factor, nitric oxide, thymic morphology determined by imaging techniques, patient height, nutritional status, weight, health, thymic function determined by immunologic assays, diet, gender, age, vitamin A levels, zinc levels, and environmental considerations to assist in scoring the patient's immune response. Patients' genomic backgrounds, such as mutations in other genes or genome regions, races and gender differences, may also be considered.
- the practitioner will analyze the genotype of the individuals to determine whether an individual has or lacks one or more nucleic acid sequences, thereby altering levels or patterns of gene expression ( 104 ).
- the genotype is later used to correlate the presence or absence of the one or more nucleic acids with the immune response score of step ( 103 ).
- nucleic acids of particular interest include those known to affect the concentration of mRNA or protein in a sample, nucleic acids known to affect the kinetics of nucleic acid and/or protein expression, nucleic acids that affect the rate of nucleic acid and/or protein decomposition, and nucleic acids that affect protein stability profile, Km, or Vmax.
- the practitioner may either use part of the biological sample of step ( 102 ) to analyze for the nucleic acid, or the practitioner may take another biological sample from the individual for analysis.
- the nucleic acid may be purified or isolated from the sample by any means convenient to the practitioner, but such isolation may not be necessary in certain forms of detection.
- the practitioner will analyze the genotype of the individuals to determine which allele(s) is/are present at any given genetic region of interest by methods well known in the art.
- the neighboring sequence can be used to design nucleic acid detection reagents such as oligonucleotide probes, which may optionally be implemented in a kit format.
- Common genotyping methods include, but are not limited to, TaqMan assays, molecular beacon assays, nucleic acid arrays, allele-specific primer extension, allele-specific PCR, arrayed primer extension, homogeneous primer extension assays, primer extension with detection by mass spectrometry, pyrosequencing, multiplex primer extension sorted on genetic arrays, ligation with rolling circle amplification, homogeneous ligation, OLA, multiplex ligation reaction sorted on genetic arrays, restriction-fragment length polymorphism, single base extension-tag assays, and the Invader assay.
- Such methods may be used in combination with detection mechanisms such as, for example, luminescence or chemiluminescence detection, fluorescence detection, time-resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, and electrical detection.
- detection mechanisms such as, for example, luminescence or chemiluminescence detection, fluorescence detection, time-resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, and electrical detection.
- Various methods for detecting polymorphisms include, but are not limited to, methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA, comparison of the electrophoretic mobility of variant and wild type nucleic acid molecules, and assaying the movement of polymorphic or wild-type fragments in polyacrylamide gels containing a gradient of denaturant using denaturing gradient gel electrophoresis. Sequence variations at specific locations can also be assessed by nuclease protection assays such as RNase and SI protection or chemical cleavage methods.
- genotyping is performed using the TaqMan assay, which is also known as the 5′ nuclease assay.
- the TaqMan assay detects the accumulation of a specific amplified product during PCR.
- the TaqMan assay utilizes an oligonucleotide probe labeled with a fluorescent reporter dye and a quencher dye.
- the reporter dye is excited by irradiation at an appropriate wavelength, it transfers energy to the quencher dye in the same probe via a process called fluorescence resonance energy transfer (FRET).
- FRET fluorescence resonance energy transfer
- the excited reporter dye does not emit a signal.
- the proximity of the quencher dye to the reporter dye in the intact probe maintains a reduced fluorescence for the reporter.
- the reporter dye and quencher dye may be at the 5′ most and the 3′ most ends, respectively, or vice versa.
- the reporter dye may be at the 5′ or 3′ most end while the quencher dye is attached to an internal nucleotide, or vice versa.
- both the reporter and the quencher may be attached to internal nucleotides at a distance from each other such that fluorescence of the reporter is reduced.
- the 5′ nuclease activity of DNA polymerase cleaves the probe, thereby separating the reporter dye and the quencher dye and resulting in increased fluorescence of the reporter. Accumulation of PCR product is detected directly by monitoring the increase in fluorescence of the reporter dye.
- the DNA polymerase cleaves the probe between the reporter dye and the quencher dye only if the probe hybridizes to the target SNP-containing template which is amplified during PCR, and the probe is designed to hybridize to the target SNP site only if a particular SNP allele is present.
- Preferred TaqMan primer and probe sequences can readily be determined using the SNP and associated nucleic acid sequence information provided herein.
- a number of computer programs such as Primer Express (Applied Biosystems, Foster City, Calif.), can be used to rapidly obtain optimal primer/probe sets. It will be apparent to one of skill in the art that such primers and probes for detecting the nucleic acids of the present invention are useful in diagnostic assays for stenosis and related pathologies, and can be readily incorporated into a kit format.
- the present invention also includes modifications of the Taqman assay well known in the art such as the use of Molecular Beacon probes and other variant formats.
- Another method for genotyping the nucleic acids of the present invention is the use of two oligonucleotide probes in an OLA.
- one probe hybridizes to a segment of a target nucleic acid with its 3′ most end aligned with the nucleic acid site.
- a second probe hybridizes to an adjacent segment of the target nucleic acid molecule directly 3′ to the first probe.
- the two juxtaposed probes hybridize to the target nucleic acid molecule, and are ligated in the presence of a linking agent such as a ligase if there is perfect complementarity between the 3′ most nucleotide of the first probe with the nucleic acid site. If there is a mismatch, efficient ligation cannot occur.
- OLA may also be used for performing nucleic acid detection using universal arrays, wherein a zipcode sequence can be introduced into one of the hybridization probes, and the resulting product, or amplified product, hybridized to a universal zip code array.
- OLA may be used where zipcodes are incorporated into OLA probes, and amplified PCR products are determined by electrophoretic or universal zipcode array readout.
- OLA is carried out prior to PCR (or another method of nucleic acid amplification). In other embodiments, PCR (or another method of nucleic acid amplification) is carried out prior to OLA.
- Mass spectrometry takes advantage of the unique mass of each of the four nucleotides of DNA. Nucleic acids can be unambiguously genotyped by mass spectrometry by measuring the differences in the mass of nucleic acids having alternative nucleic acid alleles. MALDI-TOF (Matrix Assisted Laser Desorption Ionization-Time of Flight) mass spectrometry technology is preferred for extremely precise determinations of molecular mass, such as for SNPs. Numerous approaches to genotype analysis have been developed based on mass spectrometry. Preferred mass spectrometry-based methods of nucleic acid genotyping include primer extension assays, which can also be utilized in combination with other approaches, such as traditional gel-based formats and microarrays.
- primer extension assays which can also be utilized in combination with other approaches, such as traditional gel-based formats and microarrays.
- the primer extension assay involves designing and annealing a primer to a template PCR amplicon upstream (5′) from a target nucleic acid position.
- a mix of dideoxynucleotide triphosphates (ddNTPs) and/or deoxynucleotide triphosphates (dNTPs) are added to a reaction mixture containing template.
- this is a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR.
- Primer and DNA polymerase may further be added.
- Extension of the primer terminates at the first position in the template where a nucleotide complementary to one of the ddNTPs in the mix occurs.
- the primer can be either immediately adjacent (i.e., the nucleotide at the 3′ end of the primer hybridizes to the nucleotide next to the target SNP site) or two or more nucleotides removed from the nucleic acid position. If the primer is several nucleotides removed from the target nucleic acid position, the only limitation is that the template sequence between the 3′ end of the primer and the nucleic acid position cannot contain a nucleotide of the same type as the one to be detected, or this will cause premature termination of the extension primer.
- primers are designed to bind one nucleotide upstream from the SNP position (i.e., the nucleotide at the 3′ end of the primer hybridizes to the nucleotide that is immediately adjacent to the target SNP site on the 5′ side of the target SNP site). Extension by only one nucleotide is preferable, as it minimizes the overall mass of the extended primer, thereby increasing the resolution of mass differences between alternative SNP nucleotides.
- mass-tagged ddNTPs can be employed in the primer extension reactions in place of unmodified ddNTPs. This increases the mass difference between primers extended with these ddNTPs, thereby providing increased sensitivity and accuracy, and is particularly useful for typing heterozygous base positions. Mass-tagging also alleviates the need for intensive sample-preparation procedures and decreases the necessary resolving power of the mass spectrometer.
- the extended primers can then be purified and analyzed by MALDI-TOF mass spectrometry to determine the identity of the nucleotide present at the target SNP position.
- the products from the primer extension reaction are combined with light absorbing crystals that form a matrix.
- the matrix is then hit with an energy source such as a laser to ionize and desorb the nucleic acid molecules into the gas-phase.
- the ionized molecules are then ejected into a flight tube and accelerated down the tube towards a detector.
- the time between the ionization event, such as a laser pulse, and collision of the molecule with the detector is the time of flight of that molecule.
- the time of flight is precisely correlated with the mass-to-charge ratio (m/z) of the ionized molecule. Ions with smaller m/z travel down the tube faster than ions with larger m/z and therefore the lighter ions reach the detector before the heavier ions. The time-of-flight is then converted into a corresponding, and highly precise, m/z. In this manner, SNPs can be identified based on the slight differences in mass, and the corresponding time of flight differences, inherent in nucleic acid molecules having different nucleotides at a single base position.
- Nucleic acids can also be scored by direct DNA sequencing.
- a variety of automated sequencing procedures can be used, including sequencing by mass spectrometry.
- the nucleic acid sequences of the present invention enable one of ordinary skill in the art to readily design sequencing primers for such automated sequencing procedures.
- Commercial instrumentation such as the Applied Biosystems 377, 3100, 3700, 3730, and 3730 ⁇ 1 DNA Analyzers (Foster City, Calif.), is commonly used in the art for automated sequencing.
- Nucleic acid sequences can also be determined by employing a high throughput mutation screening system, such as the SpectruMedix system.
- SSCP single-strand conformational polymorphism
- DGGE denaturing gradient gel electrophoresis
- Sequence-specific ribozymes can also be used to score nucleic acids, in particular SNPs, based on the development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature. Thus, for example, if the SNP affects a restriction enzyme cleavage site, the SNP can be identified by alterations in restriction enzyme digestion patterns, and the corresponding changes in nucleic acid fragment lengths determined by gel electrophoresis
- Genotyping can include the steps of, for example, collecting a biological sample from a human subject (e.g., sample of tissues, cells, fluids, secretions, etc.), isolating nucleic acids (e.g., genomic DNA, mRNA or both) from the cells of the sample, contacting the nucleic acids with one or more primers which specifically hybridize to a region of the isolated nucleic acid containing a target nucleic acid region of interest under conditions such that hybridization and amplification of the target nucleic acid region occurs, and determining the nucleotide present at the nucleic acid position of interest, or, in some assays, detecting the presence or absence of an amplification product (assays can be designed so that hybridization and/or amplification will only occur if a particular nucleic acid sequence allele is present or absent).
- the size of the amplification product is detected and compared to the length of a control sample; for example, deletions and insertions can be detected by a change
- nucleic acid or in particular the SNP, found may then be compared to the nucleic acids of other individuals whom have also received the antigen to induce an immune response.
- Methods of comparing the identity of two or more sequences may be performed by any reasonable means, including programs available in the Wisconsin Sequence Analysis Package version 9.1 (Genetics Computer Group, Madison, Wis., USA).
- BESTFIT may be used to find the “local homology” algorithm of Smith and Waterman and finds the best single region of similarity between two sequences.
- programs such as GAP may be used, which aligns two sequences finding a “maximum similarity.”
- % identities and similarities are determined when the two sequences being compared are optimally aligned.
- the immune response score is associated with the nucleic acid results.
- the practitioner may then determine if one or more nucleic acids, preferably SNPs, are associated with individuals who did or did not respond to the antigen with altered immune tolerance.
- the mechanisms of induction of immune tolerance may vary with different diseases and disorders.
- the SNP involved with induction of systemic lupus erthematosus may be different from the SNPs involved with other diseases, such as autoimmune encephalopathy.
- the practitioner may repeat the process of FIG. 1 for each disease and disorder that the pracititioner wishes to induce immune tolerance to.
- the method of FIG. 1 is particularly beneficial because it allows the practitioner to determine what nucleic acid sequences, including SNPs, may be involved with induction of immune tolerance. More importantly, once the method of FIG. 1 is complete, the practitioner may simply test a new individual for the nucleic acid sequence or SNP of interest, as outlined in FIG. 2 .
- the practitioner categorizes or diagnoses the patient as having a disease or disorder ( 201 ).
- the categorization or diagnosis may be based on present or past symptoms, medical history, family history, tests such as assays or medical scans, and the like.
- the sample may be in any form convenient for the practitioner and patient, including but not limited to, whole blood, blood plasma, urine, tears, semen, saliva, buccal mucosa, interstitial fluid, lymph fluid, meningeal fluid, amniotic fluid, glandular fluid, sputum, feces, perspiration, mucous, vaginal secretion, cerebrospinal fluid, hair, skin, fecal material, wound exudate, wound homogenate, and wound fluid.
- the individual's nucleic acid is then isolated from the sample ( 203 ).
- the isolation may occur by any means convenient to the practitioner. For instance, the isolation may occur by first lysing the cell using detergents, enzymatic digestion or physical disruption. The contaminating material is then removed from the nucleic acids by use of, for example, enzymatic digestion, organic solvent extraction, or chromatographic methods.
- the individual's nucleic acid may be purified and/or concentrated by any means, including precipitation with alcohol, centrifugation and/or dialysis.
- the individual's nucleic acid is then assayed for presence or absence of one or more predetermined nucleic acids of interest ( 204 ).
- the one or more predetermined nucleic acids of interest may be any nucleic acid the practitioner believes may be related to immune tolerance to any disease or disorder. Exemplary examples of appropriate diseases or disorders are listed in Table 1.
- the determination of whether one or more predetermined nucleic acids of interest are presence or absence, may be done by any mean ( 205 ).
- the predetermined nucleic acid of interest is an approximately 50 KB non gene region on chromosome 12, located about 55.5 Mbp from the proximal end of chromosome 12 between 66,603,791 and 66,603,991 bps, where the nucleic acid of interest is either TTTTTTTTTTGTACCTAGTTCTATGGTTACCTT (SEQ ID NO. 1) or TTTTTTTTTTGTACCTGGTTCTATGGTTACCTT (SEQ ID NO. 2).
- the A/G is the polymorphic site.
- AA represents AA homozygous
- AB represents A/G heterozygous
- BB represents GG genotype
- a ⁇ G represents the polymorphism site.
- the predetermined nucleic acid of interest may include part of the approximately 265143 bp at 5′ side of SNP A-1515737.
- the predetermined nucleic acid of interest may include part of the approximately 231513 bp at 3′ side of SNP-1515737.
- the predetermined nucleic acid of interest includes part of all of SEQ. ID. 3 or 4.
- the predetermined nucleic acid of interest is located between 66507155-66507464 on chromosome 12, within the proximity of the marker D1251503.
- the predetermined nucleic acid of interest is located within the proximity of D12S1676, i.e., part or all of the predetermined nucleic acid of interest is located between 66499298-66499423 on chromosome 12.
- the predetermined nucleic acid of interest is located within the proximity of D12S335, i.e., part or all of the predetermined nucleic acid of interest is located between 66415802-66416056 on chromosome 12.
- the predetermined nucleic acid of interest is located within the proximity of D12S102, i.e., part or all of the predetermined nucleic acid of interest is located between 66781046-66781298 on chromosome 12.
- the predetermined nucleic acid of interest is located within the proximity of D12S1506, i.e., part or all of the predetermined nucleic acid of interest is located between 66785380-66785614 on chromosome 12.
- the predetermined nucleic acid of interest is SNP_A-1508498 (TSC51977), with the polymorphism of C or T.
- the predetermined nucleic acid of interest is SNP_A-1512645 (TSC1720860) with the polymorphism of C or T.
- the predetermined nucleic acid of interest is SNP_A-1512719 (TSC1720861) with the polymorphism of C or T.
- the predetermined nucleic acid of interest is SNP_A-1515330 (TSC1244733) with the polymorphism of C or T.
- the predetermined nucleic acid of interest is SNP_A-1518829 (TSC51583) with the polymorphism of A or G.
- the predetermined nucleic acid of interest is SNP_A-1518878 (TSC51584) with the polymorphism of C or G.
- the predetermined nucleic acid of interest is located within 30 kbp of SNP_A-1515737.
- the predetermined nucleic acid of interest is D12S1503 (SEQ. ID. NO. 5). In another embodiment, the predetermined nucleic acid of interest is D12S1676 (SEQ. ID. NO. 6). In another embodiment, the predetermined nucleic acid of interest is D12S335 (SEQ. ID. NO. 7). In another embodiment, the predetermined nucleic acid of interest is D12S102 (SEQ. ID. NO. 8).
- the predetermined nucleic acid of interest is SNP_A-1508498 with a polymorphism of C or T. (SEQ. ID. NO. 9 and 10). In another embodiment, the predetermined nucleic acid of interest is SNP_A-1512645 with a polymorphism of C or T. (SEQ. ID. NO. 11 or 12). In another embodiment, the predetermined nucleic acid of interest is SNP_A-1512719 with a polymorphism of C or T. (SEQ. ID. NO. 13 or 14). In another embodiment, the predetermined nucleic acid of interest is SNP_A-1515330 with a polymorphism of C or T. (SEQ. ID. NO. 15 or 16).
- the predetermined nucleic acid of interest is SNP_A-1518829 with a polymorphism of A or G. (SEQ. ID. NO. 17 or 18). In another embodiment, the predetermined nucleic acid of interest is SNP_A-1518878 with a polymorphism of C or G. (SEQ. ID. NO. 19 or 20).
- the predetermined nucleic acid of interest may also be any marker or gene between 63.3 mbp and 69.4 mbp on human chromosome 12. See, e.g., FIG. 15 .
- the practitioner uses visual confirmation of the presence or absence of particular variants of the nucleic acid.
- the method provides a computer based system with one or more algorithms to determine the presence and/or absence of one or more predetermined nucleic acids of interest and, if present, quantifies the amount of one or more predetermined nucleic acids of interest present in the individual's nucleic acid.
- the predetermined nucleic acids of interest are one or more SNPs.
- the computer based system may comprise information about observed SNP alleles, alternative codons, populations, allele frequencies, SNP types, and/or affected proteins and the like.
- the computer based system includes at least one of the following: hardware means, software means, and data storage means used to analyze any information of the present invention.
- the minimum hardware means of the computer-based systems of the present invention typically comprises a central processing unit (CPU), input means, output means, and data storage means.
- CPU central processing unit
- input means input means
- output means output means
- data storage means data storage means.
- the computer-based systems of the present invention comprise a data storage means having stored therein information and the necessary hardware means and software means for supporting and implementing a search means.
- the search means of the computer-based system includes one or more software programs or algorithms that are implemented on the computer-based system to identify or analyze nucleic acid sequences, including SNPs in a target sequence, based on nucleic acid information stored within the data storage means. Search means can be used to determine the presence or absence of a nucleic acid sequence, and/or which nucleotide is present at a particular SNP position in a nucleic acid sequence.
- the practitioner may provide the computer-based system with information regarding nucleic acids of interests on a computer readable medium.
- Computer readable medium is any medium that can be read and accessed directly by a computer, including but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media.
- a variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon a nucleotide or amino acid sequence of the present invention.
- the choice of the data storage structure will generally be based on the means chosen to access the stored information.
- a variety of data processor programs and formats can be used to store the nucleic acid sequence information of the present invention on computer readable medium.
- the sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, represented in the form of an ASCII file, or stored in a database application, such as OB2, Sybase, Oracle, or the like.
- a skilled artisan can readily adapt any number of data processor structuring formats (e.g., text file or database) in order to obtain computer readable medium having recorded thereon the nucleic acid sequence information of the present invention.
- nucleic acid sequences including SNPs
- computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium. Examples of publicly available computer software include BLAST and BLAZE search algorithms.
- the present invention further provides systems, particularly computer-based systems, which contain the nucleic acid sequence information described herein.
- Such systems may be designed to store and/or analyze information on, for example, a large number of SNP positions, or information on genotypes, including SNP genotypes, from a large number of individuals.
- the nucleic acid sequence information of the present invention represents a valuable information source.
- the nucleic acid sequence information of the present invention stored/analyzed in a computer-based system may be used for such computer-intensive applications as determining or analyzing nucleic acid allele frequencies in a population, mapping disease genes, genotype-phenotype association studies, grouping SNPs into haplotypes, correlating SNP haplotypes with response to particular drugs, or for various other bioinformatic, pharmacogenomic, drug development, or human identification/forensic applications.
- a treatment for the individual is then formulated based on the presence and/or absence of one or more predetermined nucleic acids of interest ( 206 ).
- the treatment may include anything within the means of the practitioner, including a determination of likelihood of inducing immune tolerance can be induced, if so then the type of antigen, dose, method of administration, regimen of treatment, and the like.
- NSAIDS non-steroidal anti-inflammatory drugs
- the practitioner can modulate the creation of immune tolerance by either having the individual desiring treatment stop using NSAIDS or administering pharmaceuticals to reverse the NSAID inhibition of immune tolerance, such as, for example, misoprostol.
- the methods of the instant invention may be used to treat idiopathic pulmonary fibrosis (“IPF”).
- IPF is a lethal, chronic, progressive, interstitial lung disease in which normal lung tissue is gradually replaced by fibrotic tissue, or an abnormal and excessive amount of fibrotic tissue is deposited in the pulmonary interstitium. This may be described as a scarring of the lung.
- About 60% of IPF patients have an antigen-specific autoimmune reaction to Type V collagen. Without wishing to be bound to a particular mechanism or theory, it is believed that the immune systems of such patients attack the Type V collagen of the lungs, thereby causing fibrosis.
- IPF patients having an autoimmune reaction to Type V collagen would benefit if the immune response attacking the Type V collagen of the lungs could be halted or lessened.
- This immune response could be halted or lessened by induction of immune tolerance to Type V collagen using the methods of the present invention.
- Tolerance could be induced by repeated administration of collagen antigens, preferably Type V collagen antigens, according to the methods of the present invention.
- collagen or collagen antigens preferably Type V collagen or antigens thereof
- a test for identifying such patients is desirable.
- an association study may be performed to determine whether IPF patients having an antigen-specific autoimmune reaction to Type V collagen carry one or more SNPs—or other nucleic acid sequences linked in some manner to the SNPs—that is not found in IPF patients who do not have an antigen-specific autoimmune reaction to Type V collagen.
- the presence of the one or more SNPs or linked nucleic acid sequences associated with an antigen-specific autoimmune reaction to Type V collagen can then be used to identify patients most likely to benefit from administration of collagen or collagen antigens, preferably Type V collagen or antigens thereof.
- Autoimmune reactions to Type V collagen are also believed to contribute to rejection of lung transplants. Accordingly, SNP(s) and/or linked nucleic acid sequences found to be associated with an antigen-specific autoimmune reaction to Type V collagen may also be used to assess a patient's propensity to successfully undergo lung or other transplants.
- the invention may also be used by the practitioner to determine the regimen of treatment for the individual. That is, based on individual-specific information, the invention may recommend to the practitioner treatment regimens, such as whether to induce immune tolerance, type of antigen, dose, method of administration, regimen of treatment, and the like.
- the recommendation of treatment regimens may not only be a function of the disease or disorder the individual has, but also a function of the individual characteristics.
- the individual characteristics are first placed into one or more databases ( 301 ).
- the individual characteristic information may be received by any means, including using an integrated consultation process with one or more practitioners, a questionnaire filled out by the individual, an electronic database, a diagnostic or an expert panel measurement tool, client summary report, and an outcomes measurement report. Further, the individual characteristic information may be received by one or more of a network, oral communication, visual communication, written communication, physical data carrier, and/or any other means capable of conveying information.
- Individual characteristics may include, but are not limited to, age, sex, height, weight, individual medical history, family medical history, ethnicity, allergy information, lifestyle information, and the like.
- the individual's nucleic acids are then collected and analyzed ( 302 ).
- the method of collecting the individual nucleic acid may be any contemplated by the practitioner, including those mentioned within the instant specification.
- the presence or absence of one or more predetermined nucleic acids of interest is then determined ( 303 ).
- the determination which nucleic acids would be examined, i.e., the predetermined nucleic acids of interest may be determined either individually by the practitioner.
- the determination includes accessing a database containing information reflecting the relationship between the current disease or diagnosis of the individual, or what the practitioner believes the current disease or diagnosis to be, and the nucleic acids of interest associated with the disease or diagnosis.
- the one or more databases of the current invention are local to the practitioner's location. In other embodiments, the one or more databases are remote, dynamic databases.
- a dynamic database is one in which the data within may be easily changed or updated. For instance, one can use a software system to access information from a dynamic database via a network and upload information from the database to the software system. If the information stored in the database changes, the software system connected to the database will also change accordingly and automatically without human intervention. The software system may update the individual's information in the dynamic database on any time bases, including, but not limited to, an event driven, minute-by-minute, hourly, daily or weekly basis.
- the treatment of the individual may be determined.
- the practitioner relies upon his expertise in the medical field to determine the treatment regimen.
- a software system stored in one or more databases recommends a treatment regimen.
- the recommended treatment regimen may include, but is not limited to, whether to induce immune tolerance, type of antigen, dose, method of administration, regimen of treatment, over the counter or prescription medication, lifestyle changes, and the like.
- the recommendation of treatment regimens may not only be a function of the disease or disorder the individual has, but also a function of the individual characteristics.
- the one or more databases may allow a software system to input more information about the individual, the disease or disorder to be treated, the outcome of the treatment, and other compatible information. It is contemplated that the information for multiple individuals may be pooled together, thus as the amount of data for one or more parameters increases, the algorithm in the software system becomes more robust and accurate at calculating what treatment/procedure best suits the individual's set of criteria.
- the database may further include a warehouse of “Best Practices,” that is, specific treatment protocols judged optimal by a panel of medical experts.
- the determination of which nucleic acids are the predetermined nucleic acids of interest may be determined by the method of FIG. 4 .
- information on multiple individuals with a disease or disorder is collected and saved in one or more databases ( 401 ).
- the information includes at least the disease or disorder of the individuals, the ability of the individual to develop immune tolerance after administration of antigens, and the nucleic acid information of the individual.
- the nucleic acid information is the presence or absence of one or more SNPs.
- the presence of absence of one or more SNPs and the ability of the individual to develop immune tolerance is compared to determine the increased (or decreased) occurrence of the nucleic acid in a specific disease or disorder condition ( 402 ).
- the comparison of the SNPs and ability to develop immune tolerance may be accomplished by using a mathematical algorithm.
- the region around the SNP can optionally be thoroughly screened to identify the causative genetic locus/sequence(s) (e.g., causative SNP/mutation, gene, regulatory, region, etc.) that influences the ability to induce immune tolerance.
- the causative genetic locus/sequence(s) e.g., causative SNP/mutation, gene, regulatory, region, etc.
- an association study of a SNP and a specific disease or disorder may be performed, to determine the presence or frequency of the SNP allele in biological samples from individuals with the disorder or disease of interest and comparing the information to that of controls (i.e., individuals who do not have the disorder; controls may be also referred to as “healthy” or “normal” individuals) who are preferably of similar age and race.
- controls i.e., individuals who do not have the disorder; controls may be also referred to as “healthy” or “normal” individuals
- the patients and controls should be as alike as possible in physical characteristics, and a pool of individuals with well-characterized phenotypes is extremely desirable.
- association studies may also be conducted within the general population and are not limited to studies performed on related individuals in affected families (linkage studies).
- the information on the one or more SNPs is then stored in one or more databases, along with information regarding its presence or absence in individuals with the ability to induce immune tolerance ( 403 ).
- the nucleic acid of individuals who desire treatment for a disease or disorder is then collected and analyzed to find if the individual has the one or more SNPs that are statistically significant associated with the ability of other individuals to induce immune tolerance ( 404 ).
- the medical practitioner alone, or with the assistance of a software system comprising one or more databases, may then determine what medical regimens are feasible, and the parameters of those medical treatments.
- a method is first used to determining polypeptides that are present or absent in an individual who is susceptible to immune tolerance development, comprising screening for at least one polypeptide, as show in FIG. 5 .
- the medical practitioner first administers an oral antigen to a patient to induce immune tolerance ( 501 ).
- Antigens suitable for use in the present invention include those previously discussed, and may include any associated with or responsible for the induction of auto-immune diseases, clinical (allergic) hypersensitivities, and allograft rejection, and subunits or extracts therefrom; or recombinantly generated whole proteins, subunits or fragments thereof; or any combination thereof.
- the antigen may include, but is not limited to, all of the antigens of Table 1, to treat the associated diseases.
- the antigen may further be combined with other components such as a pharmaceutically acceptable excipient and/or a carrier, prior to administration to the individual.
- the individual dose size, number of doses, frequency of dose administration, and mode of administration may vary be determined by those skilled in the art. Suitable doses of antigen are those previously discussed. Further, the modes of administration can include, but are not limited to, aerosolized, subcutaneous, rectally, intradermal, intravenous, nasal, oral, transdermal and intramuscular routes.
- a biological sample is taken from the individual for use in determining the individual's immune response ( 502 ), whereby the individual immune system response to the antigen is scored based upon their response ( 503 ).
- the method to determine the individual immune response may include any method previously discussed, including but not limited to, use of an enzyme-linked immunoabsorbent assay (ELISA), ELISA/ACT® Lymphocyte Response Assay (LRA), in vitro measurement of antibody production, mixed leukocyte reaction, cytotoxic T lymphocyte assay, flow cytometry, Western blots, limiting dilution assay, mass spectroscopy, immunoprecipitation, immunofluorescence, ELISPOT, transvivo DTH assay, tetramer assay, CFSE assay, characterization of the TCR repertoire, measuring T cell responses to polyclonal, non-antigen-specific stimulation, detection of the presence of nucleic acids including PCR, LCR, hybridization techniques and proteomics.
- ELISA enzyme-linked immunoabsorbent assay
- LRA Lymphocyte Response Assay
- in vitro measurement of antibody production mixed leukocyte reaction
- cytotoxic T lymphocyte assay cytotoxic T lymphocyte assay
- flow cytometry Western
- the patients are scored based upon the respective levels and/or changes of cytokine production, including IL-17, IL-2 or IFN- ⁇ production before, during and/or after receiving the antigen.
- levels of T regulatory cells such as Trl cells or CD4 + , CD25 + , FoxP3 + , cells can be used to score patient response.
- other cytokines may be measured to determine individual scores. For instance, levels of IL-10, IL-4, IL-5 or TGF- ⁇ 1, 2 or 3 in ⁇ 1(I)- and ⁇ 2(I)-stimulated PBMC culture supernatants and/or sIL-2R may be used to score a patient.
- the method of scoring is dependent upon the practitioner, and includes any methods that separate patients based upon their immune response to the antigen.
- the practitioner may measure compare the immune response before, during and/or after receiving the antigen. The determination of when the immune response is measured, and what method is used, is based upon the practitioner needs. Further, it is contemplated that the practitioner may further take into consideration other physiological factors of the individual, such as other cytokines, oxidative radicals, connective tissue growth factor, nitric oxide, patient height, weight, health, diet, and environmental considerations to assist in scoring the patient's immune response.
- the practitioner will analyze the polypeptides of the individuals to determine whether an individual has one or more polypeptides or variant polypeptides ( 504 ).
- the practitioner may either examine specific known polypeptides of interest or examine part or whole of the proteins present in the sample to look for the presence or absence of differential or unique polypeptides or polypeptide patterns, and correlate the polypeptides presence/absence with the individual's immune response score.
- Polypeptides may be detected by various methods known to one skilled in the art. Before polypeptide detection, the polypeptides within the individual's biological sample may be purified to substantial purity by standard techniques, including but not limited to, selective precipitation with such substances as ammonium sulfate, cold ethanol precipitation, ultrafiltration, column chromatography, immunopurification methods, and the like.
- the polypeptides may be detected by use of any method convenient to the practitioner, including, but not limited to sandwich assays and competition or displacement assays.
- a sandwich or competition/displacement assays includes a “capture agent” that specifically bind to and often immobilize the analyte (in this case one or more polypeptides in the sample).
- the capture agent is a moiety that specifically binds to the analyte.
- a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means.
- useful labels in the present invention include magnetic beads, fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g., 3 H, 125 I, 35 S, 14 C, or 32 P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads.
- fluorescent dyes e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like
- radiolabels e.g., 3 H, 125 I, 35 S, 14 C, or 32 P
- enzymes e.g., horse
- the label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art.
- the antibody may be produced by any of a number of means well known to those of skill in the art and as described above.
- the label may be on a third moiety that binds to the capture agent/analyte complex, or secondarily binds to a moiety distinct for the capture agent/analyte complex.
- polypeptide detection and/or quantify the polypeptide includes western blot (immunoblot) analysis, liposome immunoassays (LIA), proteomics such as protein microarrays or mass spectrometry.
- western blot immunoblot
- LIA liposome immunoassays
- proteomics such as protein microarrays or mass spectrometry.
- the amino acid sequence of the polypeptides of interest found in the individual's sample may be determined, and compared to one or more databases containing polypeptides amino acid sequences that are statistically significant associated with the ability of other individuals to induce immune tolerance ( 404 ).
- the medical practitioner alone, or with the assistance of a software system comprising one or more databases, may then determine what medical regimens are feasible, and the parameters of those medical treatments.
- the disease or disorder may be linked to race, ethnicity, or sex.
- women comprise 78% of diagnosed autoimmune diseases.
- systemic sclerosis has a sex and race specific prevalence, where women are more likely than men to have the disorder, and African Americans are more likely then Caucasians to have the disorder.
- the presence or absence of the nucleic acid of interest may be tied to a hormone, the X chromosome, or to enzymes, receptors, or other compounds that have different levels between the sexes and or races.
- detection reagents can be developed and used to assay any SNP of the present invention individually or in combination, and such detection reagents can be readily incorporated into one of the established kit or system formats which are well known in the art.
- Kits used in the context of SNP detection reagents are intended to refer to such things as combinations of multiple SNP detection reagents, or one or more SNP detection reagents in combination with one or more other types of elements or components (e.g., other types of biochemical reagents, containers, packages such as packaging intended for commercial sale, substrates to which SNP detection reagents are attached, electronic hardware components, etc.).
- kits and systems including but not limited to, packaged probe and primer sets (e.g., TaqMan probe/primer sets), arrays/microarrays of nucleic acid molecules, and beads that contain one or more probes, primers, or other detection reagents for detecting one or more SNPs of the present invention.
- packaged probe and primer sets e.g., TaqMan probe/primer sets
- arrays/microarrays of nucleic acid molecules e.g., aqMan probe/primer sets
- beads that contain one or more probes, primers, or other detection reagents for detecting one or more SNPs of the present invention.
- the kits/systems can optionally include various electronic hardware components; for example, arrays (“DNA chips”) and microfluidic systems (“lab-on-a-chip” systems) provided by various manufacturers typically comprise hardware components.
- kits/systems may not include electronic hardware components, but may be comprised of, for example, one or more SNP detection reagents (along with, optionally, other biochemical reagents) packaged in one or more containers.
- a SNP detection kit typically contains one or more detection reagents and other components (e.g., a buffer, enzymes such as DNA polymerases or ligases, chain extension nucleotides such as deoxynucleotide triphosphates, and in the case of Sanger-type DNA sequencing reactions, chain terminating nucleotides, positive control sequences, negative control sequences, and the like) necessary to carry out an assay or reaction, such as amplification and/or detection of a SNP-containing nucleic acid molecule.
- detection reagents e.g., a buffer, enzymes such as DNA polymerases or ligases, chain extension nucleotides such as deoxynucleotide triphosphates, and in the case of Sanger-type DNA sequencing reactions, chain terminating nucleotides, positive control sequences, negative control sequences, and the like
- kits may further contain means for determining the amount of a target nucleic acid, and means for comparing the amount with a standard, and can comprise instructions for using the kit to detect the SNP-containing nucleic acid molecule of interest.
- kits are provided which contain the necessary reagents to carry out one or more assays to detect one or more SNPs disclosed herein.
- SNP detection kits/systems are in the form of nucleic acid arrays, or compartmentalized kits, including microfluidic/lab-on-a-chip systems.
- SNP detection kits/systems may contain, for example, one or more probes, or pairs of probes, that hybridize to a nucleic acid molecule at or near each target SNP position. Multiple pairs of allele-specific probes may be included in the kit/system to simultaneously assay large numbers of SNPs, at least one of which is a SNP of the present invention.
- the allele-specific probes are immobilized to a substrate such as an array or bead.
- the same substrate can comprise allele-specific probes for detecting at least 1; 10; 100; 1000; 10,000; 100,000 (or any other number in-between) or substantially all of the SNPs shown in Table 1 and/or Table 2.
- arrays are used herein interchangeably to refer to an array of distinct polynucleotides affixed to a substrate, such as glass, plastic, paper, nylon or other type of membrane, filter, chip, or any other suitable solid support.
- the polynucleotides can be synthesized directly on the substrate, or synthesized separate from the substrate and then affixed to the substrate.
- a microarray can be composed of a large number of unique, single-stranded polynucleotides, usually either synthetic antisense polynucleotides or fragments of cDNAs, fixed to a solid support.
- Hybridization assays based on polynucleotide arrays rely on the differences in hybridization stability of the probes to perfectly matched and mismatched target sequence variants.
- stringency conditions used in hybridization assays are high enough such that nucleic acid molecules that differ from one another at as little as a single SNP position can be differentiated (e.g., typical SNP hybridization assays are designed so that hybridization will occur only if one particular nucleotide is present at a SNP position, but will not occur if an alternative nucleotide is present at that SNP position).
- Such high stringency conditions may be preferable when using, for example, nucleic acid arrays of allele-specific probes for SNP detection.
- the arrays are used in conjunction with chemiluminescent detection technology.
- a SNP detection kit/system of the present invention may include components that are used to prepare nucleic acids from a test sample for the subsequent amplification and/or detection of a SNP-containing nucleic acid molecule.
- sample preparation components can be used to produce nucleic acid extracts (including DNA and/or RNA), proteins or membrane extracts from any bodily fluids (such as blood, serum, plasma, urine, saliva, phlegm, gastric juices, semen, tears, sweat, etc.), skin, hair, cells (especially nucleated cells), biopsies, buccal swabs or tissue specimens.
- test samples used in the above-described methods will vary based on such factors as the assay format, nature of the detection method, and the specific tissues, cells or extracts used as the test sample to be assayed.
- Methods of preparing nucleic acids, proteins, and cell extracts are well known in the art and can be readily adapted to obtain a sample that is compatible with the system utilized.
- kits contemplated by the present invention are a compartmentalized kit.
- a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include, for example, small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allow one to efficiently transfer reagents from one compartment to another compartment such that the test samples and reagents are not cross-contaminated, or from one container to another vessel not included in the kit, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another or to another vessel.
- Such containers may include, for example, one or more containers which will accept the test sample, one or more containers which contain at least one probe or other SNP detection reagent for detecting one or more SNPs of the present invention, one or more containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and one or more containers which contain the reagents used to reveal the presence of the bound probe or other SNP detection reagents.
- wash reagents such as phosphate buffered saline, Tris-buffers, etc.
- the kit can optionally further comprise compartments and/or reagents for, for example, nucleic acid amplification or other enzymatic reactions such as primer extension reactions, hybridization, ligation, electrophoresis (preferably capillary electrophoresis), mass spectrometry, and/or laser-induced fluorescent detection.
- nucleic acid amplification or other enzymatic reactions such as primer extension reactions, hybridization, ligation, electrophoresis (preferably capillary electrophoresis), mass spectrometry, and/or laser-induced fluorescent detection.
- Microfluidic devices which may also be referred to as “lab-on-a-chip” systems, biomedical micro-electro-mechanical systems (bioMEMs), or multicomponent integrated systems, are exemplary kits/systems of the present invention for analyzing SNPs.
- Such systems miniaturize and compartmentalize processes such as probe/target hybridization, nucleic acid amplification, and capillary electrophoresis reactions in a single functional device.
- Such microfluidic devices typically utilize detection reagents in at least one aspect of the system, and such detection reagents may be used to detect one or more SNPs of the present invention.
- kits may also include one or more antigens, as described above.
- the medical professional may first determine if a SNP is present or absent from the patient. Then, the medical professional prepares a regimen, or uses instead a predetermined regimen, to find which antigen, in what dose, by what method of administration, to give the patient.
- the one or more antigens may be sold with, or sold separate from, the kit.
- PCR can be preformed on samples where the replicon contains these SNPs or where the replicon is closely linked to them on the genome.
- Such technology can provide a rapid assay to determine the likelihood of the ability to induce tolerance in a specific individual.
- PBMC peripheral blood mononuclear cells
- I IFN ⁇ ⁇ ⁇ ⁇ ⁇ 1 ⁇ ⁇ ( II ) - IFN ⁇ ⁇ PBS IFN ⁇ ⁇ PBS
- mice were fed oral CII at the doses indicated 8 times over 2 weeks and immunized with 100 ⁇ g bovine CII in CFA. After 4 days rest, the mice were then immunized at the base of the tail with 100 ⁇ g CII emulsified with complete Freund's adjuvant. The degree of arthritis was assessed by a blinded observer for 8 weeks.
- 10 ⁇ g/day oral dose of CII was most effective in reducing the incidence of arthritis with 500 ⁇ g/day being also, but less, effective.
- the percent of mice with grade 3 or 4 arthritis is indicated on the Y-axis.
- the biphasis response is due to induction of different tolerance mechanisms by low dose vs high dose CII.
- Low dose CII (10 ⁇ g) induces regulatory T cells while high dose (500 ⁇ g) induces anergy or clonal deletion.
- mice After 1 week, all mice were immunized (intradermally at the base of tail) with 100 ⁇ g of bovine CII emulsified in complete Freund's adjuvant. Animals were placed in coded cages and were scored by a blinded observer twice weekly for the number of arthritic joints (joints swollen, red, and/or deformed).
- mice were gavaged 8 days over 2 weeks with the following: Piroxicam a.m. —CII p.m.; Piroxicam a.m. —HAc p.m.; Saline a.m. —CII p.m.; or Saline a.m. HAc p.m. After 1 week rest, all mice were immunized at the base of the tail with a CII—complete Freund's adjuvant emulsion.
- mice were sacrificed, and spleen cells were isolated and set up in culture with PBS or ⁇ 1(II)CB peptide mixture. After 72 h culture, harvested supernatants were analyzed for IFN ⁇ levels by ELISA.
- mice fed CII+Placebo or piroxicam+Placebo had reduced production of IFN ⁇ when their spleen cells were cultured in vitro with ⁇ 1(II) CB peptide mixture. See, FIG. 8 .
- piroxicam was orally fed to mice being fed oral CII, however, there was a dramatic increase in the level of IFN ⁇ production by spleen cells stimulated in vitro with ⁇ 1(II)CB peptide mixture.
- the COX-2 inhibitor SC236 also blocked oral tolerance induction to CII in DBA/1 mice as assessed by IFN ⁇ production by spleen cells (data not shown).
- mice Groups of 8 mice each were gavaged on MTTHF ⁇ 2 weeks in the a.m. with PBS or SC′236 (5 ⁇ g/gm in 100 ⁇ l PBS).
- SC′236 (Searle) is ⁇ 2000 ⁇ more inhibitory for COX-2 than for COX-1.
- mice given PBS in the a.m. and 4 mice given SC′236 in the a.m. were gavaged in the p.m. with 10 ⁇ g bovine type II collagen (CII).
- the other 4 mice in the a.m. PBS and a.m. SC′236 group were gavaged in the p.m. with 0.1M acetic acid (HAc) the vehicle the CII was dissolved in.
- HAc acetic acid
- mice After 10 days, all mice were sacrificed, and spleen cells (2 ⁇ 10 6 /ml) were isolated and set up in culture with PBS and bovine ⁇ 1(II) (50 ⁇ g/ml) CB mixture. After 4 days culture, the supernatants were harvested and IFN ⁇ levels determined by ELISA (Endogen). Since the PBS+spleen cell culture from all mice produced between 1-12 pg/ml IFN ⁇ , only the ⁇ 1(II) data are plotted. All groups were compared to Placebo control group by Student's 2 sample t test.
- feeding CII to DBA/1 mice induced oral tolerance manifested by a significant reduction in IFN ⁇ production by spleen cells stimulated by ⁇ 1(II) CB digest (p ⁇ 0.025).
- feeding SC′236 to the mice resulted in lower IFN ⁇ production by ⁇ 1(II) CB digest, but when mice were fed SC′236+CII there was a significant increase (p ⁇ 0.01) in IFN ⁇ production by spleen cells cultured with ⁇ 1(II) CB digest.
- SC′236 may also inhibit COX-1, but to a degree ⁇ 2000 ⁇ less than it inhibits COX-2, these data suggest that COX-2 may be essential for optimal tolerance induction to low dose oral antigen.
- each mouse was immunized (intradermally at base of tail) with 100 ⁇ g native bovine CII emulsified in complete Freund's adjuvant. Mice were placed in coded cages and scored twice weekly by a blinded observer for numbers of arthritic joints. As shown in FIG. 10 , at week 7 and 8, after immunization with CII, the group of mice that 9 and 3 months before were fed piroxicam plus CII had significantly more arthritic joints (p ⁇ 0.04 at 8 weeks by chi square analysis) compared to the group of mice that were fed Placebo plus CII.
- Peyer's patch cells were isolated from each animal, and set up (2.5 ⁇ 10 5 /ml) in quadruplicate in co-culture with normal DBA/1 spleen cells (2 ⁇ 10 6 /ml) with addition of recombinant murine IL2 (10 U/ml).
- PBS as a control
- 50 ⁇ g/ml bovine ⁇ 1(II) CB peptide mixture were added to quadruplicate wells in 96 round bottom well plates. After 3 days, cultures were pulsed with 3 H thymidine and harvested onto paper filters 24 h later.
- the “stimulation index” was calculated for each mouse by dividing the cpm of ⁇ 1(II) CB peptide mixture culture by the cpm of the PBS control culture for each mouse. As shown in FIG. 11 , compared to the co-culture of Peyer's patch cells from mice fed CII alone or piroxicam alone, there was marked stimulation by the ⁇ 1(II) CB peptide mixture (p ⁇ 0.03) of cells from mice fed piroxicam plus CII.
- Peyer's patch cells (2.5 ⁇ 10 5 /ml) from DBA/1 mice or Balb/c mice in co-culture with normal syngeneic spleen cells (2 ⁇ 10 6 /ml) when stimulated with murine IL-2 results in no stimulation of the spleen cells over background cpm.
- the marked increase in the stimulation index of Peyer's patch cells with DBA/1 spleen cells in the presence of ⁇ 1(II) CB peptide mixture is quite exceptional and unexpected.
- the culture of mesenteric lymph node cells (2 ⁇ 10 6 /ml) from each mouse with the ⁇ 1(II) CB peptide mixture revealed a similar pattern ( FIG. 12 ).
- mice fed either CII or piroxicam did not proliferate in response to the ⁇ 1(II) CB peptide mixture.
- ⁇ 1(II) CB peptide mixture of mesenteric lymph node cells from mice fed piroxican plus CII FIG. 12 .
- Example 9 Administration of Oral Collagen II Reduces Autoimmunity in Patients with RA
- Immunological tolerance defined as a ⁇ 30% reduction in IFN- ⁇ production by PBMC cultured with ⁇ 1(II) of type II collagen, was examined in patients.
- Heparinized blood was obtained at baseline and after each of the 10 week treatment periods.
- the blood was diluted 1:3 with RPMI 1640 containing penicillin (100 u/ml) and streptomycin (100 ⁇ g/ml) within 1-4 hours after collection, wrapped in paper, and placed in a Styrofoam box containing a “cold pack” and shipped overnight.
- the PBMC were isolated from the blood samples and set up in culture with bovine ⁇ 1(II) 25 ⁇ g/ml, PHA 10 ⁇ g/ml or with 50 ul PBS.
- the IFN ⁇ stimulation index (SI) was calculated as
- the SI for patients receiving each of the low doses (30 ⁇ g, 50 ⁇ g and 70 ⁇ g/day) was compared with their SI at baseline before each of the 10 week treatments and similarly with the high dose CII group (90 ⁇ g, 110 ⁇ g and 130 ⁇ g/day) with their SI at baseline before each of the 10 week treatments.
- CII defined as a reduced immune response to fed antigen
- the dose response showed maximal suppression of IFN ⁇ production at 30 ⁇ g, 50 ⁇ g and 110 ⁇ g/day of oral CII.
- Example 10 Oral CII Tolerance is Associated with Response and No Response
- Blood was obtained from the patients before administering bovine CII orally to RA patients who produced ⁇ 2 ⁇ increase in IFN ⁇ by ⁇ 1(II) stimulated compared to PBS control PBMC cultures.
- the IFN ⁇ PHA S.I.s at baseline were not different between the CII oral tolerance responders and non-responders.
- Example 11 The Microarray Assessment Produced Accurate Data for Analysis of Genotypes of RA Patients
- SNP analysis was performed of 16 responders and 8 non-responders to oral CII to find the frequency of SNPs closely associated on chromosomes next to several cytokines and chemokines known to be important for oral tolerance induction.
- the 16 patients were those with had ⁇ 50% reduction in IFN ⁇ al stimulation index from baseline to either the 30 ⁇ g/day, 50 ⁇ g/day, 110 ⁇ g/day or 130 ⁇ g/day dose of CII (“OT Responders”).
- the 8 patients with increases in IFN ⁇ ⁇ 1S.I. at the 30 ⁇ g/day, 50 ⁇ g/day, 110 ⁇ g/day or 130 ⁇ g/day doses of oral CII were selected (“OT Non-Responders”).
- the 10K 2.0 Array contains genotypes greater than 10,000 human single nucleotide polymorphisms (SNPs) on a single array.
- SNPs single nucleotide polymorphisms
- the tool may be used to identify regions of the genome that are linked to or associated with, a particular trait or phenotype, in our case, the CII oral tolerance resistance.
- the protocol included four major procedures: in silico fractionation, synthesis of predicted fragments on microarrays, biochemical fractionation, and Allele specific hybridization and Genotype Calling. Two different signals that represent each of two polymorphisms of 10,000 single nucleotides were produced. The software creates the polymorphism or genotype of every of 10,000 single nucleotides. The genotype of polymorphism of each of 10,000 SNPs of every sample was called into three types, homozygous type I, AA; homozygous type II, BB; and heterozygous, AB, as indicated in table III.
- Table III is the genotyping of 15 patients (9 males, 6 females). The detectable single of SNPs in most samples was over than 99%, indicating a high quality of detection. The SNP call indicates that the percentage among 10,000 of SNPs that could be recognized and for which data were given. More than 90% of SNPs in those samples was detected by the experiment. The distribution of three genotypes, the AA, AB, and BB was about one third (33%) for each of them.
- the genotype of the patients of Example 3 was sorted into oral CII responders and non-responder groups. For each group, the total number of three genotypes, AA, AB, and BB was calculated for each SNP on the chip. Table IV shows the genotype ratio of SNP in each of those candidate genes.
- the most genotypic patterns between responder and non-responders are the same or similar.
- the patterns of the first SNP of Glutamic Acid decarboxylse is 14-0-0 (for AA-AB-BB) and 10-0-0; the second SNP is 2-8-4 and 1-6-3.
- genotype distribution of the SNP_A-1515737 between response and non-response groups being 1-9-6 and 6-1-1 respectively for responders and non-responders. While most of response patients have genotype either heterozygous (thus, the AG) or homozygous of BB (Thus the GG genotype), the majority of patients in non-response group had a AA genotype. Further analysis focused on the SNP_A-1515737.
- SNP_A-1515737 is as the following: TTTTTTTTTTGTACCTRGTTCTATGGTTACCTT (SEQ ID NO: 21).
- the R represents the polymorphic site that can be either A (resulting in SEQ ID NO. 1) or G (resulting in SEQ ID NO. 2).
- AA represents AA homozygous
- AB represents A/G heterozygous
- BB represents GG genotype
- a ⁇ G represents the polymorphism site.
- Example 13 Distribution of SNP_A-1515737 Among CII Oral Tolerance Responder and Non-Responder Patient
- Genotype patterns of responders and non-responders were compared and a significant difference in the genotype distribution found. See, FIG. 14 .
- a number was assigned to the three genotypes. The AA genotype was assigned 1, AB (thus, AG) was assigned 2, and the BB (Thus GG genotype) was assigned 3. According to those assumptions, the P values of SNP_A-1515737 reached 0.052.
- Table V and VI summarize the data based on the two groups.
- Table V lists the baseline IFN ⁇ levels in six day supernatants PBMC stimulated for six days with PHA, ⁇ 1(II), ⁇ 1(II) CB11 or no additions (PBS).
- Patients with SNP_A-1515737 AA had significantly lower IFN ⁇ ⁇ 1(II) S.I.
- Table VI the same patients were arranged and their IFN ⁇ ⁇ 1(II) S.I. at baseline and after oral CII administration (30 ⁇ g, 50 ⁇ g or 110 ⁇ g/day for 10 weeks) was compared.
- genotype patterns of other SNPs within close distance to A-1515737 was also examined. In addition to A-1515737, there are six other SNP within the same genome region. None of them has a significant association with the response or non-response to CII treatment. For example, SNP_A-1508498, which is 146068 bp at 5′ side of DYRK2 and 350588 bp at 3′ side: IFN ⁇ , is located very close to A-1515737, which is 265143 bp at 5′ side of DYRK2 and 231513 bp at 3′ side of IFN ⁇ . The genotype patterns of responders and non-responders are similar, with AA, AB, and BB of 8--5-1 and 8--2-0, respectively.
- HLA class II histocompatibility Eight SNPs relevant to the non-response histocompatibility complex (HLA class II histocompatibility) was examined but there was no evidence of an association of the segregating bands with the CII response.
- Example 15 SNP_A-1515737 and Linkage to Oral Tolerance Resistance in Other Autoimmune Diseases
- CI oral type I collagen
- SSc diffuse systemic sclerosis
- PBMCs were collected from the patients and cultured with native bovine CI and ⁇ 2(I) CB mixture and a trend toward defective production IL-10 PBMC cultured with ⁇ 1(I) CB mixture.
- Example 16 IL-10 Production After 12 Months of Oral CI and 12 Months for SScPatients With and Without ROT1 AA
- Patients with ROT1 AA, GG or GA genotype had IL-10 measured of IL-PBMC cultures stimulated by ⁇ 1(I) CB mixture, ⁇ 2(I) CB mixture, or native CI after receiving oral CI for 12 months minus the values of IL-10 in the supernatants of PBMC cultures stimulated with the same antigens at baseline before oral CI was administered to the SSc patients.
- SNP_A-1515737 (ROT1) genotype in patients and/or family members with Crohn's and/or ulcerative colitis and healthy controls with no IBD or other known autoimmune disease.
- Table X summarizes the genotype results in Crohn's diseases using DNA from buccal swabs, showing the ROT1 AA distribution was 91.67% for patients with Chron's Disease.
- ROT1AA is associated with oral tolerance resistance in Crohn's disease.
- the SSc patients with ROT1 AA exhibited less upregulation of IFN ⁇ production by ⁇ 1(I)-stimulated PBMC.
- 79 SSc patients were genotyped of the 168 enrolled in the clinical trial. Seven of the 23 ROT1AA genotype were in the Late Phase category, and deleted from the results.
- Reanalysis of the completers shows a significant difference in the change in MRSS at 12 months from baseline values in the CI treated patients when compared to the placebo treated patients using the Wilcoxon Rank Sum test (see FIG. 16 ).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
Abstract
This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy.
Description
- This application is a continuation of U.S. application Ser. No. 13/972,362, filed Aug. 21, 2013, which is a continuation of U.S. application Ser. No. 12/988,395, filed Oct. 18, 2010, which is a National Stage application of International Application No. PCT/US09/41134, filed Apr. 20, 2009, which claims the benefit of priority to U.S. Provisional Application No. 61/104,504, filed Oct. 10, 2008, U.S. Provisional Application No. 61/080,012, filed Jul. 11, 2008, and U.S. Provisional Application No. 61/071,264, filed Apr. 18, 2008, the contents of each of which is incorporated herein in its entirety.
- The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 6, 2012, is named 23848108.txt and is 6,211 bytes in size.
- The present invention is in the field of the immune system and therapy. In particular, the present invention relates to specific nucleic acid sequences in the human genome, and their association with diseases and pathologies as well as immune tolerance induction. Based on differences in allele frequencies in the patient population relative to normal individuals, the naturally-occurring nucleic acid sequences disclosed herein can be used as targets for the design of diagnostic reagents and the development of therapeutic agents, as well as for disease association and linkage analysis. In particular, the nucleic acid sequences of the present invention are useful for identifying an individual (e.g., patient) who is at an increased or decreased risk of developing a disease or pathology and for early detection of the disease or pathology, for providing clinically important information for the prevention and/or treatment of disease or pathology, and for screening and selecting therapeutic agents. Further, the presence or absence of one or more nucleic acid sequences may be used to determine the type and dose of antigen given to induce immune tolerance. One or more antigens may be administered to a patient having or not having a particular nucleic acid sequence, where the antigen may induce immune tolerance in a patient. The nucleic acid sequences disclosed herein are also useful for human identification applications. Methods, assays, kits, and reagents for detecting the presence of these polymorphisms and their encoded products are also provided. In addition, the invention addresses the use or absence of non-steroidal anti-inflammatory drugs in therapy.
- The genomes of all organisms undergo spontaneous mutation in the course of their continuing evolution, generating variant forms of progenitor genetic sequences. A variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form or may be neutral. In some instances, a variant form confers an evolutionary advantage to the species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form. Additionally, the effects of a variant form may be both beneficial and detrimental, depending on the circumstances. For example, a heterozygous sickle cell mutation confers resistance to malaria, but a homozygous sickle cell mutation is usually lethal. In many cases, both progenitor and variant forms survive and co-exist in a species population. The coexistence of multiple forms of a genetic sequence gives rise to genetic polymorphisms, including single nucleotide polymorphisms, otherwise known as “SNPs”. SNPs can also arise in areas of the genome with no apparent function, but the SNP can be genetically linked to a variant sequence in the genome. Thus, the SNP can closely correlate with the variant sequence of the genome, depending on how close the genetic linkage is.
- Approximately 90% of all polymorphisms in the human genome are SNPs. SNPs are single base positions in DNA at which different alleles, or alternative nucleotides, exist in a population. The SNP position (interchangeably referred to herein as SNP, SNP site, or SNP locus) is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations). An individual may be homozygous or heterozygous for an allele at each SNP position.
- Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Some believe the patient response is due to their genetic make-up, which results in having altered receptors, enzymes, or some change in cell physiology. Thus, the difference in genetic make-up results in a different response from others in the population. As such, researchers have expressed hope that the nucleic acid sequences of a patient can be used in pharmaceutical research to assist the drug development and selection process. To date, it is our belief that use of the nucleic acid sequence of a patient in pharmaceuticals has not been applied to immune tolerance.
- Immune or immunological tolerance is the process by which the immune system does not mount an immune response to an otherwise immunogenic antigen, or has its immune response redirected in a suppressive manner. Acquired or induced tolerance refers to the immune system's adaptation to external antigens characterized by a specific non-reactivity of the lymphoid tissues to a given antigen that in other circumstances would likely induce cell-mediated or humoral immunity. One of the most important natural kinds of acquired tolerance occurs during pregnancy, where the fetus and the placenta must be tolerated by the maternal immune system. There are numerous models for the induction of tolerance, including use of the eutherian fetoembryonic defense system and induction of tolerance primarily requires the participation of regulatory T cells.
- One specific type of immune tolerance, oral tolerance, is the specific suppression of cellular and/or humoral immune reactivity to an antigen by prior administration of the antigen by the oral route, probably evolved to prevent hypersensitivity reactions to food proteins and bacterial antigens present in the mucosal flora. It is of immense immunological importance, since it is a continuous natural immunologic event driven by exogenous antigen. Due to their privileged access to the internal milieu, antigens that continuously contact the mucosa represent a frontier between foreign and self components. Oral tolerance evolved to treat external agents that gain access to the body via a natural route as internal components without danger signals, which then become part of self. Failure of oral tolerance is attributed to the development and pathogenesis of several immunologically based diseases, including Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis). Other common forms of tolerance induction contemplated in this invention include internasel and IV tolerance induction.
- Today genomics is still not used to refine our medical management, despite the large quantities of research into the genome and SNPs. As such, there are few reliable wide-scale assays, kits and methods that examine an individual's genome to find inherited susceptibility, gene expression, and predicted pharmacogenomic response. More specifically, there is no use of genomics in the field of immune tolerance.
- The inventors are credited with providing methods, reagents, kits and assays that merge genomics with immune tolerance. As such, the inventors are able to detect nucleic acid sequences, and based on the presence and/or absence of nucleic acid sequences; tailor a method of care for the patient who desires induction of immune tolerance. In one specific embodiment, the nucleic acid sequences of interest are SNPs.
- The present invention relates to correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. This correlation may be used to assist with induction of immune tolerance. In some embodiments, the invention concerns tolerance induced by repeated administration of very large doses of antigen, or of small doses that are below the threshold required for stimulation of an immune response. In some embodiments, tolerance is most readily induced by soluble antigens administered either intravenously or sublingually. Furthermore, it's contemplated that immunosuppression also facilitates the induction of tolerance. Based on the correlation of the presence or absence of certain nucleic acid sequences associated with specific diseases or disorders, the present invention also provides for methods of detecting variants. In one specific embodiment, the nucleic acid sequences of interest are SNPs. In addition embodiments of the invention address the use or avoidance of non steroidal anti inflammatory drugs in therapy.
- The invention includes a method for screening for susceptibility to immune tolerance development, comprising screening for at least one SNP. The method of screening may include FISH, use of a DNA array, and/or hybridizing a polynucleotide probe.
- The invention includes a method for screening for susceptibility to immune tolerance development, including use of allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and/or single-stranded conformation polymorphism.
- The invention includes a method for screening for susceptibility to immune tolerance development, including correlating the presence or absence of the at least one SNP with ability of a host to develop immune tolerance as a result of administration of one or more antigens or therapeutic agents to the host. The antigen may be collagen, including collagen selected from the group types consisting of I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII and XXVIII.
- The invention includes a method for screening for susceptibility to immune tolerance development, including obtaining a sample from said host comprising nucleic acid; isolating nucleic acid from said sample; assaying said sample for the presence or absence of at least one SNP, wherein the presence or absence of the at least one SNP is indicative of an increased susceptibility to develop immune tolerance. The sample may be whole blood, blood plasma, urine, tears, semen, saliva, buccal mucosa, interstitial fluid, lymph fluid, meningeal fluid, amniotic fluid, glandular fluid, sputum, feces, perspiration, mucous, vaginal secretion, cerebrospinal fluid, hair, skin, fecal material, wound exudate, wound homogenate, and wound fluid. Further, the method may include induction of immune tolerance by administration of at least one antigen to the host, where the antigen can be a type of collagen.
- The immune tolerance may be to any autoimmune disease such as sclerotic disease like systemic sclerosis.
- The invention includes a method for screening for susceptibility to immune tolerance development, including use of one or more computer programs for use with at least one computer system, where computer program includes a plurality of instructions including at least one instruction for aiding in identification of the presence or absence of said at least one SNP; at least one instruction for associating the presence or absence of said at least one SNP with at least one disease state; and at least one instruction for correlating the presence or absence of said at least one SNP with a score indicating susceptibility of a host to develop immune tolerance. The computer may also generate a report including the results of the plurality of instruction, where the report may be transmitted over a network, on-line portal, by paper or e-mail in a secure or non-secure manner.
- The invention includes a method of administering at least one therapeutic agent, the method comprising genotyping one or more SNP(s) in the nucleic acid of a host, correlating the one or more SNP(s) with one or more diseases or disorders, using a mathematical algorithm to determine probability that said host will respond positively or negatively to administration of at least one therapeutic agent, and administrating or not administrating a therapeutic agent to the host based on the results of said mathematical algorithm.
- The invention includes a method for conducting a clinical trial in which one or more antigen(s) are evaluated, including genotyping one or more SNP(s) relating to one or more diseases or disorders; analyzing the genotyping results; determining a course of action based on the results of said genotyping, wherein said course of action comprises including individual in the clinical trial based on the results of said genotyping having indicated that said individuals are likely to respond to said one or more antigen(s), and/or excluding individuals from participating in the clinical trial based on the results of said genotyping having indicated that said individuals are not likely to respond to said one or more antigen(s).
- The invention includes a method for identifying an individual who has an altered risk for developing an autoimmune disease, comprising detecting a single nucleotide polymorphism (SNP) in SEQ ID NO: 1 in said individual's nucleic acids, wherein the presence of the SNP is correlated with an altered risk for autoimmune disease.
-
FIG. 1 illustrates a flow chart in accordance with some embodiments of the invention, demonstrating a process of determining if one or more nucleic acids is correlated with induction of immune tolerance. -
FIG. 2 illustrates a flow chart in accordance with some embodiments of the invention, demonstrating a process of determining an individual's treatment regimen by the presence of absence of one or more nucleic acids. -
FIG. 3 illustrates a flow chart in accordance with some embodiments of the invention, demonstrating a process of determining an individual's treatment regimen by the presence of absence of one or more nucleic acids. -
FIG. 4 illustrates a flow chart in accordance with some embodiments of the invention, demonstrating a process of determining an individual's treatment regimen by the presence of absence of one or more nucleic acids. -
FIG. 5 illustrates a flow chart in accordance with some embodiments of the invention, demonstrating a process of determining an individual's treatment regimen by the presence of absence of one or more polypeptides. -
FIG. 6 is a chart showing the percent of arthritic joints correlated with quantity of collagen II given by gavage to mice. -
FIG. 7 is a chart showing abrogation of certain forms of oral tolerance by piroxicam. -
FIG. 8 is a chart showing IFN-γ production by al (II) stimulated spleen cells. -
FIG. 9 is a chart showing COX-2 inhibitor SC′236 abrogates oral tolerance induction. -
FIG. 10 is a chart showing persistent abrogation of oral tolerance by piroxicam. -
FIG. 11 is a chart showing the effect of piroxicam or CII on Peyer's patch spleen co-culture. -
FIG. 12 is a chart showing the effect of piroxicam or CII on mesenteric lymph node cell proliferation -
FIG. 13 is a chart showing the effect of oral collagen II treatment of rheumatoid arthritis patients and how it modulates PBMC IFN production by PBMC. -
FIG. 14 is a chart the genotyping of persons with rheumatoid arthritis and their ability to induce immune tolerance. -
FIG. 15 is a chart showing the markers and genes contain potential SNPs of interest. -
FIG. 16 is a chart showing a significant reduction in MRSS at 12 months versus placebo patients. - In the following discussion certain articles and methods will be described for background and introductory purposes. Nothing contained herein is to be construed as an “admission” of prior art. Applicant expressly reserves the right to demonstrate, where appropriate, that the articles and methods referenced herein do not constitute prior art under the applicable statutory provisions. To assist in describing the invention, the following definitions are provided.
- The term “nucleic acid” refers to deoxyribonucleotides or ribonucleotides in either single- or double-stranded form. Those skilled in the art will readily recognize that reference to a particular site on one strand refers, as well, to the corresponding site on a complementary strand. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues. The term nucleic acid is used interchangeably with “nucleic acid sequence,” “gene,” “cDNA,” and “mRNA” encoded by a gene.
- The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, α-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. “Amino acid mimetics” refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. Amino acids may be referred to herein by either the commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
- The term “genotype” as used herein broadly refers to the genetic composition of an organism, including, for example, whether a diploid organism is heterozygous or homozygous for one or more variant alleles of interest.
- As used herein, references to “SNPs” and “SNP genotypes” include individual SNPs and/or haplotypes, which are groups of SNPs that are generally inherited together. Haplotypes can have stronger correlations with diseases or other phenotypic effects compared with individual SNPs, and therefore may provide increased diagnostic accuracy in some cases.
- The SNPs of the current invention may arise from a substitution of one or more nucleotides for another at the polymorphic site. Substitutions can be transitions or transversions. A transition is the replacement of one purine nucleotide by another purine nucleotide, or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine by a pyrimidine, or vice versa. A SNP may also be a single base insertion or deletion variant.
- The SNPs of the current invention may arise from a synonymous codon change, or silent mutation/SNP (terms such as “SNP”, “polymorphism”, “mutation”, “mutant”, “variation”, and “variant” are used herein interchangeably), is one that does not result in a change of amino acid due to the degeneracy of the genetic code. A substitution that changes a codon coding for one amino acid to a codon coding for a different amino acid (i.e., a non-synonymous codon change) is referred to as a missense mutation. A nonsense mutation results in a type of non-synonymous codon change in which a stop codon is formed, thereby leading to premature termination of a polypeptide chain and a truncated protein. A read-through mutation is another type of non-synonymous codon change that causes the destruction of a stop codon, thereby resulting in an extended polypeptide product. SNPs may include all allelics, including bi-, tri-, or tetra-allelics.
- In defining a SNP position, SNP allele, or nucleotide sequence, reference to an adenine, a thymine (uridine), a cytosine, or a guanine at a particular site on one strand of a nucleic acid molecule also defines the thymine (uridine), adenine, guanine, or cytosine (respectively) at the corresponding site on a complementary strand of the nucleic acid molecule. Thus, reference may be made to either strand to refer to a particular SNP position, SNP allele, or nucleotide sequence. Probes and primers, may be designed to hybridize to either strand and SNP genotyping methods disclosed herein may generally target either strand.
- The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. As used herein, the terms encompass amino acid chains of any length, including full-length proteins (i.e., antigens), wherein the amino acid residues are linked by covalent peptide bonds. References to “polypeptides,” “peptides” or “proteins” of the present invention include peptides, polypeptides, proteins, or fragments thereof, that contain at least one amino acid residue that differs from the corresponding amino acid sequence of the art-known peptide/polypeptide/protein (the protein may be interchangeably referred to as the “wild-type”, “reference”, or “normal” protein). Such variant peptides/polypeptides/proteins can result from a codon change caused by a nonsynonymous nucleotide substitution at a protein-coding position (i.e., a missense mutation) disclosed by the present invention. Variant peptides/polypeptides/proteins of the present invention can also result from a nonsense mutation, i.e., a SNP that creates a premature stop codon, a SNP that generates a read-through mutation by abolishing a stop codon, or due to any SNP disclosed by the present invention that otherwise alters the structure, function/activity, or expression of a protein, such as a SNP in a regulatory region (e.g., a promoter or enhancer) or a SNP that leads to alternative or defective splicing, such as a SNP in an intron or a SNP at an exon/intron boundary. As used herein, the terms “polypeptide”, “peptide”, and “protein” are used interchangeably.
- For all embodiments, the terms “individual” and “host” are used interchangably, and are not limited to humans. According to an aspect of the present invention, the “individual” may be any vertebrate, including mammals such as primates and including humans, dogs, cats, cows, goats, pigs, sheep, and monkeys. Thus, the disclosed invention may be applicable to treatment of animals through, for example, animal water, animal feed, animal pharmaceuticals, and the like. According to an aspect of the present invention, the individual may be healthy or suffering from a disease. In general, however, methods of the present invention can be effectively used if applied to a human who suffers from an auto-immunity disease or a disease caused by a pathogenic microorganism and a type of a certain nucleic acid sequence in the individual.
- The term “altered” may be used herein to encompass either an increased or a decreased risk/likelihood.
- The term “specific disease,” “disease” or “disorder” used herein encompasses auto antibody diseases as well as diseases associated with a pathogenic microorganism, such as for example, a virus, bacterium, yeast or mycoplasma as well as oncological diseases. However, the disease is not particularly limited.
- The term “practitioner” or “medical practitioner” used herein includes any person who engages in medicine or related medical arts as a profession, including the medical, biotechnology or pharmaceutical industry.
- The present invention provides methods of determining if an individual is likely to develop immune tolerance by detecting the altered expression (either higher or lower expression) or unique expression of nucleic acid sequences, as well as the gene sequence in the individual, even if they are not expressed or only transiently expressed. As such, some embodiments provide methods to determine if an individual that has the ability to develop immune tolerance has a differential and unique expression of known and unknown nucleic acid sequence from those individuals who do not have the ability to develop immune tolerance. In some embodiments, the nucleic acid sequences are SNPs.
- The present invention also provides nucleic acid sequences, methods and reagents for detecting the nucleic acid sequences, uses of nucleic acid sequences in kits or assays for use in advance of inducing immune tolerance.
- The invention contemplates use of nucleic acid sequences that are associated with either an increased risk of having or developing immune tolerance, or a decreased risk of having or developing immune tolerance. The presence of certain nucleic acid sequences (or their mRNA or protein encoded products) can be assayed to determine whether an individual possesses a nucleic acid sequences that is indicative of an increased risk of having or developing immune tolerance or a decreased risk of having or developing immune tolerance.
- Similarly, the nucleic acid sequences of the present invention can be associated with either an increased or decreased likelihood of responding to a particular treatment or antigen, or an increased or decreased likelihood of developing immune tolerance to the particular treatment or antigen.
- In some embodiments, the nucleic acid sequences are SNPs. Such nucleic acid variation can be assayed in a number of different methods that are well known to those of skill in the art, including PCR, RFLP, hybridization and direct sequencing.
- Determination of Nucleic Acid Presence/Absence in Individuals Susceptible to Immune Tolerance
- One embodiment is to a method to determine nucleic acid sequences that are present or absent in an individual who is susceptible to immune tolerance development, comprising screening for at least one nucleic acid sequence, as show in
FIG. 1 . In this method, the medical practitioner first administers an oral antigen to a patient to induce immune tolerance (101). - Antigens suitable for use in the present invention include, but are not limited to, synthetic or naturally derived proteins and peptides, and particularly those which by themselves require high doses to induce oral tolerance; carbohydrates including, but not limited to, polysaccharides and lipopolysaccharides; and antigens isolated from biological sources such as, for example, those associated with or responsible for the induction of auto-immune diseases, clinical (allergic) hypersensitivities, and allograft rejection and subunits or extracts therefrom; or any combination thereof.
- Further, the antigens may be any associated with or responsible for the induction of auto-immune diseases, clinical (allergic) hypersensitivities, and allograft rejection, and subunits or extracts therefrom; or recombinantly generated whole proteins, subunits or fragments thereof; or any combination thereof.
- The antigen administered may include, but is not limited to, all of the antigens of Table 1, to treat the associated diseases. The associated diseases or disorders listed in the Table 1 are meant to be examples and are in no way inclusive. In one specific embodiment, the at least one antigen is a collagen selected from the group of: I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, and mixtures thereof. The collagen may also be a fragment thereof. For instance, the collagen may be one or more fragments produced by CNBr cleavage of α1(I), which yields eight CB fragments: CB0, CB1, CB2, CB4, CB5, CB8, CB3, CB7 and CB6. The collagen may be one or more fragments produced by cCNBr cleavage of α2(I), which yields six CB fragments: CB1, CB0, CB4, CB2, CB3 and CB5.
- Further, in one embodiment, the disease is a sclerotic disease. In another embodiment, the disease is multiple sclerosis.
- Table 1 shows multiple embodiments of the invention. For instance, in one embodiment, collagen is the antigen used to induce immune tolerance to the disease idiopathic pulmonary fibrosis. In another embodiment, α-enolase is an antigen used to induce immune tolerance for the disease asthma.
- Furthermore, the individual dose size, number of doses, frequency of dose administration, and mode of administration may vary. Determination of such protocols can be accomplished by those skilled in the art. A suitable single dose is a dose that is capable of altering a biological response in an animal when administered one or more times over a suitable time period (e.g., from minutes to days over weeks). Preferably, a dose comprises from about 1 μg of the antigen per kilogram of body weight (ng/kg) to about 1 gram of antigen per kilogram of body weight (gm/kg), more preferably 100 μg/kg to about 100 milligrams/kilogram (mg/kg), and even more preferably from about 10 microgram of the antigen per kilogram body weight (μ/kg) to about 10 mg/kg.
- Alternatively, the dose of antigen may not be determined upon the body weight of the patient. In this embodiment, the dose may be at least 1 μg/day of antigen. Preferably, the dose ranges from 10 μg/day of antigen to 5000 μg/day. In another embodiment, the dose ranges from 10 μg/day of antigen to 500 μg/day. In another embodiment, the dose ranges from 30 μg/day of antigen to 200 μg/day.
- In one alternate embodiment, the dose of antigen is below the threshold required for stimulation of an immune response. In another embodiment, the dose of antigen is above the threshold, thereby stimulating an immune response.
- Modes of administration can include, but are not limited to, aerosolized, subcutaneous, rectally, intradermal, intravenous, nasal, oral, transdermal and intramuscular routes. In one preferred embodiment, the antigen is given orally. In another preferred embodiment, the antigen is given intraveneously or sublingually.
- Furthermore, the antigen can be combined with other components such as a pharmaceutically acceptable excipient and/or a carrier, prior to administration to the individual. The other components will depend upon the mode of administration, storage needs, and the like.
- Examples of such excipients include water, saline, Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions. Nonaqueous vehicles, such as fixed oils, sesame oil, ethyl oleate, or triglycerides may also be used. Other useful formulations include suspensions containing viscosity-enhancing agents, such as sodium carboxymethylcellulose, sorbitol, or dextran. Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability. Examples of buffers include, but are not limited to, phosphate buffer, bicarbonate buffer and Tris buffer, while examples of preservatives include, but are not limited to, thimerosal, m- or o-cresol, formalin and benzyl alcohol.
- Standard formulations can either be liquid injectables or solids that can be taken up in a suitable liquid as a suspension or solution for injection. Carriers are typically compounds that increase the half-life of an antigen in the treated individual. Suitable carriers include, but are not limited to, polymeric controlled release vehicles, biodegradable implants, liposomes, bacteria, viruses, oils, esters, and glycols. Preferred controlled release formulations are capable of slowly releasing the antigen of the present invention into an individual. Suitable controlled release vehicles include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres, and transdermal delivery systems. Other controlled release vehicles of the present invention include liquids that, upon administration to an individual, form a solid or a gel in situ. Preferred controlled release vehicles are biodegradable (i.e., bioerodible).
- A biological sample, also referred to as a “sample”, is taken from the individual for use in determining the individual's immune response (102). Such sample preparation components can be used to produce nucleic acid extracts (including DNA and/or RNA), proteins or membrane extracts from any bodily fluids (such as blood, serum, plasma, urine, saliva, phlegm, gastric juices, semen, tears, sweat, etc.), skin, hair, cells (especially nucleated cells), biopsies, buccal swabs or tissue specimens. The frequency of taking samples, and its use, will vary based on such factors as the scoring method, assay format, nature of the detection method, and the specific tissues, cells or extracts used as the test sample to be assayed. Methods of preparing nucleic acids, proteins, and cell extracts from the biological sample are well known in the art and can be readily adapted to obtain a sample that is compatible with the system utilized.
- From the biological sample, the individual immune system response to the antigen is determined, and the individuals are scored based upon their response (103). The method of scoring is dependent upon the practitioner, and includes any methods that separate patients based upon their immune response to the antigen. For instance, the patient may be scored based on antigen specific and antigen non-specific assays. Antigen specific assays measure the response of T and B cells to specific antigens, whereas antigen non-specific assays determine the phenotype of surface markers or functional state of cells for patterns associated with a particular clinical status.
- Specifically, the practitioner may use any means convenient to determine the immune system response, including but not limited to, use of an enzyme-linked immunoabsorbent assay (ELISA), ELISA/ACT® Lymphocyte Response Assay (LRA), in vitro measurement of antibody production, mixed leukocyte reaction, cytotoxic T lymphocyte assay, flow cytometry, Western blots, limiting dilution assay, mass spectroscopy, immunoprecipitation and immunofluorescence.
- For instance, in one embodiment, an ELISPOT assay is used to determine the individual immune response. Typically, an ELISPOT assay includes incubating immune cells in plates coated with a capture antibody against a cytokine of interest. Cytokines released by the cell membrane are then captured by the capture antibody during the incubation period. The cells are removed and the bound cytokine is detected using a labeling system, such as for example, a labeled secondary antibody against a different epitope of the same cytokine. This assay results in a cytokine footprint of a single cell.
- In another embodiment, a transvivo DTH assay is used to determine individual immune response. In this assay, cells from the individual are injected into the footpads of immune-deficient mice together with the antigen. The index of reactivity of T cells to the antigens is then measured by quantification of resultant swelling in the footpad.
- In another embodiment, a tetramer assay is used. Here, the frequency of T cells is measured by their binding to specific peptide-MHC complexes using flow cytometry.
- In an alternate embodiment, a CFSE assay measures the proliferation of T cells by dilution of a CFSE dye in the dividing cells. This assay may include use of flow cytometry.
- In yet another embodiment, intracellular staining of the T cells can be used to determine the frequency of cytokine-producing T cells by, for example, flow cytometry.
- In yet another embodiment, the patients are scored based upon the respective levels and/or changes in IFN-γ production before, during and/or after receiving the antigen. Alternatively, other cytokines may be measured to determine individual scores. For instance, levels of IL-10 in α1(I)- and α2(I)-stimulated PBMC culture supernatants and/or sIL-2R may be used to score a patient.
- Other means to determine the immune system response may include characterization of the TCR repertoire. This assay may include use of quantitative PCR, gel electrophoresis and DNA sequencing to determine the proporation of T cells that use the Vβ chains to determine the CFR3 length distribution along the Vβ gene product.
- Another means to determine immune system response may include T cell responses to polyclonal, non-antigen-specific stimulation. Here, the whole blood is stimulated with phytohemagglutinin for a period of time, CD4+ T cells are then isolated, and the extent of early CD4+ T cell activation is measured by the synthesis and accumulation of intracellular ATP measured after cell lysis.
- Other means to determine the immune system response may include, but is not limited to, detection of the presence of nucleic acids. Several methods of detecting nucleic acids are available including PCR, LCR and hybridization techniques. Hybridization techniques involve detecting the hybridization of two or more nucleic acid molecules, where detection is achieved in a variety of ways, including labeling the nucleic acid molecules and observing the signal generated from such a label. Hybridization techniques may include any of the following: Northern and Southern blotting, cycling probe reaction, branched DNA, Invader™ Assay, and Hybrid Capture. Hybridization techniques may also be used to identify a specific sequence of nucleic acid present in a sample by using microarrays (or “bioarrays”) of known nucleic acid sequences to probe a sample. Bioarray technologies generally use known single stranded nucleic acid, where each unique short chain is attached in a specific known location and then adding the sample nucleic acid and allowing sequences present in the sample to hybridize to the immobilized strands. Detection of this hybridization is then carried out by labeling, typically end labeling, of the fragments of the sample to be detected prior to the hybridization. Further, hybridization may be determined by use of a fluorescent in situ hybridization technique.
- Furthermore, in one embodiment, a proteomics approach may be used. Here, protein microarrays or mass spectrometry may be used to determine the presence and quantification of protein fragments present in an individual's sample. In addition, by analyzing more than one protein, the practitioner can determine the immune response by the unique patterns of protein expression in the individual.
- To score the patients based on immune system response, the practitioner may measure compare the immune response before, during and/or after receiving the antigen. The determination of when the immune response is measured, and what method is used, is based upon the practitioner needs. Further, it is contemplated that the practitioner may further take into consideration other physiological factors of the individual, such as other cytokines, percentage of T cell, NK cell, B cell, dendritic cell, monocyte, subpopulations, oxidative radicals, connective tissue growth factor, nitric oxide, thymic morphology determined by imaging techniques, patient height, nutritional status, weight, health, thymic function determined by immunologic assays, diet, gender, age, vitamin A levels, zinc levels, and environmental considerations to assist in scoring the patient's immune response. Patients' genomic backgrounds, such as mutations in other genes or genome regions, races and gender differences, may also be considered.
- Once the individual is scored based on antigen response, the practitioner will analyze the genotype of the individuals to determine whether an individual has or lacks one or more nucleic acid sequences, thereby altering levels or patterns of gene expression (104). The genotype is later used to correlate the presence or absence of the one or more nucleic acids with the immune response score of step (103).
- The practitioner may either examine specific known nucleic acids of interest or examine part or whole of the entire genome to look for the presence or absence of differential or unique nucleic acids or nucleic acid patterns, and correlate the one or more nucleic acids presence/absence with the individual's immune response score. Nucleic acids of particular interest include those known to affect the concentration of mRNA or protein in a sample, nucleic acids known to affect the kinetics of nucleic acid and/or protein expression, nucleic acids that affect the rate of nucleic acid and/or protein decomposition, and nucleic acids that affect protein stability profile, Km, or Vmax.
- Further, the practitioner may either use part of the biological sample of step (102) to analyze for the nucleic acid, or the practitioner may take another biological sample from the individual for analysis. The nucleic acid may be purified or isolated from the sample by any means convenient to the practitioner, but such isolation may not be necessary in certain forms of detection.
- In one preferred embodiment, the practitioner will analyze the genotype of the individuals to determine which allele(s) is/are present at any given genetic region of interest by methods well known in the art. The neighboring sequence can be used to design nucleic acid detection reagents such as oligonucleotide probes, which may optionally be implemented in a kit format.
- Common genotyping methods include, but are not limited to, TaqMan assays, molecular beacon assays, nucleic acid arrays, allele-specific primer extension, allele-specific PCR, arrayed primer extension, homogeneous primer extension assays, primer extension with detection by mass spectrometry, pyrosequencing, multiplex primer extension sorted on genetic arrays, ligation with rolling circle amplification, homogeneous ligation, OLA, multiplex ligation reaction sorted on genetic arrays, restriction-fragment length polymorphism, single base extension-tag assays, and the Invader assay. Such methods may be used in combination with detection mechanisms such as, for example, luminescence or chemiluminescence detection, fluorescence detection, time-resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, and electrical detection.
- Various methods for detecting polymorphisms include, but are not limited to, methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA, comparison of the electrophoretic mobility of variant and wild type nucleic acid molecules, and assaying the movement of polymorphic or wild-type fragments in polyacrylamide gels containing a gradient of denaturant using denaturing gradient gel electrophoresis. Sequence variations at specific locations can also be assessed by nuclease protection assays such as RNase and SI protection or chemical cleavage methods.
- In one embodiment, genotyping is performed using the TaqMan assay, which is also known as the 5′ nuclease assay. The TaqMan assay detects the accumulation of a specific amplified product during PCR. The TaqMan assay utilizes an oligonucleotide probe labeled with a fluorescent reporter dye and a quencher dye. The reporter dye is excited by irradiation at an appropriate wavelength, it transfers energy to the quencher dye in the same probe via a process called fluorescence resonance energy transfer (FRET). When attached to the probe, the excited reporter dye does not emit a signal. The proximity of the quencher dye to the reporter dye in the intact probe maintains a reduced fluorescence for the reporter. The reporter dye and quencher dye may be at the 5′ most and the 3′ most ends, respectively, or vice versa. Alternatively, the reporter dye may be at the 5′ or 3′ most end while the quencher dye is attached to an internal nucleotide, or vice versa. In yet another embodiment, both the reporter and the quencher may be attached to internal nucleotides at a distance from each other such that fluorescence of the reporter is reduced.
- During PCR, the 5′ nuclease activity of DNA polymerase cleaves the probe, thereby separating the reporter dye and the quencher dye and resulting in increased fluorescence of the reporter. Accumulation of PCR product is detected directly by monitoring the increase in fluorescence of the reporter dye. The DNA polymerase cleaves the probe between the reporter dye and the quencher dye only if the probe hybridizes to the target SNP-containing template which is amplified during PCR, and the probe is designed to hybridize to the target SNP site only if a particular SNP allele is present.
- Preferred TaqMan primer and probe sequences can readily be determined using the SNP and associated nucleic acid sequence information provided herein. A number of computer programs, such as Primer Express (Applied Biosystems, Foster City, Calif.), can be used to rapidly obtain optimal primer/probe sets. It will be apparent to one of skill in the art that such primers and probes for detecting the nucleic acids of the present invention are useful in diagnostic assays for stenosis and related pathologies, and can be readily incorporated into a kit format. The present invention also includes modifications of the Taqman assay well known in the art such as the use of Molecular Beacon probes and other variant formats.
- Another method for genotyping the nucleic acids of the present invention is the use of two oligonucleotide probes in an OLA. In this method, one probe hybridizes to a segment of a target nucleic acid with its 3′ most end aligned with the nucleic acid site. A second probe hybridizes to an adjacent segment of the target nucleic acid molecule directly 3′ to the first probe. The two juxtaposed probes hybridize to the target nucleic acid molecule, and are ligated in the presence of a linking agent such as a ligase if there is perfect complementarity between the 3′ most nucleotide of the first probe with the nucleic acid site. If there is a mismatch, efficient ligation cannot occur. After the reaction, the ligated probes are separated from the target nucleic acid molecule, and detected as indicators of the presence of a nucleic acid sequence. OLA may also be used for performing nucleic acid detection using universal arrays, wherein a zipcode sequence can be introduced into one of the hybridization probes, and the resulting product, or amplified product, hybridized to a universal zip code array. Alternatively OLA may be used where zipcodes are incorporated into OLA probes, and amplified PCR products are determined by electrophoretic or universal zipcode array readout.
- Alternatively one may use SNPlex methods and software for multiplexed SNP detection using OLA followed by PCR, wherein zipcodes are incorporated into OLA probes, and amplified PCR products are hybridized with a zipchute reagent, and the identity of the SNP determined from electrophoretic readout of the zipchute. In some embodiments, OLA is carried out prior to PCR (or another method of nucleic acid amplification). In other embodiments, PCR (or another method of nucleic acid amplification) is carried out prior to OLA.
- Another method for genotyping is based on mass spectrometry. Mass spectrometry takes advantage of the unique mass of each of the four nucleotides of DNA. Nucleic acids can be unambiguously genotyped by mass spectrometry by measuring the differences in the mass of nucleic acids having alternative nucleic acid alleles. MALDI-TOF (Matrix Assisted Laser Desorption Ionization-Time of Flight) mass spectrometry technology is preferred for extremely precise determinations of molecular mass, such as for SNPs. Numerous approaches to genotype analysis have been developed based on mass spectrometry. Preferred mass spectrometry-based methods of nucleic acid genotyping include primer extension assays, which can also be utilized in combination with other approaches, such as traditional gel-based formats and microarrays.
- Typically, the primer extension assay involves designing and annealing a primer to a template PCR amplicon upstream (5′) from a target nucleic acid position. A mix of dideoxynucleotide triphosphates (ddNTPs) and/or deoxynucleotide triphosphates (dNTPs) are added to a reaction mixture containing template. For example, in some embodiments this is a SNP-containing nucleic acid molecule which has typically been amplified, such as by PCR. Primer and DNA polymerase may further be added. Extension of the primer terminates at the first position in the template where a nucleotide complementary to one of the ddNTPs in the mix occurs. The primer can be either immediately adjacent (i.e., the nucleotide at the 3′ end of the primer hybridizes to the nucleotide next to the target SNP site) or two or more nucleotides removed from the nucleic acid position. If the primer is several nucleotides removed from the target nucleic acid position, the only limitation is that the template sequence between the 3′ end of the primer and the nucleic acid position cannot contain a nucleotide of the same type as the one to be detected, or this will cause premature termination of the extension primer.
- Alternatively, if all four ddNTPs alone, with no dNTPs, are added to the reaction mixture, the primer will always be extended by only one nucleotide, corresponding to the target SNP position. In this instance, primers are designed to bind one nucleotide upstream from the SNP position (i.e., the nucleotide at the 3′ end of the primer hybridizes to the nucleotide that is immediately adjacent to the target SNP site on the 5′ side of the target SNP site). Extension by only one nucleotide is preferable, as it minimizes the overall mass of the extended primer, thereby increasing the resolution of mass differences between alternative SNP nucleotides. Furthermore, mass-tagged ddNTPs can be employed in the primer extension reactions in place of unmodified ddNTPs. This increases the mass difference between primers extended with these ddNTPs, thereby providing increased sensitivity and accuracy, and is particularly useful for typing heterozygous base positions. Mass-tagging also alleviates the need for intensive sample-preparation procedures and decreases the necessary resolving power of the mass spectrometer.
- The extended primers can then be purified and analyzed by MALDI-TOF mass spectrometry to determine the identity of the nucleotide present at the target SNP position. In one method of analysis, the products from the primer extension reaction are combined with light absorbing crystals that form a matrix. The matrix is then hit with an energy source such as a laser to ionize and desorb the nucleic acid molecules into the gas-phase. The ionized molecules are then ejected into a flight tube and accelerated down the tube towards a detector. The time between the ionization event, such as a laser pulse, and collision of the molecule with the detector is the time of flight of that molecule. The time of flight is precisely correlated with the mass-to-charge ratio (m/z) of the ionized molecule. Ions with smaller m/z travel down the tube faster than ions with larger m/z and therefore the lighter ions reach the detector before the heavier ions. The time-of-flight is then converted into a corresponding, and highly precise, m/z. In this manner, SNPs can be identified based on the slight differences in mass, and the corresponding time of flight differences, inherent in nucleic acid molecules having different nucleotides at a single base position.
- Nucleic acids can also be scored by direct DNA sequencing. A variety of automated sequencing procedures can be used, including sequencing by mass spectrometry. The nucleic acid sequences of the present invention enable one of ordinary skill in the art to readily design sequencing primers for such automated sequencing procedures. Commercial instrumentation, such as the Applied Biosystems 377, 3100, 3700, 3730, and 3730×1 DNA Analyzers (Foster City, Calif.), is commonly used in the art for automated sequencing. Nucleic acid sequences can also be determined by employing a high throughput mutation screening system, such as the SpectruMedix system.
- Other methods that can be used to genotype the nucleic acids of the present invention include single-strand conformational polymorphism (SSCP), and denaturing gradient gel electrophoresis (DGGE). SSCP identifies base differences by alteration in electrophoretic migration of single stranded PCR products. Single-stranded PCR products can be generated by heating or otherwise denaturing double stranded PCR products. Single-stranded nucleic acids may refold or form secondary structures that are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products are related to base-sequence differences at nucleic acid positions. DGGE differentiates nucleic acid alleles based on the different sequence-dependent stabilities and melting properties inherent in polymorphic DNA and the corresponding differences in electrophoretic migration patterns in a denaturing gradient gel.
- Sequence-specific ribozymes can also be used to score nucleic acids, in particular SNPs, based on the development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature. Thus, for example, if the SNP affects a restriction enzyme cleavage site, the SNP can be identified by alterations in restriction enzyme digestion patterns, and the corresponding changes in nucleic acid fragment lengths determined by gel electrophoresis
- Genotyping can include the steps of, for example, collecting a biological sample from a human subject (e.g., sample of tissues, cells, fluids, secretions, etc.), isolating nucleic acids (e.g., genomic DNA, mRNA or both) from the cells of the sample, contacting the nucleic acids with one or more primers which specifically hybridize to a region of the isolated nucleic acid containing a target nucleic acid region of interest under conditions such that hybridization and amplification of the target nucleic acid region occurs, and determining the nucleotide present at the nucleic acid position of interest, or, in some assays, detecting the presence or absence of an amplification product (assays can be designed so that hybridization and/or amplification will only occur if a particular nucleic acid sequence allele is present or absent). In some assays, the size of the amplification product is detected and compared to the length of a control sample; for example, deletions and insertions can be detected by a change in size of the amplified product compared to a normal genotype.
- Furthermore, the nucleic acid, or in particular the SNP, found may then be compared to the nucleic acids of other individuals whom have also received the antigen to induce an immune response. Methods of comparing the identity of two or more sequences may be performed by any reasonable means, including programs available in the Wisconsin Sequence Analysis Package version 9.1 (Genetics Computer Group, Madison, Wis., USA). Other programs such as BESTFIT may be used to find the “local homology” algorithm of Smith and Waterman and finds the best single region of similarity between two sequences. Further, programs such as GAP may be used, which aligns two sequences finding a “maximum similarity.” Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned. Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs, available from the National Center for Biotechnology Information (NCB), Bethesda, Md., USA) and FASTA, available as part of the Wisconsin Sequence Analysis Package.
- Once the presence or absence or pattern of nucleic acids present in an individual is determined, the immune response score is associated with the nucleic acid results. The practitioner may then determine if one or more nucleic acids, preferably SNPs, are associated with individuals who did or did not respond to the antigen with altered immune tolerance.
- It is contemplated that the mechanisms of induction of immune tolerance may vary with different diseases and disorders. For example, the SNP involved with induction of systemic lupus erthematosus may be different from the SNPs involved with other diseases, such as autoimmune encephalopathy. As such, the practitioner may repeat the process of
FIG. 1 for each disease and disorder that the pracititioner wishes to induce immune tolerance to. - Determination of Treatment Based Upon an Individual's Genotyping
- The method of
FIG. 1 is particularly beneficial because it allows the practitioner to determine what nucleic acid sequences, including SNPs, may be involved with induction of immune tolerance. More importantly, once the method ofFIG. 1 is complete, the practitioner may simply test a new individual for the nucleic acid sequence or SNP of interest, as outlined inFIG. 2 . - First, the practitioner categorizes or diagnoses the patient as having a disease or disorder (201). The categorization or diagnosis may be based on present or past symptoms, medical history, family history, tests such as assays or medical scans, and the like.
- Once the practitioner has diagnosed the patient, the practitioner takes a biological sample from the patient (202). The sample may be in any form convenient for the practitioner and patient, including but not limited to, whole blood, blood plasma, urine, tears, semen, saliva, buccal mucosa, interstitial fluid, lymph fluid, meningeal fluid, amniotic fluid, glandular fluid, sputum, feces, perspiration, mucous, vaginal secretion, cerebrospinal fluid, hair, skin, fecal material, wound exudate, wound homogenate, and wound fluid.
- The individual's nucleic acid is then isolated from the sample (203). The isolation may occur by any means convenient to the practitioner. For instance, the isolation may occur by first lysing the cell using detergents, enzymatic digestion or physical disruption. The contaminating material is then removed from the nucleic acids by use of, for example, enzymatic digestion, organic solvent extraction, or chromatographic methods. The individual's nucleic acid may be purified and/or concentrated by any means, including precipitation with alcohol, centrifugation and/or dialysis.
- The individual's nucleic acid is then assayed for presence or absence of one or more predetermined nucleic acids of interest (204). The one or more predetermined nucleic acids of interest may be any nucleic acid the practitioner believes may be related to immune tolerance to any disease or disorder. Exemplary examples of appropriate diseases or disorders are listed in Table 1.
- The determination of whether one or more predetermined nucleic acids of interest are presence or absence, may be done by any mean (205).
- In one embodiment, the predetermined nucleic acid of interest is an approximately 50 KB non gene region on
chromosome 12, located about 55.5 Mbp from the proximal end ofchromosome 12 between 66,603,791 and 66,603,991 bps, where the nucleic acid of interest is either TTTTTTTTTTGTACCTAGTTCTATGGTTACCTT (SEQ ID NO. 1) or TTTTTTTTTTGTACCTGGTTCTATGGTTACCTT (SEQ ID NO. 2). The A/G is the polymorphic site. Thus, AA represents AA homozygous, while AB represents A/G heterozygous and BB represents GG genotype, A→G represents the polymorphism site. - Alternatively, the predetermined nucleic acid of interest may include part of the approximately 265143 bp at 5′ side of SNP A-1515737. Alternatively, the predetermined nucleic acid of interest may include part of the approximately 231513 bp at 3′ side of SNP-1515737. Alternatively, the predetermined nucleic acid of interest includes part of all of SEQ. ID. 3 or 4.
- In another embodiment, the predetermined nucleic acid of interest is located between 66507155-66507464 on
chromosome 12, within the proximity of the marker D1251503. - In another embodiment, the predetermined nucleic acid of interest is located within the proximity of D12S1676, i.e., part or all of the predetermined nucleic acid of interest is located between 66499298-66499423 on
chromosome 12. - In another embodiment, the predetermined nucleic acid of interest is located within the proximity of D12S335, i.e., part or all of the predetermined nucleic acid of interest is located between 66415802-66416056 on
chromosome 12. - In another embodiment, the predetermined nucleic acid of interest is located within the proximity of D12S102, i.e., part or all of the predetermined nucleic acid of interest is located between 66781046-66781298 on
chromosome 12. - In another embodiment, the predetermined nucleic acid of interest is located within the proximity of D12S1506, i.e., part or all of the predetermined nucleic acid of interest is located between 66785380-66785614 on
chromosome 12. - In another embodiment, the predetermined nucleic acid of interest is SNP_A-1508498 (TSC51977), with the polymorphism of C or T. In another embodiment, the predetermined nucleic acid of interest is SNP_A-1512645 (TSC1720860) with the polymorphism of C or T. In another embodiment, the predetermined nucleic acid of interest is SNP_A-1512719 (TSC1720861) with the polymorphism of C or T. In another embodiment, the predetermined nucleic acid of interest is SNP_A-1515330 (TSC1244733) with the polymorphism of C or T. In another embodiment, the predetermined nucleic acid of interest is SNP_A-1518829 (TSC51583) with the polymorphism of A or G. In another embodiment, the predetermined nucleic acid of interest is SNP_A-1518878 (TSC51584) with the polymorphism of C or G. Further, in one specific embodiment, the predetermined nucleic acid of interest is located within 30 kbp of SNP_A-1515737. These other markers and transcripts can also be used to determine a patient's ability to have tolerance, especially oral tolerance, induced.
- In another embodiment, the predetermined nucleic acid of interest is D12S1503 (SEQ. ID. NO. 5). In another embodiment, the predetermined nucleic acid of interest is D12S1676 (SEQ. ID. NO. 6). In another embodiment, the predetermined nucleic acid of interest is D12S335 (SEQ. ID. NO. 7). In another embodiment, the predetermined nucleic acid of interest is D12S102 (SEQ. ID. NO. 8).
- In another embodiment, the predetermined nucleic acid of interest is SNP_A-1508498 with a polymorphism of C or T. (SEQ. ID. NO. 9 and 10). In another embodiment, the predetermined nucleic acid of interest is SNP_A-1512645 with a polymorphism of C or T. (SEQ. ID. NO. 11 or 12). In another embodiment, the predetermined nucleic acid of interest is SNP_A-1512719 with a polymorphism of C or T. (SEQ. ID. NO. 13 or 14). In another embodiment, the predetermined nucleic acid of interest is SNP_A-1515330 with a polymorphism of C or T. (SEQ. ID. NO. 15 or 16). In another embodiment, the predetermined nucleic acid of interest is SNP_A-1518829 with a polymorphism of A or G. (SEQ. ID. NO. 17 or 18). In another embodiment, the predetermined nucleic acid of interest is SNP_A-1518878 with a polymorphism of C or G. (SEQ. ID. NO. 19 or 20). The predetermined nucleic acid of interest may also be any marker or gene between 63.3 mbp and 69.4 mbp on
human chromosome 12. See, e.g.,FIG. 15 . - In one embodiment, the practitioner uses visual confirmation of the presence or absence of particular variants of the nucleic acid.
- In another embodiment, the method provides a computer based system with one or more algorithms to determine the presence and/or absence of one or more predetermined nucleic acids of interest and, if present, quantifies the amount of one or more predetermined nucleic acids of interest present in the individual's nucleic acid.
- In one preferred embodiment, the predetermined nucleic acids of interest are one or more SNPs. Further, the computer based system may comprise information about observed SNP alleles, alternative codons, populations, allele frequencies, SNP types, and/or affected proteins and the like.
- The computer based system includes at least one of the following: hardware means, software means, and data storage means used to analyze any information of the present invention. The minimum hardware means of the computer-based systems of the present invention typically comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based systems are suitable for use in the present invention. Such a system can be changed into a system of the present invention by utilizing information provided on the CD-R, or a subset thereof, without any experimentation.
- As stated above, the computer-based systems of the present invention comprise a data storage means having stored therein information and the necessary hardware means and software means for supporting and implementing a search means. The search means of the computer-based system includes one or more software programs or algorithms that are implemented on the computer-based system to identify or analyze nucleic acid sequences, including SNPs in a target sequence, based on nucleic acid information stored within the data storage means. Search means can be used to determine the presence or absence of a nucleic acid sequence, and/or which nucleotide is present at a particular SNP position in a nucleic acid sequence.
- In one application of this embodiment, the practitioner may provide the computer-based system with information regarding nucleic acids of interests on a computer readable medium. Computer readable medium is any medium that can be read and accessed directly by a computer, including but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media.
- A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon a nucleotide or amino acid sequence of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleic acid sequence information of the present invention on computer readable medium. For example, the sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, represented in the form of an ASCII file, or stored in a database application, such as OB2, Sybase, Oracle, or the like. A skilled artisan can readily adapt any number of data processor structuring formats (e.g., text file or database) in order to obtain computer readable medium having recorded thereon the nucleic acid sequence information of the present invention.
- By providing the nucleic acid sequences, including SNPs, of the present invention in computer readable form, a practitioner can routinely access the nucleic acid sequence information for a variety of purposes. Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium. Examples of publicly available computer software include BLAST and BLAZE search algorithms.
- The present invention further provides systems, particularly computer-based systems, which contain the nucleic acid sequence information described herein. Such systems may be designed to store and/or analyze information on, for example, a large number of SNP positions, or information on genotypes, including SNP genotypes, from a large number of individuals. The nucleic acid sequence information of the present invention represents a valuable information source. The nucleic acid sequence information of the present invention stored/analyzed in a computer-based system may be used for such computer-intensive applications as determining or analyzing nucleic acid allele frequencies in a population, mapping disease genes, genotype-phenotype association studies, grouping SNPs into haplotypes, correlating SNP haplotypes with response to particular drugs, or for various other bioinformatic, pharmacogenomic, drug development, or human identification/forensic applications.
- A treatment for the individual is then formulated based on the presence and/or absence of one or more predetermined nucleic acids of interest (206). The treatment may include anything within the means of the practitioner, including a determination of likelihood of inducing immune tolerance can be induced, if so then the type of antigen, dose, method of administration, regimen of treatment, and the like.
- The inventors have also discovered that non-steroidal anti-inflammatory drugs (NSAIDS) can interfere with the generation of immune tolerance. Thus, in one alternate embodiment, the practitioner can modulate the creation of immune tolerance by either having the individual desiring treatment stop using NSAIDS or administering pharmaceuticals to reverse the NSAID inhibition of immune tolerance, such as, for example, misoprostol.
- Further, in one preferred embodiment, the methods of the instant invention may be used to treat idiopathic pulmonary fibrosis (“IPF”). IPF is a lethal, chronic, progressive, interstitial lung disease in which normal lung tissue is gradually replaced by fibrotic tissue, or an abnormal and excessive amount of fibrotic tissue is deposited in the pulmonary interstitium. This may be described as a scarring of the lung. About 60% of IPF patients have an antigen-specific autoimmune reaction to Type V collagen. Without wishing to be bound to a particular mechanism or theory, it is believed that the immune systems of such patients attack the Type V collagen of the lungs, thereby causing fibrosis.
- IPF patients having an autoimmune reaction to Type V collagen would benefit if the immune response attacking the Type V collagen of the lungs could be halted or lessened. This immune response could be halted or lessened by induction of immune tolerance to Type V collagen using the methods of the present invention. Tolerance could be induced by repeated administration of collagen antigens, preferably Type V collagen antigens, according to the methods of the present invention.
- Administration of collagen or collagen antigens, preferably Type V collagen or antigens thereof, will be most effective in treating IPF patients who have an antigen-specific autoimmune reaction to Type V collagen. Thus, a test for identifying such patients is desirable.
- Using the methods of the present invention, an association study may be performed to determine whether IPF patients having an antigen-specific autoimmune reaction to Type V collagen carry one or more SNPs—or other nucleic acid sequences linked in some manner to the SNPs—that is not found in IPF patients who do not have an antigen-specific autoimmune reaction to Type V collagen. The presence of the one or more SNPs or linked nucleic acid sequences associated with an antigen-specific autoimmune reaction to Type V collagen can then be used to identify patients most likely to benefit from administration of collagen or collagen antigens, preferably Type V collagen or antigens thereof. Autoimmune reactions to Type V collagen are also believed to contribute to rejection of lung transplants. Accordingly, SNP(s) and/or linked nucleic acid sequences found to be associated with an antigen-specific autoimmune reaction to Type V collagen may also be used to assess a patient's propensity to successfully undergo lung or other transplants.
- Use of Individual Genotype to Determine Whether to Induce Immune Tolerance
- The invention may also be used by the practitioner to determine the regimen of treatment for the individual. That is, based on individual-specific information, the invention may recommend to the practitioner treatment regimens, such as whether to induce immune tolerance, type of antigen, dose, method of administration, regimen of treatment, and the like. The recommendation of treatment regimens may not only be a function of the disease or disorder the individual has, but also a function of the individual characteristics.
- In this embodiment, the method of which is located in
FIG. 3 , the individual characteristics are first placed into one or more databases (301). The individual characteristic information may be received by any means, including using an integrated consultation process with one or more practitioners, a questionnaire filled out by the individual, an electronic database, a diagnostic or an expert panel measurement tool, client summary report, and an outcomes measurement report. Further, the individual characteristic information may be received by one or more of a network, oral communication, visual communication, written communication, physical data carrier, and/or any other means capable of conveying information. - Individual characteristics may include, but are not limited to, age, sex, height, weight, individual medical history, family medical history, ethnicity, allergy information, lifestyle information, and the like.
- The individual's nucleic acids are then collected and analyzed (302). The method of collecting the individual nucleic acid may be any contemplated by the practitioner, including those mentioned within the instant specification.
- The presence or absence of one or more predetermined nucleic acids of interest is then determined (303). Here, the determination which nucleic acids would be examined, i.e., the predetermined nucleic acids of interest, may be determined either individually by the practitioner. Alternatively, the determination includes accessing a database containing information reflecting the relationship between the current disease or diagnosis of the individual, or what the practitioner believes the current disease or diagnosis to be, and the nucleic acids of interest associated with the disease or diagnosis.
- In some embodiments, the one or more databases of the current invention are local to the practitioner's location. In other embodiments, the one or more databases are remote, dynamic databases. Generally, a dynamic database is one in which the data within may be easily changed or updated. For instance, one can use a software system to access information from a dynamic database via a network and upload information from the database to the software system. If the information stored in the database changes, the software system connected to the database will also change accordingly and automatically without human intervention. The software system may update the individual's information in the dynamic database on any time bases, including, but not limited to, an event driven, minute-by-minute, hourly, daily or weekly basis.
- Based upon the results of step (303), i.e., the presence or absence of one or more predetermined nucleic acids of interest, the treatment of the individual may be determined. In one embodiment, the practitioner relies upon his expertise in the medical field to determine the treatment regimen. In another embodiment, a software system stored in one or more databases recommends a treatment regimen. The recommended treatment regimen may include, but is not limited to, whether to induce immune tolerance, type of antigen, dose, method of administration, regimen of treatment, over the counter or prescription medication, lifestyle changes, and the like.
- The recommendation of treatment regimens may not only be a function of the disease or disorder the individual has, but also a function of the individual characteristics. As such, the one or more databases may allow a software system to input more information about the individual, the disease or disorder to be treated, the outcome of the treatment, and other compatible information. It is contemplated that the information for multiple individuals may be pooled together, thus as the amount of data for one or more parameters increases, the algorithm in the software system becomes more robust and accurate at calculating what treatment/procedure best suits the individual's set of criteria. Further, the database may further include a warehouse of “Best Practices,” that is, specific treatment protocols judged optimal by a panel of medical experts.
- These embodiments allow the practitioner to better tailor the individual's treatment and avoid unnecessary cost and time of unnecessary treatments.
- Determination of Nucleic Acids Associated with Immune Tolerance
- The determination of which nucleic acids are the predetermined nucleic acids of interest may be determined by the method of
FIG. 4 . First, information on multiple individuals with a disease or disorder is collected and saved in one or more databases (401). The information includes at least the disease or disorder of the individuals, the ability of the individual to develop immune tolerance after administration of antigens, and the nucleic acid information of the individual. Preferably, the nucleic acid information is the presence or absence of one or more SNPs. - The presence of absence of one or more SNPs and the ability of the individual to develop immune tolerance is compared to determine the increased (or decreased) occurrence of the nucleic acid in a specific disease or disorder condition (402). The comparison of the SNPs and ability to develop immune tolerance may be accomplished by using a mathematical algorithm.
- Once a statistically significant association is established between one or more SNPs and ability to induce immune tolerance, then the region around the SNP can optionally be thoroughly screened to identify the causative genetic locus/sequence(s) (e.g., causative SNP/mutation, gene, regulatory, region, etc.) that influences the ability to induce immune tolerance.
- In addition, an association study of a SNP and a specific disease or disorder may be performed, to determine the presence or frequency of the SNP allele in biological samples from individuals with the disorder or disease of interest and comparing the information to that of controls (i.e., individuals who do not have the disorder; controls may be also referred to as “healthy” or “normal” individuals) who are preferably of similar age and race. The patients and controls should be as alike as possible in physical characteristics, and a pool of individuals with well-characterized phenotypes is extremely desirable. Further, association studies may also be conducted within the general population and are not limited to studies performed on related individuals in affected families (linkage studies).
- The information on the one or more SNPs is then stored in one or more databases, along with information regarding its presence or absence in individuals with the ability to induce immune tolerance (403).
- The nucleic acid of individuals who desire treatment for a disease or disorder is then collected and analyzed to find if the individual has the one or more SNPs that are statistically significant associated with the ability of other individuals to induce immune tolerance (404). The medical practitioner alone, or with the assistance of a software system comprising one or more databases, may then determine what medical regimens are feasible, and the parameters of those medical treatments.
- Determination of Altered Polypeptide Presentation in Individuals Susceptible to Immune Tolerance
- In another embodiment, a method is first used to determining polypeptides that are present or absent in an individual who is susceptible to immune tolerance development, comprising screening for at least one polypeptide, as show in
FIG. 5 . In this method, the medical practitioner first administers an oral antigen to a patient to induce immune tolerance (501). - Antigens suitable for use in the present invention include those previously discussed, and may include any associated with or responsible for the induction of auto-immune diseases, clinical (allergic) hypersensitivities, and allograft rejection, and subunits or extracts therefrom; or recombinantly generated whole proteins, subunits or fragments thereof; or any combination thereof. Furthermore, the antigen may include, but is not limited to, all of the antigens of Table 1, to treat the associated diseases. The antigen may further be combined with other components such as a pharmaceutically acceptable excipient and/or a carrier, prior to administration to the individual.
- The individual dose size, number of doses, frequency of dose administration, and mode of administration may vary be determined by those skilled in the art. Suitable doses of antigen are those previously discussed. Further, the modes of administration can include, but are not limited to, aerosolized, subcutaneous, rectally, intradermal, intravenous, nasal, oral, transdermal and intramuscular routes.
- A biological sample is taken from the individual for use in determining the individual's immune response (502), whereby the individual immune system response to the antigen is scored based upon their response (503).
- The method to determine the individual immune response may include any method previously discussed, including but not limited to, use of an enzyme-linked immunoabsorbent assay (ELISA), ELISA/ACT® Lymphocyte Response Assay (LRA), in vitro measurement of antibody production, mixed leukocyte reaction, cytotoxic T lymphocyte assay, flow cytometry, Western blots, limiting dilution assay, mass spectroscopy, immunoprecipitation, immunofluorescence, ELISPOT, transvivo DTH assay, tetramer assay, CFSE assay, characterization of the TCR repertoire, measuring T cell responses to polyclonal, non-antigen-specific stimulation, detection of the presence of nucleic acids including PCR, LCR, hybridization techniques and proteomics. In addition, in one specific embodiment, the patients are scored based upon the respective levels and/or changes of cytokine production, including IL-17, IL-2 or IFN-γ production before, during and/or after receiving the antigen. Further, levels of T regulatory cells such as Trl cells or CD4+, CD25+, FoxP3+, cells can be used to score patient response. Alternatively, other cytokines may be measured to determine individual scores. For instance, levels of IL-10, IL-4, IL-5 or TGF-β1, 2 or 3 in α1(I)- and α2(I)-stimulated PBMC culture supernatants and/or sIL-2R may be used to score a patient.
- The method of scoring is dependent upon the practitioner, and includes any methods that separate patients based upon their immune response to the antigen. To score the patients based on immune system response, the practitioner may measure compare the immune response before, during and/or after receiving the antigen. The determination of when the immune response is measured, and what method is used, is based upon the practitioner needs. Further, it is contemplated that the practitioner may further take into consideration other physiological factors of the individual, such as other cytokines, oxidative radicals, connective tissue growth factor, nitric oxide, patient height, weight, health, diet, and environmental considerations to assist in scoring the patient's immune response.
- Once the individual is scored based on antigen response, the practitioner will analyze the polypeptides of the individuals to determine whether an individual has one or more polypeptides or variant polypeptides (504).
- The practitioner may either examine specific known polypeptides of interest or examine part or whole of the proteins present in the sample to look for the presence or absence of differential or unique polypeptides or polypeptide patterns, and correlate the polypeptides presence/absence with the individual's immune response score.
- Polypeptides may be detected by various methods known to one skilled in the art. Before polypeptide detection, the polypeptides within the individual's biological sample may be purified to substantial purity by standard techniques, including but not limited to, selective precipitation with such substances as ammonium sulfate, cold ethanol precipitation, ultrafiltration, column chromatography, immunopurification methods, and the like.
- The polypeptides may be detected by use of any method convenient to the practitioner, including, but not limited to sandwich assays and competition or displacement assays. Typically, a sandwich or competition/displacement assays includes a “capture agent” that specifically bind to and often immobilize the analyte (in this case one or more polypeptides in the sample). The capture agent is a moiety that specifically binds to the analyte.
- The presence or absence of the polypeptide may be determined by any means convenient to the practitioner, including electrochemical means or use of labels. A label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention include magnetic beads, fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g., 3H, 125I, 35S, 14C, or 32P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads. The label may be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. The antibody may be produced by any of a number of means well known to those of skill in the art and as described above. Further, the label may be on a third moiety that binds to the capture agent/analyte complex, or secondarily binds to a moiety distinct for the capture agent/analyte complex.
- Other techniques that may be used to detect and/or quantify the polypeptide includes western blot (immunoblot) analysis, liposome immunoassays (LIA), proteomics such as protein microarrays or mass spectrometry.
- The amino acid sequence of the polypeptides of interest found in the individual's sample may be determined, and compared to one or more databases containing polypeptides amino acid sequences that are statistically significant associated with the ability of other individuals to induce immune tolerance (404). The medical practitioner alone, or with the assistance of a software system comprising one or more databases, may then determine what medical regimens are feasible, and the parameters of those medical treatments.
- It is recognized that in any of the embodiments described herein, the disease or disorder may be linked to race, ethnicity, or sex. For example, one study found women comprise 78% of diagnosed autoimmune diseases. Further, systemic sclerosis has a sex and race specific prevalence, where women are more likely than men to have the disorder, and African Americans are more likely then Caucasians to have the disorder. As such, the presence or absence of the nucleic acid of interest may be tied to a hormone, the X chromosome, or to enzymes, receptors, or other compounds that have different levels between the sexes and or races.
- SNP Detection Kits and Systems
- Based on the SNP and associated sequence information disclosed herein, detection reagents can be developed and used to assay any SNP of the present invention individually or in combination, and such detection reagents can be readily incorporated into one of the established kit or system formats which are well known in the art. Kits used in the context of SNP detection reagents, are intended to refer to such things as combinations of multiple SNP detection reagents, or one or more SNP detection reagents in combination with one or more other types of elements or components (e.g., other types of biochemical reagents, containers, packages such as packaging intended for commercial sale, substrates to which SNP detection reagents are attached, electronic hardware components, etc.). Accordingly, the present invention further provides SNP detection kits and systems, including but not limited to, packaged probe and primer sets (e.g., TaqMan probe/primer sets), arrays/microarrays of nucleic acid molecules, and beads that contain one or more probes, primers, or other detection reagents for detecting one or more SNPs of the present invention. The kits/systems can optionally include various electronic hardware components; for example, arrays (“DNA chips”) and microfluidic systems (“lab-on-a-chip” systems) provided by various manufacturers typically comprise hardware components.
- Other kits/systems (e.g., probe/primer sets) may not include electronic hardware components, but may be comprised of, for example, one or more SNP detection reagents (along with, optionally, other biochemical reagents) packaged in one or more containers.
- In some embodiments, a SNP detection kit typically contains one or more detection reagents and other components (e.g., a buffer, enzymes such as DNA polymerases or ligases, chain extension nucleotides such as deoxynucleotide triphosphates, and in the case of Sanger-type DNA sequencing reactions, chain terminating nucleotides, positive control sequences, negative control sequences, and the like) necessary to carry out an assay or reaction, such as amplification and/or detection of a SNP-containing nucleic acid molecule. A kit may further contain means for determining the amount of a target nucleic acid, and means for comparing the amount with a standard, and can comprise instructions for using the kit to detect the SNP-containing nucleic acid molecule of interest. In one embodiment of the present invention, kits are provided which contain the necessary reagents to carry out one or more assays to detect one or more SNPs disclosed herein. In a preferred embodiment of the present invention, SNP detection kits/systems are in the form of nucleic acid arrays, or compartmentalized kits, including microfluidic/lab-on-a-chip systems.
- SNP detection kits/systems may contain, for example, one or more probes, or pairs of probes, that hybridize to a nucleic acid molecule at or near each target SNP position. Multiple pairs of allele-specific probes may be included in the kit/system to simultaneously assay large numbers of SNPs, at least one of which is a SNP of the present invention. In some kits/systems, the allele-specific probes are immobilized to a substrate such as an array or bead. For example, the same substrate can comprise allele-specific probes for detecting at least 1; 10; 100; 1000; 10,000; 100,000 (or any other number in-between) or substantially all of the SNPs shown in Table 1 and/or Table 2.
- The terms “arrays”, “microarrays”, and “DNA chips” are used herein interchangeably to refer to an array of distinct polynucleotides affixed to a substrate, such as glass, plastic, paper, nylon or other type of membrane, filter, chip, or any other suitable solid support. The polynucleotides can be synthesized directly on the substrate, or synthesized separate from the substrate and then affixed to the substrate. A microarray can be composed of a large number of unique, single-stranded polynucleotides, usually either synthetic antisense polynucleotides or fragments of cDNAs, fixed to a solid support.
- Hybridization assays based on polynucleotide arrays rely on the differences in hybridization stability of the probes to perfectly matched and mismatched target sequence variants. For SNP genotyping, it is generally preferable that stringency conditions used in hybridization assays are high enough such that nucleic acid molecules that differ from one another at as little as a single SNP position can be differentiated (e.g., typical SNP hybridization assays are designed so that hybridization will occur only if one particular nucleotide is present at a SNP position, but will not occur if an alternative nucleotide is present at that SNP position). Such high stringency conditions may be preferable when using, for example, nucleic acid arrays of allele-specific probes for SNP detection.
- In other embodiments, the arrays are used in conjunction with chemiluminescent detection technology.
- A SNP detection kit/system of the present invention may include components that are used to prepare nucleic acids from a test sample for the subsequent amplification and/or detection of a SNP-containing nucleic acid molecule. Such sample preparation components can be used to produce nucleic acid extracts (including DNA and/or RNA), proteins or membrane extracts from any bodily fluids (such as blood, serum, plasma, urine, saliva, phlegm, gastric juices, semen, tears, sweat, etc.), skin, hair, cells (especially nucleated cells), biopsies, buccal swabs or tissue specimens. The test samples used in the above-described methods will vary based on such factors as the assay format, nature of the detection method, and the specific tissues, cells or extracts used as the test sample to be assayed. Methods of preparing nucleic acids, proteins, and cell extracts are well known in the art and can be readily adapted to obtain a sample that is compatible with the system utilized.
- Another form of kit contemplated by the present invention is a compartmentalized kit. A compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include, for example, small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allow one to efficiently transfer reagents from one compartment to another compartment such that the test samples and reagents are not cross-contaminated, or from one container to another vessel not included in the kit, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another or to another vessel. Such containers may include, for example, one or more containers which will accept the test sample, one or more containers which contain at least one probe or other SNP detection reagent for detecting one or more SNPs of the present invention, one or more containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and one or more containers which contain the reagents used to reveal the presence of the bound probe or other SNP detection reagents. The kit can optionally further comprise compartments and/or reagents for, for example, nucleic acid amplification or other enzymatic reactions such as primer extension reactions, hybridization, ligation, electrophoresis (preferably capillary electrophoresis), mass spectrometry, and/or laser-induced fluorescent detection.
- Microfluidic devices, which may also be referred to as “lab-on-a-chip” systems, biomedical micro-electro-mechanical systems (bioMEMs), or multicomponent integrated systems, are exemplary kits/systems of the present invention for analyzing SNPs. Such systems miniaturize and compartmentalize processes such as probe/target hybridization, nucleic acid amplification, and capillary electrophoresis reactions in a single functional device. Such microfluidic devices typically utilize detection reagents in at least one aspect of the system, and such detection reagents may be used to detect one or more SNPs of the present invention.
- Further, the kits may also include one or more antigens, as described above. As such, the medical professional may first determine if a SNP is present or absent from the patient. Then, the medical professional prepares a regimen, or uses instead a predetermined regimen, to find which antigen, in what dose, by what method of administration, to give the patient. The one or more antigens may be sold with, or sold separate from, the kit.
- Given the disclosure in this application along with information well known to those of skill in the art, many SNPs that correlate with the ability or difficulty of generating immune tolerance can be determined. PCR can be preformed on samples where the replicon contains these SNPs or where the replicon is closely linked to them on the genome. Such technology can provide a rapid assay to determine the likelihood of the ability to induce tolerance in a specific individual.
- It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.
- Throughout this disclosure, various aspects of this invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- 120 RA patients on maintenance conventional therapies for their RA were tested for the ability of their peripheral blood mononuclear cells (PBMC) to produce IFNγ when cultured for six days with the autoantigen, purified bovine al chain of Collagen II (CII) or α1(II) at 50 μg/u. Culture supernatants were harvested and IFNγ levels determined by ELISA.
-
- As shown below (Table I), 76 patients had increased by two-fold over their unstimulated or (PBS) cultured PBMC, or a prevalence of 63% RA patients with an immune responses to CII (termed “Responders”). Although there is a high prevalence of RA patients with CII autoimmunity, it is one of several possible antigens apparent during the disease.
-
TABLE I PERCENTAGE of RA PATIENTS WITH IMMUNE RESPONSE by CULTURED PBMC to CII* Patient N % Mean IFNγ αl(II) SI ± SEM Responders E 76 63 1494 ± 313 Non-Responders 44 37 20.6 ± 6.5 Total 120 100 p = <0.001** **Mann-Whitney Rank Sum Test - Groups of 12 mice were fed oral CII at the doses indicated 8 times over 2 weeks and immunized with 100 μg bovine CII in CFA. After 4 days rest, the mice were then immunized at the base of the tail with 100 μg CII emulsified with complete Freund's adjuvant. The degree of arthritis was assessed by a blinded observer for 8 weeks.
- As can be seen in
FIG. 6 , 10 μg/day oral dose of CII was most effective in reducing the incidence of arthritis with 500 μg/day being also, but less, effective. The percent of mice withgrade - To determine whether tolerance induction to orally fed bovine CII in DBA/1 mice would be abrogated by orally fed NSAID, 3 groups of 20-22 DBA/1 mice were fed (by gavage) eight doses (Monday, Tuesday, Thursday, and Friday for 2 weeks) of the following: Placebo (saline) in the a.m. and Placebo (0.1 M HAc) in the p.m.; Placebo (saline) in the a.m. and 10 μg native bovine CII in the p.m.; or piroxicam (2.4 μg/gm) in the a.m. and native bovine CII (10 μg) in the p.m. After 1 week, all mice were immunized (intradermally at the base of tail) with 100 μg of bovine CII emulsified in complete Freund's adjuvant. Animals were placed in coded cages and were scored by a blinded observer twice weekly for the number of arthritic joints (joints swollen, red, and/or deformed).
- As shown in
FIG. 7 , compared to Placebo+Placebo fed controls, the percent of arthritic joints was less over the observation period in the group of mice fed Placebo+CII (p<0.03 by Cochran-Mantel-Haenszel analysis). By contrast, there were significantly more arthritic joints over the same period of observation in mice fed Piroxicam+CII. In similar studies, we found that nabumatone (Relafen) also abrogated OT induction in DBA/1 mice (data not shown). - To assess the effect of oral feeding of piroxicam to another group of mice fed Placebo or CII on spleen cell IFNγ production in a manner similar to the experiment in
FIG. 7 , four groups of mice (4 mice per group) were gavaged 8 days over 2 weeks with the following: Piroxicam a.m. —CII p.m.; Piroxicam a.m. —HAc p.m.; Saline a.m. —CII p.m.; or Saline a.m. HAc p.m. After 1 week rest, all mice were immunized at the base of the tail with a CII—complete Freund's adjuvant emulsion. After 14 days, mice were sacrificed, and spleen cells were isolated and set up in culture with PBS or α1(II)CB peptide mixture. After 72 h culture, harvested supernatants were analyzed for IFNγ levels by ELISA. - Mice fed CII+Placebo or piroxicam+Placebo had reduced production of IFNγ when their spleen cells were cultured in vitro with α1(II) CB peptide mixture. See,
FIG. 8 . When piroxicam was orally fed to mice being fed oral CII, however, there was a dramatic increase in the level of IFNγ production by spleen cells stimulated in vitro with α1(II)CB peptide mixture. In other experiments, it was found that the COX-2 inhibitor SC236 also blocked oral tolerance induction to CII in DBA/1 mice as assessed by IFNγ production by spleen cells (data not shown). - Groups of 8 mice each were gavaged on MTTHF×2 weeks in the a.m. with PBS or SC′236 (5 μg/gm in 100 μl PBS). SC′236 (Searle) is ˜2000× more inhibitory for COX-2 than for COX-1.
- Four of the mice given PBS in the a.m. and 4 mice given SC′236 in the a.m. were gavaged in the p.m. with 10 μg bovine type II collagen (CII). The other 4 mice in the a.m. PBS and a.m. SC′236 group were gavaged in the p.m. with 0.1M acetic acid (HAc) the vehicle the CII was dissolved in. After these 8 day feedings, all mice were rested for 1 week and then immunized with 100 μg of CII in complete Freund's adjuvant. After 10 days, all mice were sacrificed, and spleen cells (2×106/ml) were isolated and set up in culture with PBS and bovine α1(II) (50 μg/ml) CB mixture. After 4 days culture, the supernatants were harvested and IFNγ levels determined by ELISA (Endogen). Since the PBS+spleen cell culture from all mice produced between 1-12 pg/ml IFNγ, only the α1(II) data are plotted. All groups were compared to Placebo control group by Student's 2 sample t test.
- As shown in
FIG. 9 , feeding CII to DBA/1 mice induced oral tolerance manifested by a significant reduction in IFNγ production by spleen cells stimulated by α1(II) CB digest (p<0.025). In contrast, feeding SC′236 to the mice resulted in lower IFNγ production by α1(II) CB digest, but when mice were fed SC′236+CII there was a significant increase (p<0.01) in IFNγ production by spleen cells cultured with α1(II) CB digest. Given the caveat that SC′236 may also inhibit COX-1, but to a degree ˜2000× less than it inhibits COX-2, these data suggest that COX-2 may be essential for optimal tolerance induction to low dose oral antigen. - To determine whether chronic feeding of piroxicam with CII would have a persistent effect on tolerance induction to CII in DBA/1 mice, three groups of 10-11 DBA/1 mice were fed 8 doses of CII over two weeks (as above) on two occasions separated by 6 months: piroxicam (2.4 μg/gm) a.m. and Placebo (0.1M HAc, 100 μl) p.m.; Placebo (saline) a.m. and native bovine CII (10 μg) p.m; or piroxicam (2.4 μg/gm) a.m. and native bovine CII (10 μg) p.m. Three months after the second 8 dose feeding, each mouse was immunized (intradermally at base of tail) with 100 μg native bovine CII emulsified in complete Freund's adjuvant. Mice were placed in coded cages and scored twice weekly by a blinded observer for numbers of arthritic joints. As shown in
FIG. 10 , atweek - To assess the status of the GALT in these three groups of mice, Peyer's patch cells were isolated from each animal, and set up (2.5×105/ml) in quadruplicate in co-culture with normal DBA/1 spleen cells (2×106/ml) with addition of recombinant murine IL2 (10 U/ml). PBS (as a control) or 50 μg/ml bovine α1(II) CB peptide mixture were added to quadruplicate wells in 96 round bottom well plates. After 3 days, cultures were pulsed with 3H thymidine and harvested onto paper filters 24 h later. The “stimulation index” was calculated for each mouse by dividing the cpm of α1(II) CB peptide mixture culture by the cpm of the PBS control culture for each mouse. As shown in
FIG. 11 , compared to the co-culture of Peyer's patch cells from mice fed CII alone or piroxicam alone, there was marked stimulation by the α1(II) CB peptide mixture (p<0.03) of cells from mice fed piroxicam plus CII. Moreover, we have consistently found that Peyer's patch cells (2.5×105/ml) from DBA/1 mice or Balb/c mice in co-culture with normal syngeneic spleen cells (2×106/ml) when stimulated with murine IL-2 results in no stimulation of the spleen cells over background cpm. Thus, the marked increase in the stimulation index of Peyer's patch cells with DBA/1 spleen cells in the presence of α1(II) CB peptide mixture is quite exceptional and unexpected. The culture of mesenteric lymph node cells (2×106/ml) from each mouse with the α1(II) CB peptide mixture revealed a similar pattern (FIG. 12 ). The mesenteric lymph node cells from mice fed either CII or piroxicam did not proliferate in response to the α1(II) CB peptide mixture. In contrast there was marked stimulation by α1(II) CB peptide mixture of mesenteric lymph node cells from mice fed piroxican plus CII (FIG. 12 ). - Further, studies were conducted using oral OVA (1 μg/day×5 days) in BALB/c mice and oral bovine CII (10 μg×8 doses over 14 days) in DBA/1 lac J mice to test the effects of commonly used immunomodulatory drugs on immune induction (prednisone ≤7.5 μg/day, hydroxychloroquine 400 μg/day, methotrexate 17.5 mg/week, leflunomide 20 μg/day after 100 μg/day×3 loading doses, sulfasalazine 2.5 gm/day, D-penicillamine 750 μg/day, IM gold, and etanercept 25 mg twice weekly). These immunomodulatory drugs did not completely suppress tolerance, and that it may be feasible to induce tolerance in RA patients to CII still taking these immunomodulatory drugs. Prednisone ≥10 μg/day equivalent in DBA/1 lac J mice and auranofin did block OT induction to CII.
- Immunological tolerance, defined as a ≥30% reduction in IFN-γ production by PBMC cultured with α1(II) of type II collagen, was examined in patients. Patients that were taking disease-modifying antirheumatic drugs, anti-TNF agents and/or non steroidal inflammatories were administered misoprostol 100 μg bid to reverse the non steroidal antiinflammatory inhibition of oral tolerance. Patients were randomized to receive “low” or “high” doses of CII. The Low Dose group (n=38) took daily 30 μg/day bovine CII for 10 weeks, then 50 μg/day for 10 weeks and then 70 μg/day for 10 weeks. The High Dose group (n=41) took 90 μg/day for 10 weeks, 110 μg/day for 10 weeks and then 130 μg/day for 10 weeks.
- Heparinized blood was obtained at baseline and after each of the 10 week treatment periods. The blood was diluted 1:3 with RPMI 1640 containing penicillin (100 u/ml) and streptomycin (100 μg/ml) within 1-4 hours after collection, wrapped in paper, and placed in a Styrofoam box containing a “cold pack” and shipped overnight. The PBMC were isolated from the blood samples and set up in culture with bovine α1(II) 25 μg/ml,
PHA 10 μg/ml or with 50 ul PBS. After 6 days in culture, cell free supernatants were collected and stored at −70° for up to 7 months at which time all samples from a given patient were assayed for IFNγ by commercial ELISA (R & D Systems). The results are shown as inFIG. 13 . - The IFNγ stimulation index (SI) was calculated as
-
- The SI for patients receiving each of the low doses (30 μg, 50 μg and 70 μg/day) was compared with their SI at baseline before each of the 10 week treatments and similarly with the high dose CII group (90 μg, 110 μg and 130 μg/day) with their SI at baseline before each of the 10 week treatments.
- There was marked suppression of IFNγ SI. After ten weeks treatment with 30 μg, 50 μg, 110 μg and 130 μg/day oral CII with ≥62 to 69% of patients exhibiting ≥50% reduction in α1(II) IFNγ SI. 70 μg and 90 μg/day doses did not reduce the IFNγ SI, and the 70 μg/day dose significantly increased the IFNγ SI compared to baseline values.
- Further, the data showed that oral tolerance to CII, defined as a reduced immune response to fed antigen (CII), can be induced while patients are taking DMARDs, anti-TNF agents and NSAIDS if low dose misoprostol is given. The 30 and 50 μg/day doses had greater reduction in more categories.
- The dose response showed maximal suppression of IFNγ production at 30 μg, 50 μg and 110 μg/day of oral CII. For the percent of patients that had a ≥50% reduction in IFNγ by α1(II)-stimulated PBMC, most patients could be tolerized (69% had a ≥50% reduction in α1(II) stimulated IFNγ production to orally administered CII) at these doses.
- Further analysis of patients revealed that there were 30% non-responders to oral CII to the 30-50 μg/day dose of CII and 28% non-responders to the 110-130 μg/day dose (
FIG. 13 ). - To investigate if any particular genotype was associated with response or no response to oral CII in this cohort, 24 patients from Example 9 were selected.
- Blood was obtained from the patients before administering bovine CII orally to RA patients who produced ≥2× increase in IFNγ by α1(II) stimulated compared to PBS control PBMC cultures. Isolated (10 μg/mL), bovine α1(II) (50 mg/mL), bovine α1(II) CB11 (50 μg/mL) or with 25 μl PBS added to culture at 2×106 per 500 μl 48 well tissue culture plates of Dulbecos MEM supplemented with penicillin (100 μg/mL), streptomycin (100 μg/mL) and 9% fetal calf serum. After 6 days, supernatants were harvested, centrifuged at 2000×G for 5 minutes and levels of IFNγ were quantitiated by commercial ELISA (R & D Systems). Differences in IFNγ levels and in SI for PHA, α1(II) and α1(II) CB11 between responders and non-responders were analyzed for significance using Mann-Whitney rank sum test.
- Of the 24 patients, 16 patients responded to oral CII with reduction of α1(II) and α1(II) CB11 stimulated IFNγ production by PBMC cultures and 8 patients did not reduce IFNγ by PBMC culture with these antigens. The baseline IFNγ levels of the 16 responders and 8 non-responders to PBS, α1(II) 50 μg/ml α1(II)
CB11 50 μg/ml andPHA 10 μg/ml in six day PBMC cultures are given in Table I. - The IFNγ stimulation index (S.I.) calculated for PHA as follows:
-
- for α1(II) as follows:
-
- and for α1(II) CB11 as follows:
-
- As shown in Table II, the CII oral tolerance non-responders had lower mean baseline IFNγ α1(II) S.I.s than the CII oral tolerance responders (190±40 vs 1800±520, p=0.002). CII oral tolerance non-responders had lower mean baseline IFNγ α1(II)
CB 11 S.I.s than the CII oral tolerance responders (1060±197 vs 210±90, p=0.003). The IFNγ PHA S.I.s at baseline were not different between the CII oral tolerance responders and non-responders. -
TABLE II Comparison of IFNγ Production at Baseline Between CII OT Responders and Non-Responders CII OT Responders (N = 16) CII OT Non-Responders (N = 8) Culture IFNγ IFNγ Adds PG/mL IFNγ S.I. PG/mL IFNγ S.I. PBS 142 ± 41 — 203 ± 159 — (p = 0.395) α1(II) 1774 ± 501 1800 ± 520 581 ± 183 190 ± 40 (p = 0.150) (p = 0.002) α1(II) 1391 ± 295 1060 ± 197 523 ± 167 210 ± 90 CB11 (p = 0.06) (p = 0.003) PHA 6979 ± 2291 6400 ± 3100 3150 ± 1278 4200 ± 3200 (p = 0.520) (p = 0.349) - SNP analysis was performed of 16 responders and 8 non-responders to oral CII to find the frequency of SNPs closely associated on chromosomes next to several cytokines and chemokines known to be important for oral tolerance induction. The 16 patients were those with had ≥50% reduction in IFNγ al stimulation index from baseline to either the 30 μg/day, 50 μg/day, 110 μg/day or 130 μg/day dose of CII (“OT Responders”). The 8 patients with increases in IFNγ α1S.I. at the 30 μg/day, 50 μg/day, 110 μg/day or 130 μg/day doses of oral CII were selected (“OT Non-Responders”).
- Commercial whole genome mapping chips were used to map the potential genetic loci in a timely and economic manner. The genome of the two groups of Example 2 were analyzed by DNA extraction using a commercial DNA extraction kit, the Qiagen kit (Qiagen Inc., Alameda, Calif.) following the manufacturer's instructions. After determining the quality and quantity of the DNA in an Eppendorf photometer (Eppendorf Scientific Inc., Westbury, N.Y.), and by electrophoresis, DNA with OD260/280 ratios ratio >1 and high integrity was used for genotyping. For each sample, 250 μg of DNA was used for genotyping using Affy GeneChip® Mapping 10K 2.0 Array, a SNP-based genetic mapping tool. The 10K 2.0 Array contains genotypes greater than 10,000 human single nucleotide polymorphisms (SNPs) on a single array. The tool may be used to identify regions of the genome that are linked to or associated with, a particular trait or phenotype, in our case, the CII oral tolerance resistance.
- The protocol included four major procedures: in silico fractionation, synthesis of predicted fragments on microarrays, biochemical fractionation, and Allele specific hybridization and Genotype Calling. Two different signals that represent each of two polymorphisms of 10,000 single nucleotides were produced. The software creates the polymorphism or genotype of every of 10,000 single nucleotides. The genotype of polymorphism of each of 10,000 SNPs of every sample was called into three types, homozygous type I, AA; homozygous type II, BB; and heterozygous, AB, as indicated in table III.
-
TABLE III Genotyping of 15 Patients Called SNP Signal AA AB BB Patient # Gender Call Detection Call Call Call 001-101 M 94.41% 99.67% 33.27% 32.90% 33.83% 023-117re M 93.70% 99.59% 33.54% 32.89% 33.56% 046-123 F 78.89% 99.25% 32.53% 35.37% 32.10% 073-127 M 93.57% 99.40% 34.21% 31.30% 34.49% 090-323 F 95.87% 99.89% 32.21% 33.99% 33.80% 095--325 F 94.57% 99.05% 32.66% 33.82% 33.51% 109-319 F 85.35% 97.53% 34.89% 30.66% 34.45% 121-329 M 93.44% 99.55% 33.70% 32.28% 34.02% 127-137 M 93.82% 99.57% 33.35% 33.30% 33.34% 142-343 M 94.93% 99.80% 34.12% 31.86% 34.02% 143-339 M 96.28% 99.92% 32.76% 34.00% 33.25% 146-139 M 92.07% 99.05% 33.45% 32.09% 34.45% 148-341 F 91.31% 99.18% 33.38% 33.21% 33.41% 154-347 F 96.89% 99.95% 33.06% 34.18% 32.76% - Table III is the genotyping of 15 patients (9 males, 6 females). The detectable single of SNPs in most samples was over than 99%, indicating a high quality of detection. The SNP call indicates that the percentage among 10,000 of SNPs that could be recognized and for which data were given. More than 90% of SNPs in those samples was detected by the experiment. The distribution of three genotypes, the AA, AB, and BB was about one third (33%) for each of them.
- To find the possible polymorphism that linked non-tolerogenic response to CII treatment, the genotype of the patients of Example 3 was sorted into oral CII responders and non-responder groups. For each group, the total number of three genotypes, AA, AB, and BB was calculated for each SNP on the chip. Table IV shows the genotype ratio of SNP in each of those candidate genes.
-
TABLE IV Polymorphism of Candidate Genes. AA-AB-BB (responder/ Candidate Gene name SNP IDs non-responders) TGF beta 1, 2 3 SNP_A-1511117 3--4-6/3--2--4 SNP_A-1515879 8--6-0/9--1--0 ICOS SNP_A-1509114 3--4-5/0--8--2 SNP_A-1509255 6--7-1/2--6--2 SNP_A-1513931 13-1-0/9--1--0 SNP_A-1515899 0--0-14/0--0--10 SNP_A-1519289 2--1-7/2--4--4 IL-4R SNP_A-1509275 3--9-1/7--3--0 IL-10R SNP_A-1518241 2--3-7/4--3--2 CCL2 SNP_A-1514598 1--5-8/3--4--3 IFN gamma SNP_A-1508498 8--5-1/8--2--0 SNP_A-1512645 3-11-2/0--4--4 SNP_A-1512719 2-10-2/5--5--0 SNP_A-1515330 3--9-2/5--4--0 SNP_A-1515737 1--9-6/6--1--1 SNP_A-1518829 2-10-4/0--2--6 SNP_A-1518878 3-10-1/7--2--1 Glutamic Acid decarboxylse SNP_A-1513856 14-0-0/10--0-0 SNP_A-1509772 2--8-4/1--6-3 IL-1ra SNP_A-1511280 2--5-7/0--3--7 - As shown in Table IV, in 20 SNPs of 8 candidate genes, the most genotypic patterns between responder and non-responders are the same or similar. The patterns of the first SNP of Glutamic Acid decarboxylse is 14-0-0 (for AA-AB-BB) and 10-0-0; the second SNP is 2-8-4 and 1-6-3. However, there is a large difference of genotype distribution of the SNP_A-1515737 between response and non-response groups, being 1-9-6 and 6-1-1 respectively for responders and non-responders. While most of response patients have genotype either heterozygous (thus, the AG) or homozygous of BB (Thus the GG genotype), the majority of patients in non-response group had a AA genotype. Further analysis focused on the SNP_A-1515737.
- The sequences of SNP_A-1515737 is as the following: TTTTTTTTTTGTACCTRGTTCTATGGTTACCTT (SEQ ID NO: 21). The R represents the polymorphic site that can be either A (resulting in SEQ ID NO. 1) or G (resulting in SEQ ID NO. 2). Thus, AA represents AA homozygous, while AB represents A/G heterozygous and BB represents GG genotype, A→G represents the polymorphism site.
- Genotype patterns of responders and non-responders were compared and a significant difference in the genotype distribution found. See,
FIG. 14 . To calculate the P values, a number was assigned to the three genotypes. The AA genotype was assigned 1, AB (thus, AG) was assigned 2, and the BB (Thus GG genotype) was assigned 3. According to those assumptions, the P values of SNP_A-1515737 reached 0.052. - The 24 patients were grouped into those had the AA genotype (or A→G) of SNP_A-1515737 and those that did not have the AA genotype (i.e. were AB or BB). Table V and VI summarize the data based on the two groups. Table V lists the baseline IFNγ levels in six day supernatants PBMC stimulated for six days with PHA, α1(II), α1(II) CB11 or no additions (PBS). Patients with SNP_A-1515737 AA had significantly lower IFNγ α1(II) S.I. values (mean 270±90), compared to those patients not having three SNP_A-1515737 AA (mean 1674±505, p=0.028 by Mann-Whitney Rank Sum Test). Of the 7 patients with SNP_A-1515737 AA only one had CII oral tolerance response and of the 17 patients who have SNP_A-1515737 GG only 2 more non CII oral tolerance responders.
-
TABLE V Baseline IFNγ (PG/ML) in 6 Day PBMC Culture Supernatants No of SNP A-1515737 AA Genotype α1(II) PHA α1 (II) α1(II) CB11 OT Patient # Genotype PHA SI A1(II) SI CB11 SI PBS Responder 073-127 BB 16278 2533 3937 6052 4574 7047 234 Yes 001-101 AB 486 817 1348 2443 292 451 53 Yes 023-117 AB 14638 47119 256 726 389 1155 31 Yes 039-303 AB 446 1012 98.5 146 51 27 40.1 No 046-123 BB 7679 1474 1474 203 486 −0.4 488 No 090-323 BB 1163 2054 1483 2646 1451 2587 54 Yes 109-319 BB 4444 11443 61 58 123 219 38.5 Yes 121-329 AB 6983 3017 1728 671 2243 901 224 Yes 127-137 BB 618 301 505 228 500 225 154 Yes 143-339 AB 1056 1752 4188 7247 1273 2133 57 Yes 142-343 AB 189 133 325 301 383 373 81 Yes 148-341 BB 23427 8876 1019 290 1523 484 261 Yes 146-139 AB 1431 3821 630 1626 1271 3382 36.5 Yes 154-347 AB 3774 6521 284 398 843 1379 57 Yes 072-128 BB 2755 300 7688 1017 2205 220 688 Yes 113-332 AB 245 113 2641 2197 1865 1522 115 Yes 040-302 AB 29527 64089 1058 2200 433 841 46 Yes 6723 ± 2165 9140 ± 4373 1690 ± 481 1674 ± 505 1171 ± 274 1350 ± 425 146 ± 94 SNP A-1515737 AA Genotype α1(II) PHA α1(II) α1(II) CB11 OT Patient # Genotype PHA SI α1(II) SI CB11 SI PBS Responder 097-320 AA 273 82 1208 265 1268 280 331 No 050-308 AA 707 1314 90 80 120 140 50 No 058-309 AA 2093 776 455 90 294 23 239 No 061-311 AA 3173 1256 671 187 1240 430 234 No 095-325 AA 1744 1103 1228 747 2894 1896 145 Yes 155-348 AA 1050 405 461 122 428 106 208 No 014-109 AA 9777 26686 182 399 293 703 36.5 No 2688 ± 1236 4517 ± 3699 614 ± 172 270 ± 90 934 ± 371 511 ± 247 245 ± 40 P = 0.546 P = 0.240 P = 0.172 P = 0.028 P = 0.391 P = 0.153 P = 0.070 - In Table VI, the same patients were arranged and their IFNγ α1(II) S.I. at baseline and after oral CII administration (30 μg, 50 μg or 110 μg/day for 10 weeks) was compared. As shown in Table VI, patients who did not have SNP_A-1515737 AA (ROT1 AA) genotype had a significant reduction in the IFNγ α1(II) S.I. after oral CII compared to baseline values (p<0.001 by Wilxocon Rank Sum Test). In contrast, patients who carried the SNP_A-1515737 AA had no significant change in IFNγ α1(II) S.I. after oral CII treatment (p=0.230 by Wilcoxon Rank Sum Test). This was also reflected when data are represented as a ratio of IFNγ α1(II) S.I. after oral CII/baseline (p=0.011).
-
TABLE VI REDUCTION IN α1(II) SI AFTER ORAL CII IN PATIENTS WITH RA No SNP A-1515737 AA Genotype Patient α1(II) SI After Oral OT Ratio: # Genotype Baseline CII Responder After/baseline 073-127 BB 6065 18 Yes 0.0030 001-101 AB 2443 246 Yes 0.1008 023-117 AB 726 360 Yes 0.4932 039-303 AB 146 280 No 1.9178 046-123 BB 203 590 No 2.9064 090-323 BB 2646 152 Yes 0.0573 109-319 BB 58 6 Yes 0.1034 121-329 AB 671 276 Yes 0.4119 127-137 BB 228 18 Yes 0.0789 143-339 AB 7247 503 Yes 0.0694 142-343 AB 301 19 Yes 0.0631 148-341 BB 290 0 Yes 0 146-139 AB 1626 3 Yes 0.0018 154-347 AB 398 7 Yes 0.0176 072-128 BB 1017 358 Yes 0.3520 113-332 AB 2197 93 Yes 0.0423 040-302 AB 2200 540 Yes 0.2454 2081 ± 505 175 ± 46 0.427 ± 0.217 p = 0.011 p ≤ 0.001 SNP A-1515737 AA Genotype Patient α1(II) SI After Oral OT Ratio: # Genotype Baseline CII Responder After/baseline 097-320 AA 265 630 No 2.3774 050-308 AA 80 404 No 5.0500 058-309 AA 90 268 No 2.9778 061-311 AA 187 2020 No 10.8021 095-325 AA 747 3 Yes 0.0040 155-348 AA 122 167 No 1.3688 014-109 AA 399 800 No 2.0050 270 ± 90 613 ± 256 3.512 ± 1.347 p = 0.230 - The data was analyzed by use of Chi Square with Fisher's exact test, there is a highly significant difference (p=0.0017) between oral CII responders and non-responders in patients with SNP_A-1515737 AA genotype and those not having this genotype (Table VII).
-
TABLE VII Chi Square of SNP A-1515737 AA Genotype vs Non SNP A-1515737 AA Genotype AA Non-AA CII OT Non-Responder 7 2 CII OT Responder 1 15 - The genotype patterns of other SNPs within close distance to A-1515737 was also examined. In addition to A-1515737, there are six other SNP within the same genome region. None of them has a significant association with the response or non-response to CII treatment. For example, SNP_A-1508498, which is 146068 bp at 5′ side of DYRK2 and 350588 bp at 3′ side: IFNγ, is located very close to A-1515737, which is 265143 bp at 5′ side of DYRK2 and 231513 bp at 3′ side of IFNγ. The genotype patterns of responders and non-responders are similar, with AA, AB, and BB of 8--5-1 and 8--2-0, respectively.
- The segregating patterns of an average of 10 SNP along each chromosome was examined, but there was no evidence of an association of any segregating pattern with the CII response.
- Eight SNPs relevant to the non-response histocompatibility complex (HLA class II histocompatibility) was examined but there was no evidence of an association of the segregating bands with the CII response.
- Samples from 26 patients from a trial of oral type I collagen (CI) in patients with diffuse systemic sclerosis (SSc) who took 500 μg/day CI for 12 months were collected. Six of the 26 had A-1515737 AA genotype (Table VII). No patients were on DMARDs, biologies, NSAIDS or prednisone.
- PBMCs were collected from the patients and cultured with native bovine CI and α2(I) CB mixture and a trend toward defective production IL-10 PBMC cultured with α1(I) CB mixture.
- Patients who were tolerized by oral CI had upregulation of the Th2 cytokine, IL-10 by PBMC stimulated with CI, or α1(I) or α2(I). As shown in table VII, SSc patients with ROT1AA genotype and did not upregulate IL-10 production by α2(I) or CI stimulated PBMC in SSc patients after 12 months of treatment with oral CI. THE SNP_A-1515737 was also examined in 53 additional SSc patients and found the overall prevalence of AA was 32%, 35%
-
TABLE VII IL-10 PRODUCTION CHANGE AFTER 12 MONTHS OF ORAL CI and 12 MONTHS FOR SSc PATIENTS WITH and WITHOUT ROT1 AA* Genotype AA Bovine Native CI Patient # IL-10 pg/ml N = 6 −825 ± 338 Genotype BB or BA Bovine Native CI Patient # IL-10 pg/ ml Mann Whitney 27 ± 97 Rank Sum Test p = 0.008 Fisher's Exact Test p = 0.014
were GG and 30% were GA. Like in RA patients, SSc patients with AA exhibited less upregulation of IFNγ production by α2(I)-stimulated PBMC (Tables VII and VIII). -
TABLE VIII IFNγ Production by Hα1(I)-Stimulated PBMC from SSc Patients at Baseline # of Patients IFNγ pg/ ml ROT1AA+ 25 16 ± 134 ROT1GG or GA 54 3146 ± 2574 Mann Whitney Rank Sum Test p = 0.036 * PBMC of patients enrolled in Phase II CI/SSc Study were cultured with 25 μg/ml human α1(I) for 6 days after which culture supernatants were harvested and IFNγ levels determined by ELISA. - Patients with ROT1 AA, GG or GA genotype had IL-10 measured of IL-PBMC cultures stimulated by α1(I) CB mixture, α2(I) CB mixture, or native CI after receiving oral CI for 12 months minus the values of IL-10 in the supernatants of PBMC cultures stimulated with the same antigens at baseline before oral CI was administered to the SSc patients.
- Patients with ROT1 AA genotype received oral bovine CI 500 ug/day for 12 months had deficient upregulation of IL-10 production by their PBMC when cultured with native bovine CI and α2(I) CB mixture and a trend toward defective production IL-10 PBMC cultured with α1(I) CB mixture, demonstrating that ROT1 AA is associated with impaired oral tolerance to protein antigen. See, Table IX.
-
TABLE IX IL-10 PRODUCTION CHANGE AFTER 12 MONTHS OF ORAL CI and 12 MONTHS FOR SCLEROSIS PATIENTS WITH and WITHOUT ROT1AA* Bovine α1(I) Bovine α2(I) Bovine Genotype AA CB Mix CB Mix Native CI Patient # IL-10 pg/ml IL-10 pg/ml IL-10 pg/ml 071109 −342 −1692 −1726 130403 −19 +28 +70 061009 −611 −494 −920 060507 −112 +490 −233 060403 −2942 −3736 −1886 040104 +295 −448 −253 −622 ± 480 −975 ± 627 −825 ± 338 Genotype Bovine α1(I) Bovine α2(I) Bovine GG or GA CB Mix CB Mix Native CI Patient # IL-10 pg/ml IL-10 pg/ml IL-10 pg/ml 020705 −314 −388 −135 030504 +410 +203 +566 070101 −104 −86 −334 080101 −391 −180 +192 011008 +529 +859 +103 021308 +216 +546 +386 040806 −968 −1000 −1564 020906 +347 +261 +233 021411 −397 −2021 +21 041308 +1364 +1460 +237 072317 +108 +145 +150 061211 −205 −113 −94 072014 −81 +141 +32 090605 −561 −509 −282 091310 +582 +5 +232 030103 −46 +381 +192 030201 −538 +252 −52 050303 −227 −115 +43 072418 +663 −415 +269 080403 +221 +141 +341 Mann Whitney 30 ± 119 22 ± 156 27 ± 97 Rank Sum Test p = 0.062 p = 0.039 p = 0.008 Fisher's Exact Test NS NS p = 0.014 - We assessed SNP_A-1515737 (ROT1) genotype in patients and/or family members with Crohn's and/or ulcerative colitis and healthy controls with no IBD or other known autoimmune disease. Table X summarizes the genotype results in Crohn's diseases using DNA from buccal swabs, showing the ROT1 AA distribution was 91.67% for patients with Chron's Disease.
-
TABLE X Distribution of ROT1 Genotypes in Patients with Definite Crohn's Disease ROT1 Genotype Total (%) AA 8 AG 0 GG 0 Distribution of ROT1 Genotypes in First Degree Relatives of Patients with Crohn's Disease or Crohn's plus Ulcerative Colitis ROT1 Genotype Total (%) AA* 9 AG 0 GG 0 *Relatives have CD or CD and UC - Of all the Crohn's disease patients and their first degree relatives genotyped, 91.67% have ROT1AA. This evinces that ROT1AA is associated with oral tolerance resistance in Crohn's disease.
- The prevalence of ROT1AA in 12 Crohn's disease and first degree relatives (91.6%) was greater than 79 patients with SSc (31.6%), 54 patients with RA (38.9%) and in healthy controls (35.7%) (See Table XI).
-
TABLE XI Distribution of ROT1 Genotype in Patients with Systemic Sclerosis, Rheumatoid Arthritis and Healthy Controls Systemic Rheumatoid Normal ROT1 Sclerosis Arthritis Controls Genotype Total Percent Total Percent Total Percent AA 25 31.6% 21 38.9% 5 35.7 % AG 24 30.3% 17 31.5% 6 42.86 % GG 30 38% 16 29.6% 3 21.43% - Banked PBMC cell pellets were surveyed for all the patients with diffuse SSc, and 32% were found to be homozygous for ROT1 AA, 35% were homozygous for ROT1 GG, and 30% were heterozygous ROT1 GA.
- The SSc patients with ROT1 AA exhibited less upregulation of IFNγ production by α1(I)-stimulated PBMC. In the Phase II oral CI tolerance clinical trial at 12 months, 79 SSc patients were genotyped of the 168 enrolled in the clinical trial. Seven of the 23 ROT1AA genotype were in the Late Phase category, and deleted from the results. Reanalysis of the completers shows a significant difference in the change in MRSS at 12 months from baseline values in the CI treated patients when compared to the placebo treated patients using the Wilcoxon Rank Sum test (see
FIG. 16 ). -
TABLE 1 Antigen Disease 1D protein Endocrine orbitopathy 59-kD renal antigen Progressive glomerulonephritis Acetylcholine receptor subunit Myastenia gravis Aggrecan, fibrillin and Juvenile idiopathic arthritis metalloproteinase-3 Alpha3 (IV) NI1 Anti-GBM disease Alpha-enolase Asthma Alpha-fetoprotein Juvenile Batten disease Annexin A6 Neonatal lupus erythematosus Apoptotic cell-binding protein Systemic lupus erythematosus AUF1 Systemic rheumatic diseases Autologous colon extracted Crohn's disease proteins Beta2-glycoprotein-I Antiphospholipid syndrome Blood cell autoantigen Autoimmune hemolytic anemia Borrelia burgdorferi lysine- Lyme encephalitis enriched protein Borrelia T cell epitope Lyme arthritis BP180 Bullous pemphigoid BPAg2 IgA disease C1D Polymyositis-scleroderma overlap syndrome Collagen, preferably Type V Idiopathic pulmonary fibrosis collagen Cytochrome P450 1A2 Hepatitis graft-versus-host disease Cytokeratin-10 Lyme arthritis Deamidated gliadin peptide Celiac disease Desmocollin 1 Pemphigus Desmoglein 1 Pemphigus foliaceus Desmoglein 1 and 3 Pemphigus Desmoglein 1 and 3 Pemphigus vulgaris Desmoglein 1 and 3 Pustular dermatosis (Sneddon-Wilkinson disease) Desmoglein 3 ectodomain Pemphigus vulvaris Desmoglein-3 peptides Pemphigus vulgaris Enolase and arrestin Multiple sclerosis GAD65 Type 1 diabetes Glatiramer acetate Multiple sclerosis Globular domain of human C1q Systemic lupus erythematosus Glutathione S-transferase theta 1 Primary sclerosing cholangitis GPI-anti-oxLDL/beta2GPI SLE Heat shock proteins Carotid atherosclerosis Heparin Thrombocytopenia Histidyl-transfer RNA synthetase Jo-1 autoantibody-associated myositis hnRNP A/B proteins Systemic rheumatic diseases and hnRNP L hnRNP-A2 (RA33) Pristane-induced arthritis HRES-1 endogenous retrovirus Systemic lupus erythematosus Hsp60 Juvenile dermatomyositis hsp60, -65 and -70 Juvenile idiopathic arthritis Human insulin Diabetes mellitus type I Human intestinal antigens Crohn's disease Intrinsic factor Autoimmune gastritis Jo-1 or Ro-52/Ro 60 Myositis patients Ku Connective Tissue Lens proteins Uveitis MBL RA Megalin Donnai-Barrow and faciooculo- acoustico-renal syndromes Myelin basis protein peptides Multiple Sclerosis Neurofascin Autoantibody-mediated axonal injury Neuron-specific enolase Sudden acquired retinal degeneration syndrome Noncollagenous 1 and 2 Childhood epidermolysis bullosa domains of type VII collagen acquisita Noncollagenous domain of type Herpes gestationis VII collagen Nuclear ribonucleoprotein A2 Systemic lupus erythematosus (hnRNP-A2) Nucleosome antigen Lupus erythematosus Nucleosomes Lupus nephritis p200 Pemphigoid p200 pemphigoid antigen Epidermolysis bullosa acquisita Parotid antigens Sjögren's syndrome Pemphigus vulgaris IgG Acantholysis Phenylalanyl transfer RNA Polymyositis synthetase Plasma membrane autoantigens Autoimmune hepatitis Poly (ADP-ribose) polymerase 1 Systemic lupus erythematosus Rabaptin 5 as a novel autoantigen Alzheimer's disease RAP and megalin Heymann nephritis Recombinant 70 kDa Mixed connective tissue diseases ribonuceloprotein Red blood cells as model antigens Autoimmunity Retinal antigen Macular degeneration Retinal Soluble Antigen Uveitis Ribosomal P protein Systemic lupus erythematosus Ribosomal P Protein PO Mixed connective tissues RNA helicase A Systemic lupus erythematosus Selenium binding proteins Behcet's disease Sm Systemic lupus erythematosus Smd 183-119-autoantigen SLE Spinal cord cells Amyotrophic lateral sclerosis (ALS) Squamous Cell Carinoma Antigen Psoriasis Protein Family SSA/SSB antibodies Systemic lupus erythematosus Subunit of RLIP76 Immune-mediated vascular diseases and atherosclerosis Testis-expressed protein TSGA10 Autoimmune polyendocrine syndrome type I TG3 Celiac disease Thyroid hormone Autoimmune encephalopathy Thyroid peroxidase Type 1 diabetes Transglutaminase Dermatitis herpetiformis and celiac sprue TRIM proteins Sjögren syndrome Type I collagen Systemic sclerosis Scleroderma Type I collagen Idiopathic Pulmonary Fibrosis Type II collagen RA Type III collagen Systemic sclerosis (Scleroderma) Type III collagen Idiopathic Pulmonary Fibrosis Type V collagen Idiopathic Pulmonary Fibrosis Vimentin RA ZnT8 (S1c30A8) Human type 1 diabetes
Claims (28)
1. A method for screening for susceptibility to immune tolerance development, comprising screening for at least one SNP.
2. A method of claim 1 , wherein said method of screening comprises FISH.
3. The method of claim 1 , wherein said method of screening comprises use of a DNA array.
4. The method of claim 1 , wherein said method of screening comprises hybridizing a polynucleotide probe.
5. The method of claim 4 , wherein said method is selected from the group consisting of: allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.
6. The method of claim 1 , wherein said method comprises correlating the presence or absence of the at least one SNP with ability of a host to develop immune tolerance as a result of administration of one or more antigens to the host.
7. The method of claim 6 , wherein said host is a human.
8. The method of claim 6 , wherein said at least one or more therapeutic agents comprises at least one antigen.
9. The method of claim 8 , wherein said at least one antigen is a collagen.
10. The method of claim 8 , wherein said collagen is selected from the group types consisting of: I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII and XVIII.
11. A method of screening for susceptibility of a host to immune tolerance development, said method comprising:
a. obtaining a sample from said host comprising nucleic acid;
b. isolating nucleic acid from said sample;
c. assaying said sample for the presence or absence of at least one SNP, wherein the presence or absence of the at least one SNP is indicative of an increased susceptibility to develop immune tolerance.
12. The method of claim 11 , wherein said host is human.
13. The method of claim 11 , wherein said sample is selected from the group comprising: whole blood, blood plasma, urine, tears, semen, saliva, buccal mucosa, interstitial fluid, lymph fluid, meningeal fluid, amniotic fluid, glandular fluid, sputum, feces, perspiration, mucous, vaginal secretion, cerebrospinal fluid, hair, skin, fecal material, wound exudate, wound homogenate, and wound fluid.
14. The method of claim 11 , wherein said immune tolerance is induced by administration of at least one antigen to the host.
15. The method of claim 14 , wherein said at least one or more antigens is a collagen.
16. The method of claim 15 , wherein said collagen is selected from the group types consisting of: I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII and XVIII.
17. The method of claim 11 , wherein said immune tolerance developed is to a sclerotic disease.
18. The method of claim 17 , wherein said sclerotic disease is systemic sclerosis.
19. The method of claim 11 , wherein said method further comprises at least one computer program for use with at least one computer system, wherein said computer program includes a plurality of instructions comprising:
a. at least one instruction for aiding in identification of the presence or absence of said at least one SNP;
b. at least one instruction for associating the presence or absence of said at least one SNP with at least one disease state; and
c. at least one instruction for correlating the presence or absence of said at least one SNP with a score indicating susceptibility of a host to develop immune tolerance.
20. The method of claim 19 , wherein said computer program further generates a report comprising the results of the plurality of instructions.
21. The method of claim 20 , wherein said report is transmitted over a network.
22. The method of claim 20 , wherein said report is transmitted through an on-line portal.
23. The method of claim 20 , wherein said report is transmitted by paper or e-mail.
24. The method of claim 20 , wherein said report is transmitted in a secure manner.
25. The method of claim 20 , wherein said report is stored in a database.
26. A method of administering at least one therapeutic agent, the method comprising
a. genotyping one or more SNP(s) in the nucleic acid of a host,
b. correlating the one or more SNP(s) with one or more diseases or disorders,
c. using a mathematical algorithm to determine probability that said host will respond positively or negatively to administration of at least one therapeutic agent, and
d. administrating or not administrating a therapeutic agent to the host based on the results of said mathematical algorithm.
27. A method for conducting a clinical trial in which one or more antigen(s) are evaluated, said method comprising:
a. genotyping one or more SNP(s) relating to one or more diseases or disorders;
b. analyzing the genotyping results;
c. determining a course of action based on the results of said genotyping, wherein said course of action comprises
i. including individual in the clinical trial based on the results of said genotyping having indicated that said individuals are likely to respond to said one or more antigen(s), and/or
ii. excluding individuals from participating in the clinical trial based on the results of said genotyping having indicated that said individuals are not likely to respond to said one or more antigen(s).
28. A method for identifying an individual who has an altered risk for developing an autoimmune disease, comprising detecting a single nucleotide polymorphism (SNP) in SEQ ID NO: 1 in said individual's nucleic acids, wherein the presence of the SNP is correlated with an altered risk for autoimmune disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/659,277 US20200149108A1 (en) | 2008-04-18 | 2019-10-21 | Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7126408P | 2008-04-18 | 2008-04-18 | |
US8001208P | 2008-07-11 | 2008-07-11 | |
US10450408P | 2008-10-10 | 2008-10-10 | |
PCT/US2009/041134 WO2009146213A2 (en) | 2008-04-18 | 2009-04-20 | Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction |
US98839510A | 2010-10-18 | 2010-10-18 | |
US201313972362A | 2013-08-21 | 2013-08-21 | |
US14/243,998 US20140286971A1 (en) | 2008-04-18 | 2014-04-03 | Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction |
US15/183,764 US10450610B2 (en) | 2008-04-18 | 2016-06-15 | Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction |
US16/659,277 US20200149108A1 (en) | 2008-04-18 | 2019-10-21 | Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/183,764 Continuation US10450610B2 (en) | 2008-04-18 | 2016-06-15 | Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200149108A1 true US20200149108A1 (en) | 2020-05-14 |
Family
ID=41377885
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/988,395 Abandoned US20120135014A1 (en) | 2008-04-18 | 2009-04-20 | Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction |
US14/243,998 Abandoned US20140286971A1 (en) | 2008-04-18 | 2014-04-03 | Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction |
US15/183,764 Expired - Fee Related US10450610B2 (en) | 2008-04-18 | 2016-06-15 | Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction |
US16/659,277 Abandoned US20200149108A1 (en) | 2008-04-18 | 2019-10-21 | Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/988,395 Abandoned US20120135014A1 (en) | 2008-04-18 | 2009-04-20 | Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction |
US14/243,998 Abandoned US20140286971A1 (en) | 2008-04-18 | 2014-04-03 | Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction |
US15/183,764 Expired - Fee Related US10450610B2 (en) | 2008-04-18 | 2016-06-15 | Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction |
Country Status (12)
Country | Link |
---|---|
US (4) | US20120135014A1 (en) |
EP (1) | EP2286218B1 (en) |
JP (1) | JP2011520425A (en) |
KR (1) | KR20110014595A (en) |
CN (1) | CN102089655A (en) |
AU (1) | AU2009251508A1 (en) |
BR (1) | BRPI0911104A2 (en) |
CA (1) | CA2721651A1 (en) |
EA (1) | EA201001667A1 (en) |
IL (1) | IL208777A0 (en) |
MX (1) | MX2010011445A (en) |
WO (1) | WO2009146213A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3404116B1 (en) | 2013-03-15 | 2022-10-19 | The University of Chicago | Methods and compositions related to t-cell activity |
KR102217060B1 (en) * | 2019-01-30 | 2021-02-18 | (주)메디젠휴먼케어 | Apparatus for analysis and management of individual single nucleotide polymorphism |
CN111537315B (en) * | 2020-07-13 | 2020-10-02 | 天津德祥生物技术有限公司 | Erythrocyte membrane separation liquid and erythrocyte membrane separation method |
CN114107474B (en) * | 2020-08-28 | 2024-05-07 | 复旦大学附属华山医院 | ANXA6 polymorphic site as gene marker and psoriasis kit combined with methotrexate |
CN113215230B (en) * | 2021-06-22 | 2024-02-09 | 艾康健(武汉)基因技术有限公司 | SNP nucleic acid mass spectrometry typing detection method for non-disease diagnosis purpose |
CN117904318B (en) * | 2024-01-25 | 2024-07-12 | 中国农业科学院兰州畜牧与兽药研究所 | SNP molecular marker related to Tibetan sheep immune traits and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1512014T3 (en) * | 2002-06-13 | 2009-10-05 | Merck Patent Gmbh | Methods for identifying alloantigens and their use in cancer treatment and transplantation |
US7629164B2 (en) * | 2002-10-08 | 2009-12-08 | Affymetrix, Inc. | Methods for genotyping polymorphisms in humans |
US20040146870A1 (en) * | 2003-01-27 | 2004-07-29 | Guochun Liao | Systems and methods for predicting specific genetic loci that affect phenotypic traits |
JP2006521812A (en) * | 2003-03-18 | 2006-09-28 | アプレラ コーポレイション | Genetic polymorphism associated with rheumatoid arthritis, detection method and use thereof |
CA2539708A1 (en) * | 2003-09-24 | 2005-04-07 | Bioxell S.P.A. | 1,3-diaclyated,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof |
US20050250125A1 (en) * | 2003-12-19 | 2005-11-10 | Novakoff James L | Method for conducting pharmacogenomics-based studies |
MXPA04005080A (en) * | 2004-05-27 | 2005-11-30 | Aspid S A De C V | Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone. |
US20060178910A1 (en) * | 2005-01-10 | 2006-08-10 | George Eisenberger | Publisher gateway systems for collaborative data exchange, collection, monitoring and/or alerting |
AU2006205571B2 (en) * | 2005-01-13 | 2012-03-22 | Progenika Biopharma, S.A. | Methods and products for in vitro genotyping |
US20060253263A1 (en) * | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
US20080070792A1 (en) * | 2006-06-14 | 2008-03-20 | Roland Stoughton | Use of highly parallel snp genotyping for fetal diagnosis |
-
2009
- 2009-04-20 US US12/988,395 patent/US20120135014A1/en not_active Abandoned
- 2009-04-20 JP JP2011505254A patent/JP2011520425A/en not_active Withdrawn
- 2009-04-20 EA EA201001667A patent/EA201001667A1/en unknown
- 2009-04-20 CA CA2721651A patent/CA2721651A1/en not_active Abandoned
- 2009-04-20 KR KR1020107025767A patent/KR20110014595A/en not_active Application Discontinuation
- 2009-04-20 AU AU2009251508A patent/AU2009251508A1/en not_active Abandoned
- 2009-04-20 CN CN2009801231763A patent/CN102089655A/en active Pending
- 2009-04-20 BR BRPI0911104A patent/BRPI0911104A2/en not_active IP Right Cessation
- 2009-04-20 EP EP09755575.9A patent/EP2286218B1/en not_active Not-in-force
- 2009-04-20 WO PCT/US2009/041134 patent/WO2009146213A2/en active Application Filing
- 2009-04-20 MX MX2010011445A patent/MX2010011445A/en not_active Application Discontinuation
-
2010
- 2010-10-17 IL IL208777A patent/IL208777A0/en unknown
-
2014
- 2014-04-03 US US14/243,998 patent/US20140286971A1/en not_active Abandoned
-
2016
- 2016-06-15 US US15/183,764 patent/US10450610B2/en not_active Expired - Fee Related
-
2019
- 2019-10-21 US US16/659,277 patent/US20200149108A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2010011445A (en) | 2011-02-15 |
US20120135014A1 (en) | 2012-05-31 |
CA2721651A1 (en) | 2009-12-03 |
AU2009251508A1 (en) | 2009-12-03 |
BRPI0911104A2 (en) | 2015-10-06 |
EP2286218A2 (en) | 2011-02-23 |
WO2009146213A2 (en) | 2009-12-03 |
IL208777A0 (en) | 2010-12-30 |
CN102089655A (en) | 2011-06-08 |
EP2286218B1 (en) | 2016-04-13 |
US20140286971A1 (en) | 2014-09-25 |
WO2009146213A3 (en) | 2010-02-04 |
US10450610B2 (en) | 2019-10-22 |
EP2286218A4 (en) | 2011-12-28 |
US20170016068A1 (en) | 2017-01-19 |
EA201001667A1 (en) | 2011-06-30 |
KR20110014595A (en) | 2011-02-11 |
JP2011520425A (en) | 2011-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10450610B2 (en) | Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction | |
US6162604A (en) | Methods for determining genetic predisposition to autoimmune diseases by genotyping apoptotic genes | |
US20130078244A1 (en) | Methods for detecting and regulating alopecia areata and gene cohorts thereof | |
US20180171407A1 (en) | Genetic polymorphisms associated with autoinflammatory diseases, methods of detection and uses thereof | |
AU778505B2 (en) | Genetic marker test for lupus | |
Torbati et al. | Association of CD58 polymorphism with multiple sclerosis and response to interferon ß therapy in a subset of Iranian population | |
Lee et al. | Dinucleotide repeat polymorphism in intron II of human Toll‐like receptor 2 gene and susceptibility to rheumatoid arthritis | |
Roth et al. | Myelin oligodendrocyte glycoprotein (MOG) gene polymorphisms and multiple sclerosis: no evidence of disease association with MOG | |
EP3277836B1 (en) | Method of treatment using genetic predictors of a response to treatment with ssr-125543 | |
Fichna et al. | STAT4 sequence variant and elevated gene expression are associated with type 1 diabetes in Polish children | |
García-Elorriaga et al. | Polymorphisms in tumor necrosis factor and lymphotoxin A in tuberculosis without and with response to treatment | |
US7700277B2 (en) | Use of polymorphisms in human OATP-C associated with an effect on statin pharmacokinetics in humans in statin therapy | |
Messer et al. | Allelic variation in the TNF‐β gene does not explain the low TNF‐β response in patients with primary biliary cirrhosis | |
Liu et al. | Association of PTPN22 gene polymorphism with type 1 diabetes mellitus in Chinese children and adolescents | |
JP2018517721A (en) | Method for treating primary focal segmental glomerulosclerosis | |
JP6128654B2 (en) | Use of myelin basic protein as a novel genetic factor in rheumatoid arthritis | |
Turcan et al. | Clinical and molecular characteristics of 3 moldavian children with Wiskott-Aldrich Syndrome | |
JP2014514915A (en) | Genetic association between rheumatoid arthritis and polymorphism of SSTR2 gene | |
US20130064819A1 (en) | Biomarkers | |
Hawthorne | The pharmacogenetic and immunomodulatory response to Vitamin D in tuberculosis | |
Abd-Elmonsef et al. | Association of the RETN–420C˃ G Polymorphism with Rheumatoid Arthritis in an Egyptian Population | |
NOURI et al. | Lack of Association between Promoter Gene Polymorphism (-318 C/T) and Multiple Sclerosis in Iranian Population | |
GM-CSF-n | A Granzym e A Granzyme B Perforin | |
WO2006003526A2 (en) | Human autism susceptibility gene encoding otoa and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |